annual repor one challenging years people johnson johnson delivered results impressive ever achieved stronger today year ago outstanding new products robust pipelines talented peoplepeople remain inspired united common purpose caring others cover people johnson johnson remain true motivated finding innovations touch lives example simple blood test captures identifies counts circulating tumor cells patients certain types metastatic cancer along tests support physicians making informed patient care decisions jesica harrington shown family even little bit information fight offered hope read story chairmans letter shareholders reflect year passed negative impact currency percent decades since founding adjusted earnings billion johnson johnson say without adjusted earnings per share increased hesitation year one percent also generated free cash flow challenging history faced approximately billion achieving significant patent expirations worth nearly results year operational sales billion sales severe global essentially flat reflects outstanding financial highlights vs economic downturn many us ever efforts leadership teams manage experienced increased competition businesses contain costs change across markets people delivered johnson johnson total company total ops ressaulelsts p r e bssive n b delivered total shareholder return ever achieved fundamental beliefs percent strong performance adjusted earnings b b embedded credo guided although lower rate return one adjusted eps decisions actions year comparative indices free cash flow b b delivered financial commit two three years outperformed ments continued pursue longterm growth dow jones industrial average william c weldon opportunities emerged stronger standard poors drug nn oo nn gg aa aa pp fm ine aa ns cu iare l e ex ac slu ud ree ep fr ed ac sh pg ee rs ta inn gd co ath se hr f lop c leia sl ce ps ital spending estimated chairman board directors wellpositioned sustainable growth health care indices reflects solid perfor chief executive officer exctehrroputg fhr aollm th irso thsely pneo epmle oafi l mance recent market downturn johnson johnson remained inspired united common retained relative value indices purpose caring others ever know caring longer term johnson johnson continued outperform tom health wellbeing people outstanding stock indices total shareholder returns bmusyi nceossm bumt ae mnitsss ioonn hthate rcuhlya tortusc sg lirvaepshs highlights managing shortterm challenges took important steps sustainable growth expanded divi dreesnudltss p wehr esnh bise gan se expectations financial leadership position health care results anticipating business economic challenges including forecast first reported sales decline years strengthened core businesses invested launches thanks diligence people disciplined management number recently approved innovative products rd focus results expectations investments last several years coming fruition worldwide sales billion decrease percent exciting meaningful ways invested operational results declined percent another billion rd net sales diluted earnings per share dividends paid per share billions dollars dollars dollars chairmans letter net sales diluted earnings per share dividends paid per share course must meet additional challenges ahead addition advancing pipelines internal develop effects economic downturn high unemployment ment continued acquire invest collaborate rates decreased access health care shrinking hospital companies generate new platforms growth budgets avoidance outofpocket costs discretionary since beginning made eight major acquisi health care purchases present hurdles industry tions invested several strategic transactions recent coupled rising costs regulatory requirements highlights include acquisitions cougar biotechnology inc larger costly clinical trialscreate dynamic oncology key compound elan corporation plc health care environment requires disciplined action alzheimers disease formed strategic alliances success crucell nv vaccines gilead sciences inc hiv believe brightest innovative health care therapies acquired acclarent inc minimally companieswith dedicated focused people care invasive sinus surgery business caringwill thrive evolving stillchanging also continued expand global presence including environment johnson johnson one companies building operations expanding reach bric countriesbrazil russia india chinaand growth priorities johnson johnson tremendous assets fastgrowing developing markets growth people products pipeline global presence foundation credo common set values unifying continued play role helping shape health approximately people around world care policy around world given broad perspective operating model served us well decades unwaver sector ing operating model includes commitment broadly future health care promising exciting based health care decentralized management approach however without ongoing challenges must addressed keeps people close customers managing long term development costs increasing changes patient con focus people values businesses rely sumer behaviors well constrained health care budgets credo operating model provide consistent framework lingering effects economic downturn decisionmaking leaving specific strategies local assessed evolving global environment business franchise leaders closest customer concluded restructuring organization needed within strategic framework galvanize organization ensure sustainable growth included necessary plan around highlevel business priorities reflect changing eliminate approximately positions far difficult global environment provide leaders common set decision past year however actions increase growth priorities include efficiency make additional resources available investment innovative products growth always based longterm growth platforms new product launches scientific innovations serve unmet patient customer began implementing restructuring plans shortly needs meaningful way created market leadership announcement november continuing accor positions many businesses stay focused dance required consultation procedures market bringing forth innovative accessible effective products moving ahead every difficult period brings correspond entirely new business modelsthat address ing opportunity growth despite challenging year prevalent health care needs stronger today year ago outstanding new robust pipelines johnson johnson one products robust pipelines talented people working robust product pipelines history multitude streamlined organization resources growth opportunities necessitate target invest manage addition strengths see favorable trends development mix internal external sources health care market sustain flow new products provide competitive global health care market expected grow almost advantage fully expect new products coming percent per year next five years broad base todays pipeline accelerate proportion sales driven businesses participate onethird overall newer products market focused fastest growing seg global presence global health care leader must ments health care fact many segments compete continue expand presence execute strategies growing fast faster overall market appropriate way diverse markets customers many nations china india brazil increasing approach strategic effective costefficient access care citizens progress still address local needs may mean relating customers way sizable growth opportunities companies like new ways tailoring product innovation market needs johnson johnson deeply immersed markets building health care capacity johnson johnson health care needs people also means special focus highgrowth emerging markets bric countries finally expertise business strategies aligning many evolving trends health careincluding talented people hallmark johnson johnson personalized medicine comparative effectiveness wellness talented people passionate winning prevention companion diagnostics biomarkers marketplace making difference peoples lives believe many read following pages best talent health care industry johnson johnson annual report johnson johnson annual report corporate level revisions march chairmans letterour ability develop challenge motivate reward diverse workforce cornerstone sustained growth strategic framework people medical devices diagnostics pharma ceuticals consumer segments consistently delivered plans growth segments market leaders positions many businesses fact percent sales products leading market share u r c r edo positions approximately onefourth sales last year coming new products introduced past five years operating model medical devices dia gnostics medical devices diagnostics mdd franchises comprise worlds largest medical technology business sales billion increase percent operationally four seven franchises solid sales gains past year tougher broadly based competition drugeluting stents tighter outofpocket human health spending products like contact lenses diabetes test strips pressured sales cordis corporation diabetes vision care franchises managed decentralized growth products spanned range treatment categories long term approach including wound care products biosurgicals ethicon inc energy technology realize adjustable gastric people bandc ethicon endosurgery inc artificial joints spine values sports medicine products depuy inc new products orthoclinical diagnostics inc several products introduced new standards care medical devices industry carto biosense webster inc gives physicians detailed threedimensional view heart treat cardiac arrhythmias including atrial fibrillation business priorities surgiflo hemostatic matrix kit advanced flowable hemostat use broad range surgical procedures first product launch acquisition omrix biopharma ceuticals inc example technology resulting combination medical device biologics expertise innovative robust vision care franchise continued global rollout products pipelines day acuvue trueye worlds first daily disposable silicone hydrogel contact lens exciting breakthrough contact lens technology anticipate introduction global talented us presence people mdd also strengthened portfolio several recent strategic acquisitions included acclarent inc ear nose throat surgical space finsbury orthopaedics ltd hip implants gloster europe developer innovative areadecontamination technologies help prevent health care acquired infections growing global concern pipeline strong promising new products sedasys system first computerassisted personalized sedation system pinnacle complete acetabular hip strategic framework sustainable growth system first ceramiconmetal hip replacement products received favorable recommendations us food drug source enduring strength fundamental administration fda advisory committees commitment credo operating model addition new product introductions robust pipelines served us well decades highlevel business mdd continually expanded global reach particularly priorities reflect changing global environment emerging markets research development centers provide leaders common set growth priorities professional training centers manufacturing facilities strategic framework delivered enduring performance believe continue provide pharmaceuticals pharmaceuticals segment sales longterm value shareholders billion represents worlds seventh largest pharmaceu tical business fourth largest biotech business segment chairmans letter johnson johnson annual report corporate level revisions march chairmans lettermedical devices diagnostics experienced operational sales decline percent segment sales reflecting loss nearly billion sales due losing market sales major franchise billions dollars exclusivity risperdal risperidone topamax sales billion ethicon topiramate excluding impact generic competition endosurgery sales change pharmaceutical sales increased approximately percent total operationally operational growth driven larger products including remicade infliximab treatment number ethicon orthoclinical diagnostics immunemediated inflammatory diseases concerta methylphenidate hcl extendedrelease tablets attention deficit hyperactivity disorder adhd risperdal consta risperidone longacting injection atypical dia cabe rt ees vision antipsychotic administered every two weeks treatment care schizophrenia maintenance bipolar disorder promising newer products continued positive growth trajectory prezista darunavir hiv velcade bortezomib multiple myeloma developed partnership depuy cordis millennium takeda oncology company rights outside us invega paliperidone oncedaily atypical antipsychotic treatment schizophrenia acute schizoaffective disorder intelence etravirine pharmaceutical segment sales hiv combination therapy sales major product billions dollars pharmaceutical pipeline one robust sales billion aciphexpariet history launched five newly approved drugs sales change concerta simponi golimumab stelara ustekinumab total operational immunology nucynta tapentadol immediate release duragesic tablets pain relief invega sustenna paliperidone palmitate treatment schizophrenia priligy dapoxetine select countries across world sexual health le fv la oq xu inin addition continue expand core products new indications practice done well historically example remicade fdaapproved indications across broad topamax spectrum immune system disorders procrit future pipeline promising important product eprex registration rivaroxaban codeveloping bayer healthcare ag rivaroxaban novel oral anticoagulant risperdal consta may prevent host thrombotic conditions including venous risperdal mi ca de thromboembolism stroke atrial fibrillation evaluated five different indications important compounds phase iii clinical trials including treatments consumer segment sales diabetes prostate cancer alzheimers disease building already strong pipeline engaged sales major franchise billions dollars sales billion acquisitions innovative agreements collaborations sales change companies offer potentially significant advances patient total care include potential firstinclass treatment slowing operational w ho em ale tn hs progression alzheimers disease elan corporation plc potential universal monoclonal antibody product otc pharmaceuticals treatment prevention influenza crucell nv hiv nutritionals therapy single combination pill gilead sciences inc potential breakthrough prostate cancer cougar wound care biotechnology inc strengthening pipeline pharmaceuticals business expanded geographically focus emerging markets oral care expanding sales reach china maintaining strong manufacturing footprint china mexico brazil developing rd presence emerging markets like india baby care china establishing rd operation mumbai rd head skin care quarters shanghai collaboration tianjin medical university cancer hospital biomarker research operational excludes impact currency johnson johnson annual report johnson johnson annual report corporate level revisions march chairmans letterconsumer consumer business enduring business preventing diseases johnson johnson continues distinguish science companies worldwide people make model strength based innovation proprietary technologies difference local communities current products recommendations health care profes putting others first reminds us sionals premier consumer health pipelines never johnson johnson people transcend care business billion people around whatever challenges come way robust world count consumer products world citizens continually strong balance sheet families make strides enhance sustainability consumer sales growing global facilities packaging year billion growing percent operationally annual report environmentally presence provide despite soft economy operational sales friendly adopted percent critical ingredients increased skin care womens health postconsumer recycled paper inside oral care wound care franchises sustained leadership pages reduced number printed pages growth several product lines including developed online version accessible neutrogena aveeno listerine wwwinvestorjnjcomannualreport splenda innovation iconic brands invite join sustainability cornerstone consumer business efforts electing receive next years launched listerine total care annual report shareholder materials us aveeno nourish hair electronically tearoff card end care among others report provides easytofollow also developed new ways instructions business noteworthy developments include opening first neutrogena store mumbai india expansion commitment shareholders commit skin id online personalized acne solution sold directly johnson johnson leader health care led consumers selling products home shopping channels many firsts health care industry first antiseptic half consumer sales come markets outside bandages first soft disposable contact lenses first united states deep consumer insights local markets coronary stent among others continue leadership relevant product introductions drive global expansion particu tradition well future company deeply larly developing markets recent acquisitions continue fuel committed people serve global growth thriving dabao brand china vania enduring business model strength current expansion snc europe le petit marseillais expanding products pipelines never robust strong beyond french heritage new markets balance sheet growing global presence provide critical ingredients sustained leadership important people changing us health c landscape health care johnson johnson carry companys legacy landscape changed unprecedented pace past inspiration caring passes generation generation years continue evolve employees health care debate unfolds united states reasons remain confident johnson johnson markets johnson johnson supports reform expands access lead health care drive important innovations customers care improves longterm sustainability us health patients achieve longterm superior rates return care system builds best aspects including incentives loyal shareholders medical progress believe appropriate reforms improve patient care create growth opportunities health care companies johnson johnson wellpositioned changing landscape remain focused adding value health care system william c weldon developing programs promote wellness creating better chairman board directors chief executive officer solutions chronic care remain true motivated goal providing meaningful innovations march benefit society citizen w orld care ways change world beyond medical breakthroughs committed people causes need support work hun dreds partners worldwide make lifechanging sustainable differences health care natural disasters strike earthquake haiti work partners provide cash well products across businesses excludes purchased inprocess research development special items philanthropic efforts globally focus saving improving free cash flow defined operating cash flow less capital spending lives women children building health care capacity see reconciliation nongaap financial measures chairmans letter johnson johnson annual report corporate level revisions march chairmans lettermmeeddiiccaall ddeevviicceess ddiiaaggnnoossttiiccss china japan centers training designed serve countrys empowering health care regions unique clinical needs centers designed train professionals around world providers worldwide brazil russia training needed improve patient carean professional education centers help surgeons improve skills important part mdd strategy emerging markets perform advanced surgeries johnson johnson medical innovation institute opened paolo first quarter first johnson johnson institute kind latin america includes surgery rooms equipped latest medical w hile russia needs skilled technology simulators institute train health care physicians meet patient demands professionals year hightech medical procedures institute help health care professionals keep current latest trained perform techniques medical advances enhance medical firstofitskind professional mistakes significant risk says teaching encourage clinical studies education center bringing together olga vereschagina strategic affairs facilitate knowledgesharing much government scientific community director johnson johnson llc says george marques institute international business fill gap addition patients endure director short improve improve health care russia since conventional invasive surgeries standard care latin americans training russian center doctors trained beyond latin america global professional education ive performed perform minimally invasive procedures orthopaedic neurological care laparoscopic operations need advanced surgical advancing thanks depuy institute widespread conditions russia training one greatest barriers llc education training research appendectomies ovarian cysts quality health care russia says center opened raynham mass peritonitis says sergey gorodkov md arman voskertchyan managing director august offer one physicians johnson johnson llc goal programs annually covering trained center ive improved transform professional education latest concepts techniques skills im performing operations help fulfill credo technologies areas minimally quicker greater confidence responsibility health care professionals invasive surgery aging spine deformity center publicprivate patients neurological disease joint replacement partnership ministry russian center kazan percent trauma care health care republic tatarstan study based theory percent commitment professional johnson johnson practice simulators center education long established established record timeless gave opportunity improve united states originated yearand officially opened manual skills im trained take part endosurgery institute cincinnati ohio february president russia complicated laparoscopy interventions depuy institute dmitry medvedev says dr gorodkov centers serve tangible evidence whats significant centers serious setting new standards impact patient care result caring throughout world excellence professional education partnership number high johnson johnson says diana bacciwalsh worldwide vice technology interventions past professional education centers around president professional education two years region alone world including johnson johnson depuy institute llc commitment increased says diabetes institute llc vision continue address unmet airat farrakhov minister health care care institute llc educational clinical needs rapidly republic tatarstan achieve medical devices diagnostics changing health care environment another twofold increment mdd business centers support help lead better patient care next two years organizations desire improve education improved skills dr gorodkov one emerging developed markets physicians trained skills transform care establish innovative partnerships russian center professional historically medical school training government recently centers opened education ive improved skills russia focused lecture rather paulo brazil raynham mass im performing operations quicker applied practice fatal medical sites include germany france india greater confidence says johnson johnson annual reportmedical devices diagnostics breakthrough breast reconstruction new singlesurgery option speeds healing weeks innovation ethicon inc mentor worldwide llc elyssa weintraubs dr downey used flexhd surgery breast accellular dermal matrix donated human dermis allograft cancer summer available exclusively returned ethicon create sling elyssas breast support cheering sons memorygel breast implants sporting events produced mentor johnson johnson stationary bike subsidiary ethicon inc hiking acquired mentor corp leading supplier medical husband products large fast got right back growing aesthetic market swing things says january mentor yearold womens boutique natural fit ethicon leading owner palm desert calif provider suture mesh positive attitude products wide range elyssa diagnosed surgical procedures breast cancer plastic combining forces ethicon surgeon susan downey md mentor aspire facs told trusted global leader good candidate aesthetic medicine breasts reconstructed addition mentor single surgery expands capacity provide mastectomy innovative sciencebased surgeons found nearly broad surgeon community slam dunk solutions restore percent eligible women mentor highly respected nobrainer says elyssa patients appearance self arent told options among plastic surgeons one operation one esteem quality life says important conversa new partnership recovery never experi gary pruden company group tion take place educate doctors patients enced breasts im chairman responsibility woman diagnosed shes make real difference busy woman able ethicon franchise informed choices lives women face get right back family patients know improve quality life says decisions says delia cook business reconstructive options dr downey group product director singlesurgery recon number breast conversation mentor worldwide llc structive option elyssa reconstruction procedures happen surgeons must know two weeks chose possible increased study offer ethicon surgery elyssa returned combined technologies american society plastic distinguished legacy confidence shop bgs johnson johnson annual reportmapping human heart new technology biosense abnormalities fix webster inc giving physicians using procedure known detailed threedimensional ablation view heart treat carto system dangerous cardiac arrhythmias represents significant including atrial fibrillation advance patients physi afib million cians says gerd hindricks people worldwide suffer md head department afib leading cause stroke electrophysiology among people age university leipzig hospital carto system germany accurate launched globally takes maps together physicians visual journey ability visualize catheter heart system guided maps crucial details heart heart chamber enable color real time helping efficiently perform cardiac physicians pinpoint ablation innovation propels hip business years continued hip bearing considered innovation depuy orthopaedics approval us inc market leader hip depuy orthopaedics awaits replacement many parts fdas final decision world pinnacle complete system offer broadest range remains investigational hip bearingsadvanced device limited us law materials ball socket investigational use joint hipof pinnacle complete orthopaedic company says ceramiconmetal bearing randy kilburn vice president marketed countries us marketing depuy outside us since orthopaedics inc surgeons also company significant range launched silent hip options choose minimally invasive hip stem singlesurger option breast cancer diagnosis meet complex clinical available outside us elyssa able mastectomy reconstruction needs patients silent stem single surgeryan option thats possible combined depuy orthopaedics continues inserted femur technologies ethicon mentor business unit pioneer new hip bearings bonepreserving eclectic crucial says provide high stability low traditional stems december look good clothes says elyssa chose advance wear meeting needs depuy orthopaedics elyssa wears colorful breast reconstruction thats growing number active announced acquisition california lifestyle clothes fantastic woman needs patients august us food finsbury orthopaedics ltd sells whats elyssas run business keep drug administration fda united kingdom customers expect see strong selfesteem says dr advisory panel recommended move makes running shop downey helped restore approval pinnacle company largediameter often alone business body return life complete acetabular hip onepiece ceramiconceramic wont prosper unless im quickly system first ceramiconmetal hip bearing johnson johnson annual report medical devices diagnostics hope fight cancer simple test allows doctors personalize care everything happened fast detect changes patients status provides information persons wasnt much prognosis help physicians make information cancer informed patient care decisions asked oncologist easy youll surgery getting blood drawn please order radiationit test id forever grateful says jesica first test came back generic recipe patient one celland anything less five breast cancer says good prognosisthat gave hope jesica harrington enumerating cancer cells breast cancer survivor cellsearch system first jesica pregnant twins diagnostic test automates capture received diagnosis november detection ctcs tumor cells month later lost one detached solid tumors babies underwent mastectomy entered patients blood assesses beginning four rounds ctcs determine prognosis chemotherapy jesica simply wanted overall survival patients know doctors would determine metastatic breast colorectal whether treatment fighting prostate cancer time cancer told hope prayer course treatment enough recalls cleveland clinic ranked jesica pregnant technology used cellsearch oncologist couldnt use usual methods system top medical innovation imaging get diagnostic information predicting significant details prognosis impact health care september beginning treatment jesicas father cellsearch ctc test honored understood daughters need firstever prix galien usa award information fuel hope beating best medical technology prix cancer internet found galien recognizes technical scientific scientist cellular research veridex llc cellsearch circulating clinical research skills necessary progress area driven tumor cell ctc test veridex llc develop innovative medicines drug development needs oncology simple blood test captures devices considered industrys trials identifies counts circulating tumor highest accolade candidates evaluated cellsearch platform used cells patients certain types innovative nature develop joint venture convergence project metastatic cancer used ment applicability technology involves veridex llc centocor combination tests whether discovery ortho biotech inc oncology cellsearch ctc test allows doctor applied future biomedical science pharmaceutical area business also used important academic collabora cellsearch circulating tumor cell test personalizing medicine future tions royal marsden approved demonstrate current goes beyond counting cancer cells toward hospital london memorial sloan line therapy less effective therapy cellsearch using cellsearch platform kettering cancer center new york results imaging results equivalent characterize individual patients tumors two clinical study sites abiraterone assessing transition patients gathering data protein genetic acetate latestage firstinclass nonprogressive disease progressive disease markers says david chianese principle compound treatment prostate johnson johnson annual reportcancer gained acquisition cougar knowledge suppor jesica teacher castle rock colo outspoken biotechnology inc johnson johnson breast cancer survivor results cellsearch circulating tumor cell test jesicas treatment fueled hope beating cancer well support family july friends students girls sported pink hairspray boys shaved pivotal trials abiraterone hair jesica lost acetate weve used cellsearch indicator drug effectiveness says whether medicine right ultimately transform treatment bill hait md phd global therapeutic effective given patient primary cancer head oncology hematology objective pursuit personalized jesica delivered healthy baby boy centocor research development inc medicine partnering drug gunner completed cancer collaborations biomarkers group pharmaceutical treatment remission developing molecular characterizations organization gives us real opportunity looking back jesica felt cancer cells begin define potentially expand capability individuality lost cookbook predictive biomarkers may help cellsearch predict monitor approach cancer treatment identify patients best therapeutic responses says mark carle says talked doctors drug connelly phd director cellular told everyone different ability understand quickly research veridex llc vision said exactly johnson johnson annual report consumer enlightening customers introducing science art beauty helps inform product selection firstofits kind flagship neutrogena store opened mumbai india creating new opportunity consumers walking store see dermatologist confidence products available meet skin care needs says geetanjali shetty md fcps ddv dermatologist works unique setting today role dermatologists assembled come innovative skin extends beyond treating problematic care solutions leveraged across areas educating consumers brands teams first things like sun damage importance stabilize retinol significant antiaging using sunscreen use skin care advance skin care develop regimens bestinclass skin care solutions like dermatologists markets helioplex also known active around world recommending photobarrier complex neutrogena dr shetty says breakthrough sun protection store good platform another example feverfew pfe educating people sciencebased proprietary botanical extract skin care antiinflammatory calming properties three scientists developed innovative skin care neutrogena feverfew pfe recognized says may every claim make along aveeno roc prestigious johnson medal substantiated testing preclinical clean clear among well given annually johnson johnson testing skin cultures invitro work known skin care franchise brands since accomplished researchers studies consumers commit bring science art beauty beauty extraordinary creativity scientific ment delivering innovative skin care science says may achievement work provided new strong shanaa vice president skin care rd scientific information area johnson johnson consumer group inflammation skin aging brought professional relationships clinical companies weve able together science natural health studies shared professionals really bring science art together supplements medical meetings american produce innovative products great skin care researchers academy dermatology meeting held clinical performance well look developed new antiaging alternative march play role forming smell feel thats right leveraged across brands launched important relationships products may explains teams early use technologies developed skin care rd marketing expertise bestinclass slogan rd researchers johnson johnson johnson johnson annual reportin eye beholder feature flagship neutrogena store mumbai india truvu analyzer digital imaging system uses photographs create objective starting point assess skins current condition monitor progress set period time truvu analyzer helps neutrogena educate communicate customers using photos show enhance problematic areas individuals skin companies recommended india welldeveloped professional named marketed directly consumers dermatologists relationships play important role dermatologists novel idea health care professionals connecting consumers heritage professional endorsement relationships integral brands skin care part product messaging key start successful franchise brought learnings success many sales channels ranging products skin care franchise developing relationships says traditional retail settings aveeno founded may today work innovative new channels home mayo clinic colloidal oatmeal dermatologists many different shopping networks online sales even bath provided naturally active levels product development doortodoor sales benefits oats neutrogena soap consumer education driving dermatologists site product company innovation meet consumer needs johnson johnson annual report consumer wholesome skin care thrives new product lines new markets existing products continue provide growth opportunities consumer skin care portfolio expanding brands france le petit marseillais outpacing biggest competi tors thanks year heritage natural ingredients good valueformoney positioning le petit marseillais expanded new markets including belgium switzerland north africa recently greece years refills less aveeno advanced science natural products johnson consumers skin care pioneer active naturals ingredients end brand launched active naturals institute online packaged goods percent total refills often used resource us company must proactively annual johnsons sales promote highvolume value europe aim manage wastethe waste asia pacific region deals consumers increase knowledge results throughout value percent johnsons consumers emerging natural ingredients chain including waste baby washes shampoos markets want smaller quanti skin care consumers generate region ties less initial packaging also brand use products says johnsons refill pouch packs launched new aveeno paulette frank vice toptotoe selffoaming also sold small sizes nourish hair care line president sustainability wash ml refill japan allowing midtier consumers latest active environmental health upgraded include spout buy primary naturals ingredient safety johnson johnson easier opening pouring pack use quality brands nourishing wheat complex consumer group refill pouch usually costs like johnsons accessible august aveeno soothing companies refillable pack fraction comparably sized price points says elkana bath treatment became aging helps us offer sustain bottle helping reduce ezekiel johnsons asia first body care product earn able solution meets consumer costs well pacific marketing director new green good needs consumers environmental impact refill johnson johnson consumer housekeeping seal refills gaining uses less material companies inc november aveeno kicked attractiveness consumers volume sold weighs less packs driving growth partnership particularly asia pacific costs less transport emerging markets like china terracycle give new life region represent developed markets india empty aveeno product johnson johnson annual reporttubes upcycling material ecofriendly items changing demographics increasing population growth rising consumer income provide ideal opportunity neutrogena recently increased focus china india first intro duced china neutrogena relaunched continue impressive tripledigit compound annual growth rate neutrogena launched india supported exciting alternative channelthe brands first flagship store see story cleaner healthier mouth naturally allnatural sweetener use sun crystals help people reduce brand including people listerine brand sweet intake calories diabetes pure cane consistent driver growth carbohydrates still satisfy sugar sun crystals throughout us sweet tooth says marc allnatural sweetener brand successfully launched robinson company group provide small amount listerine total care chairman otcnutritionals calories carbohydrates anticavity mouthwasha two natures wellness prevention per serving three multibenefit mouthwash sweetest plants sun crystals packet packets qualifies free works six ways cleaner contains five calories food diet diabetes source healthier mouth brand provides sweetness two sun crystals also continues expansion ingredients sun teaspoons sugar among first outside us crystals allnatural sweetener mixed products rinsing listerine beverages sprinkled johnson johnson family sweetener newest brand mouthwashes plus food sun crystals companies earn flossing brushing lowcalorie sweetener granulated blend earthwards reach products provides mcneil mcneil nutritionals llc designation earthwards daily essentials introduced september johnson johnson nutritionals llc healthier mouth suitable cooking program encourages makers introduced us baking halfcup provides teams find ways listerine reach march sweetness one cup sugar develop earthfriendly total care introduced stevia plant grown products sun crystals sun crystals limitededition book primarily paraguay brazil achieved earthwards partnered national first sweetener made japan china status product childrens oral health stevia plant used people around delivers sweetness foundation americas world hundreds years using percent less raw pure cane sugar toothfairy encourage better effect bloodsugar material top oral health care children nothing levels entire family competitor johnson johnson annual report pphhaarrmmaacceeuuttiiccaallss high unmet need effective therapies embracing life anew targeting unmet needs alzheimers disease another devastating neurodegenerative disorder treatment gives schizophrenia patient chance diagnosed million people reclaim independence worldwide estimates project number quadruple september johnson johnson completed acquisition substantially assets rights elan corporation plca leading company asako yoshino felt schizophrenia like conducting antibody vaccine research alzheimers diseaserelated blizzard mind today amid cold alzheimers immunotherapy blustering snow northern japan finds program aip aip includes multiple compounds currently evaluation warmth calm fourlegged friend lead compound bapineuzumab schizophrenia symptoms initially approved treatment currently phase iii clinical trialsis control yoshinosan says feel life schizophrenia us evaluated slowing new beginning wish registered countries progression alzheimers disease others suffering condition worldwide yoshinosan well vaccine alzheimers disease also medication administered development aip compounds understanding needs yoshinosan every two weeks developed one million people worldwide collaboration janssen alzheimer suffer schizophrenia disease longacting therapies longacting immunotherapy pfizer inc devastating patients families therapies professionally society presents significant burden administered allow identification collaboration innovation health care systems intervention dose missed biomarkers integrative informatics patients throughout world share patients society benefit brain imaging increasingly important common need drug therapy delaying nonadherencewhich lead researching neurodegenerative time relapse studies show relapseis addressed disorders developing solutions percent unmedicated patients years neuroscience meet patient needs work schizophrenia relapse least franchise committed meeting progress isolation says dr manji within first five years diagnosis patient needs treatment collaborations partnerships must primary reason relapse schizophrenia oncedaily risperdal play crucial role arriving taking medications prescribed risperidone first approved breakthrough solutions yoshinosan diagnosed little significant new option example october years ago hospitalized treating symptoms schizophrenia johnson johnson entered eventually received treatment risperdal consta became strategic collaboration crucell nv medication gave relief first longacting atypical antipsychotic focusing discovery development paranoia voices haunting offering everytwoweek dosing commercialization monoclonal mind fell love got job us food drug admin antibodies vaccines treatment resumed life enjoyed eventually istration granted marketing approval prevention influenza became harder take invega sustenna paliperidone infectious noninfectious diseases medication day prescribed palmitate extendedrelease injectable collaboration provides access relapsed suspension first atypical antipsychotic technology expertise vaccine new experiences oncemonthly maintenance dosing development along pushed edge approved treatment schizophrenia alzheimers disease vaccine program condition worsened says yoshinosan weve succeeded series enable broad vaccine platform gradually began skip taking innovations build strong pursuing best science part medicines heritage longterm commitment innovation strategy continue meet consulted doctor meeting patient needs schizophrenia present future patient needs recommended changing says husseini k manji md frcpc solutions future may require intramuscular injection risperdal global therapeutic area head small large molecules devices consta risperidone neuroscience johnson johnson diagnostics says dr manji granted approval japanese ministry pharmaceutical research development pieces plus willingness health early became llc also continue build strong collaborate experts inside available june risperdal consta programs treat disorders outside company johnson johnson annual reportthe treatment moderate riding painfree doug benson carpenter elko minn severe rheumatoid arthritis enjoys outdoor activities since beginning treatment promise medicine simponi hes able work without pain logged miles snowmobile year methotrexate active psoriatic relief arthritis alone disease affects application submitted methotrexate active estimated million people fda tapentadol ankylosing spondylitis worldwide present extended release er regulatory authorities various forms ranging tablets management canada europe united mild severe disabling moderate severe states simponi marketing approvals chronic pain administered subcutaneously europe united fda approved steady pace regulatory skin month states brazil mexico australia invega sustenna milestones mark using novel autoinjector singapore stelara paliperidone palmitate productive rd efforts prefilled syringe efficacy approved countries first oncemonthly critical future growth safety simponi us food drug atypical antipsychotic meeting needs shown phase iii administration fda treatment schizophrenia doctors nurses patients development program approved nucynta see feature johnson johnson patients tapentadol immediate pharmaceutical operating stelara ustekinumab release tablets first new pipeline robust companies launched multiple firstinclass biologic molecule analgesia expect file several new new products around treatment moderate years relief moderate compounds world including severe plaque psoriasis severe acute pain patients expand core four address significant administered subcutaneously age older nucynta products new indications unmet medical needs every weeks following single molecule different see pharmaceutical simponi golimumab two starter doses psoriasis approach pain relief pipeline chart approved chronic immunerelated december new drug wwwinvestorjnjcom johnson johnson annual reportpharmaceuticals touching prezista applications also pipeline product early european submitted countries remicade infliximab commission approved continues meet health oncedaily dosing mg intelence care needs patients patients prezista darunavir nonnucleoside reverse number inflammatory protease inhibitor transcriptase inhibitor diseases involving lowdose ritonavir part nnrti intelence immune system combination therapy etravirine first medica include chronic severe treatmentnaive adults tion class demonstrate plaque psoriasis moderate previously taken antiviral activity severe rheumatoid global growth market hiv medication approval nnrtiresistant virus nineteen arthritis active psoriatic expansion core brands broadens previous additional countries approved arthritis moderate severe proved successful indication darunavir use intelence crohns disease adults pharmaceutical business treatmentexperienced treatmentexperienced children moderate severe drivers hiv patients patients including brazil ulcerative colitis active several core brands following us food china croatia israel chile ankylosing spondylitis three franchise areas drug administrations intelence approved remicade available infectious disease december approval countries europe countries immunology prezista coadministered middle east africa emea achieved approvals neuroscience see story ritonavir americas asiapacific indications worldwide achieved regula antiretroviral agents remicade used tory milestones broadening treatment hiv infection remicade treat million patient populations pediatric patients age impressive example patients part benefit include lowerdose mg formula strategy address unmet growing immunology prezista darunavir tion prezista pediatric needs investigating portfolio includes intelence etravirine hiv patients introduced seeking approval additional potentially versatile remicade infliximab us february indicationsbuilding compounds pursuing ment commercialization new oncedaily fixed best dose antiretroviral product june tibotec inc science announced collaboration global alliance tb drug development breakthrough solutions accelerate discovery come many sources development new drugs several significant scientific fight tuberculosis among collaborations acquisitions infectious diseases tb evidence pursuit best second common cause science uncover adult deaths worldwide solutions improve may tibotecvirco odds success products virology bvba siemens patients areas high healthcare diagnostics inc unmet needs also see story biomarkers offer insight researchers johnson johnson announced licensing tianjin medical university cancer hospital china pursuing agreement allow best science identify biomarkers could help personalize examples related rd tibotecvirco virology bvba medicine advance cancer treatment efforts oncology develop new research infectious diseases allowing scientists identify cancer disease accounts technology platform assist biomarkers could help percent cancerrelated development johnson johnson personalize medicine deaths united states antivirals treatment tianjin medical university advance cancer treatment see related feature hepatitis c virus hcv cancer hospital china johnson johnson acquired july tibotec million established partnership cougar biotechnology inc pharmaceuticals entered people worldwide infected february hospital july clinical trials license collaboration hcv virus tumor specimens collected way compound agreement gilead lead serious fatal patients catalogued treatment prostate sciences inc develop diseases liver johnson johnson annual report citizenship commitment conservation worldwide efforts reduce water use eliminate water waste show results standing river water flowing natural declining even india social music today becoming rare find religious traditions fostered foothills himalayas says careful use sincere reverence water source northern india achal gupta water thoughtfully protect life parts country among supply future generations waterscarce areas world recalls simpler time allowed around world waterone achal manager environment different kind closeness earths critical resourcesis health safety ehs threat scarcity increasing demand johnson johnson consumer natures vital resource inequitable access lacking quality manufacturing facility baddi one nature achal foothills himalayas short drive johnson johnson consumer facility works moral responsible corporate citizen india committed conserving water leading example says johnson johnson annual reporthimachal pradesh water management efforts oversees include zerodischarge wastewater treatment facilityevery drop treated water reused irrigation toilet flushing rain harvesting began water collected rooftop recharged ground using harvest pit huge amount water monsoon season going directly storm drain wasted says achal decided make use water management efforts contribute enterprisewide water reduction goals place years companys healthy planet goal water use percent absolute reduc tion baseline thanks numerous efforts local level johnson johnson target reach goal end new goals go effect january enterpriselevel goals demanding says radhakrishnan manager environment health safety johnson johnson ltd keeping children mulund india careful review local efforts ensure compliance enterprise standards well free infection community needs efforts made within regions share best practices well understand context combined impact local initiatives additional efforts way include using treated wastewater maintain lawns front fernanda jinotepe nicaragua medication mebendazole donated consumer manufacturing research gets intestinal worms athletic fourth johnson johnson approximately development center mulund grader plays several sports feels listless million worlds atrisk northeastern part mumbai stomach ache feel really tired children treated representing nurture trees planted property dont want eat says fernanda largest health care company donation ethicon facility aurangabad misses school days sometimes vomit targeting sth cww created western india water storage tank fernanda one million children million heal thy active kids installed along piping modifications worldwide age risk infection program children without reduced water pressure cutting soiltransmitted helminths sth worms fernanda learned ways overall consumption even small steps roundworms whipworms hookworms prevent infection sth reminds like installing autoclose taps sinks found mostly tropical subtropical mother chlorinate water helped meanwhile training areas sth caused lack clean runs brother luis scrub lectures water conservation water sanitation intestinal worms hands soap luis drops organized employees especially harmful children mango fernanda washes treated responsibility maintain lead malnutrition anemia stunted water takes another bite environment performing growth impaired cognitive development fernandas physically healthier business efforts meet customers poor school attendance shes knowledgeable doesnt needs says achal developing performance reinfect says mother way future fernandas school participates grissell children generations feel proud us children without worms cww wormfree laughs theyre active commitment actions program provides deworming eat lot dont stop johnson johnson annual report citizenship johnson johnson linking conservation health partnership task force global health first program focus solely global treatment prevention sth terai arc forests nepal provide resources nearly cww partners million people vital survival endangered species governments world wildlife fund wwf partnership johnson johnson united states organizations eight agency international development promotes community conservation improves health countries stop reinfection family services families household biogas plants built provide hygiene education clean cooking fuel also reduces wood use metric tons carbon dioxide emissions access improved tons annually sanitation clean water help people understand links conservation health livelihood must prevention communities says shubash lohani wwf deputy director eastern himalayas projects also component children way kenya democratic republic congo continuously reinfected says kim koporc cww acting director prevention component breaks cycle johnson johnson began donations mebendazole cww bangladesh cameroon uganda zambia cww expanded cambodia cape verde lao peoples democratic republic nicaragua result countries greatly expanded deworming outreach cameroon reaches million school children nicaragua expanded program reach children making difference companys support johnson johnson young lives legacy giving fundamental improving health guided children increasing employees help make difference lives credo responsibility performance school says dr martha reyes director young people johnson johnson communities national immunization bridge employment bte program program nicaragua work ministry health mentors like deborah coburn program enriches lives hundreds partners ultimately cww aims manager sales operations young people go eliminate intestinal worms planning lifescan inc share experiences worldwide make countries currently encourage high school students many different individuals works expand pursue higher education bte partnership lifechanging long donations countries introducing academy term differences vision rid worlds career opportunities educational development children intestinal worms health care reached human health grow play students work alongside students since learn says william lin business colleagues active us colombia learn www director corporate develop critical skills ireland scotland jnjcomourgiving contributions help college expanding brazil czech johnson johnson beyond says deborah republic spain johnson johnson annual report modgnik detinufwwetihwyert ed nomisfirst row committees board william c weldon board chairman board directors directors chief executive officer audit audit committee second row left right comprised entirely mary sue coleman phd independent directors president university michigan helps board oversee james g cullen companys accounting retired president chief reporting practices recom operating officer bell atlantic mends independent public corporation accountants appointment board reviews third row left right performance monitors michael e johns md adequacy internal chancellor emory university accounting practices arnold g langbo procedures controls retired chairman reviews significant changes chief executive officer accounting policies kellogg company fourth row left right james g cullen chairman susan l lindquist phd mary sue coleman phd member former director leo f mullin whitehead institute biomedical research professor biology massachusetts compensation benefits institute technology compensation benefits anne mulcahy committee comprised chairman retired entirely independent chief executive officer directors establishes xerox corporation companys executive compensation philosophy fifth row left right principles approves leo f mullin annual compensation retired chairman longterm incentives chief executive officer companys directors delta air lines inc executive officers william perez committee also reviews senior advisor greenhill co philosophy policies inc retired president nonboard management chief executive officer compensation committee wm wrigley jr company determines manage sixth row left right ment compensation charles prince establishes perquisites chairman sconset group llc compensation policies senior counselor albright nonexecutive employees stonebridge group retired additionally committee chairman chief executive oversees management officer citigroup inc various retirement david satcher md phd pension longterm incentive director center excellence savings health welfare health disparities plans cover director satcher health companys employees leadership institute poussaintsatchercosby chair arnold g langbo chairman mental health morehouse michael e johns md school medicine former william perez us surgeon general charles prince johnson johnson annual report finance general counsel vice corporate officers executive committee finance committee presidents corporate affairs william c weldon executive committee exercises management government affairs policy chairman board directors johnson johnson authority board worldwide operations chief executive officer principal management intervals board chairman executive committee group responsible meetings finance leo f mullin chairman operations allocation committee comprised susan l lindquist phd dominic j caruso resources company chairman board william perez vice president finance committee oversees presiding director david satcher md phd chief financial officer coordinates activities executive committee russell c deyo consumer pharmaceuticals william c weldon chairman clifford e holland stephen j cosgrove medical devices james g cullen brian perkins corporate controller diagnostics business segments ajit shetty phd subsidiary within laverne h council business segments vice president nominating corporate exceptions managed chief information officer governance science technology citizens country nominating corporate science technology russell c deyo located governance committee advisory committee comprised vice president general counsel comprised entirely independent directors executive committee independent directors companys vice president company group responsible overseeing science technology advises colleen goggins chairmen corporate governance matters board scientific worldwide chairman reviewing possible candidates matters including major consumer group roberto de marques board membership internal projects interaction executive committee michael j f del prado recommending nominees academic outside alex gorsky election committee research organizations worldwide chairman joaquin duato also responsible overseeing acquisition technolo medical devices seth h z fischer process performance gies products diagnostics group evaluations board executive committee guy j lebeau md committees additionally david satcher md phd karen licitra committee reviews chairman raymond c jordan companys executive vice president public affairs michael f mahoney mary sue coleman phd succession plans corporate communication michael e johns md patrick mutchler executive resources susan l lindquist phd sherilyn mccoy david norton garry neil md worldwide chairman charles prince chairman pharmaceuticals group michel paul james g cullen executive committee arnold g langbo jacques peeters john papa gary j pruden treasurer public policy marc e robinson brian perkins public policy advisory vice president michael e sneed committee reviews corporate affairs companys policies programs pericles p stamatiades practices public health steven rosenberg kim taylor issues regarding environ secretary ment health safety associate general counsel nicholas j valeriani employees committee jesse j wu also reviews companys governmental affairs policies public policy issues facing company committee advises makes recommendations board issues appropriate public policy advisory committee comprised independent directors companys johnson johnson annual reportcorporategovernanceandmanagementsresponsibility johnsonjohnsonisguidedbythevaluessetforthinourcredo pricewaterhousecoopersllpanindependentregisteredpublic createdbygeneralrobertwoodjohnsonintheseprinciples accountingfirmisengagedtoperformanintegratedauditofour haveguidedusovertheyearsandcontinuetosetthetoneof consolidatedfinancialstatementsandinternalcontroloverfinancial integrityfortheentirecompanyatalllevelstheemployeesof reportingthereportofindependentregisteredpublicaccounting johnsonjohnsonarecommittedtotheethicalprinciplesembod firmisonpage iedinourcredoandtheseprincipleshavebeenwovenintothe theauditcommitteeofourboardofdirectorsiscomposed fabricofthecompany solelyofindependentdirectorswiththefinancialknowledgeand thevaluesarticulatedinourcredoextendtoouraccounting experiencetoprovideappropriateoversightwereviewinternal andfinancialresponsibilitiestojohnsonjohnsonshareholders controlmattersandkeyaccountingandfinancialreportingissues andinvestorswethemanagementofjohnsonjohnsonare withtheauditcommitteeonaregularbasisinadditiontheinde responsiblefortheintegrityandobjectivityoftheaccompanying pendentauditorsthegeneralcounselandthevicepresidentof financialstatementsandrelatedinformationwearealsoresponsi internalauditregularlymeetinprivatesessionswithouraudit bleforensuringthatfinancialdataisreportedaccuratelyandina committeetodiscusstheresultsoftheirworkincludingobserva mannerthatfacilitatestheunderstandingofthisdata tionsontheadequacyofinternalfinancialcontrolsthequality asevidenceofourcommitmenttothisresponsibilitywe offinancialreportingandconfirmationthattheyareproperly maintainawelldesignedsystemofinternalaccountingcontrols dischargingtheirresponsibilitiesandotherrelevantmatters encouragestrongandeffectivecorporategovernancefromour ourexecutivecommitteeiscontinuouslyinvolvedinthe boardofdirectorscontinuouslyreviewourbusinessresultsand reviewoffinancialresultsaswellasdevelopingandunderstanding strategicchoicesandfocusonfinancialstewardship strategiesandkeyinitiativesforlongtermgrowthourintentisto ourcorporatestaffofprofessionallytrainedinternalauditors ensurethatwemaintainobjectivityinourbusinessassessments whotravelworldwidemonitoroursystemofinternalaccounting constructivelychallengetheapproachtobusinessopportunitiesand controlsdesignedtoprovidereasonableassurancethatassetsare issuesandmonitorourbusinessresultsandtherelatedcontrols safeguardedandthattransactionsandeventsarerecordedproperly ourconsolidatedfinancialstatementsandfinancialdatathat ourinternalcontrolsincludeselfassessmentsandinternalreviews followhavebeenpreparedinconformitywithaccountingprinciples ofouroperatingcompanies generallyacceptedintheunitedstatesofamericaandinclude duringthecompanycontinuedtoinvestsignificanttime amountsthatarebaseduponourbestjudgmentswearecommit andresourcesinordertoensurecompliancewithsectionof tedtopresentanddiscussresultsofoperationsinaclearand thesarbanesoxleyactofbasedontheworkperformedwe transparentmannerinordertoprovidetimelycomprehensiveand haveconcludedthatourinternalcontroloverfinancialreporting understandableinformationtoourshareholders waseffectiveasofjanuarywereferyoutomanagements reportoninternalcontroloverfinancialreportingonpage werequirethemanagementteamsofouroperatingcompa niestocertifytheircompliancewithourpolicyonbusinessconduct whichsetsforththecompanyscommitmenttoconductitsbusi nessaffairswithintegrityandcomplywiththegoverninglaws andregulationswehaveasystematicprogramdesignedto ensurecompliancewiththesepoliciesandprovidemeansof williamcweldon dominicjcaruso reportinganyconcernsaboutviolationsofthepolicytoview chairmanboardof vicepresidentfinance ourpolicyonbusinessconductpleasevisitourwebsiteat directorsandchief andchieffinancialofficer wwwinvestorjnjcomgovernanceconductcfm executiveofficer tableofcontents managementsdiscussionandanalysis auditedconsolidatedfinancialstatements organizationandbusinesssegments consolidatedbalancesheets resultsofoperations consolidatedstatementsofearnings analysisofsalesbybusinesssegments consolidatedstatementsofequity analysisofconsolidatedearningsbeforeprovisionfor consolidatedstatementsofcashflows taxesonincome notestoconsolidatedfinancialstatements liquidityandcapitalresources reportofindependentregisteredpublicaccountingfirm otherinformation managementsreportoninternalcontrolover cautionaryfactorsthatmayaffectfutureresults financialreporting supportingschedules summaryofoperationsandstatisticaldata shareholderreturnperformancegraphs reconciliationofnongaapfinancialmeasures johnson johnson annual report managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition organizationandbusinesssegments managementsobjectives aprimaryobjectiveofthecompanyistoachievesuperiorlevelsof descriptionofthecompanyandbusinesssegments capitalefficientprofitablegrowthtoaccomplishthisthecom johnsonjohnsonanditssubsidiariesthecompanyhave panysmanagementoperatesthebusinessconsistentwithcertain approximatelyemployeesworldwideengagedinthe strategicprinciplesthathaveprovensuccessfulovertimetothis researchanddevelopmentmanufactureandsaleofabroadrangeof endthecompanyparticipatesingrowthareasinhumanhealthcare productsinthehealthcarefieldthecompanyconductsbusinessin andiscommittedtoattainingleadershippositionsinthesegrowth virtuallyallcountriesoftheworldwiththeprimaryfocusonproducts areasthroughthedevelopmentofinnovativeproductsandservices relatedtohumanhealthandwellbeing newproductsintroducedwithinthepastfiveyearsaccountedfor thecompanyisorganizedintothreebusinesssegments approximatelyofsalesinbillionorof consumerpharmaceuticalandmedicaldevicesanddiagnostics saleswasinvestedinresearchanddevelopmentthisinvestment theconsumersegmentincludesabroadrangeofproductsusedin reflectsmanagementscommitmenttotheimportanceofongoing thebabycareskincareoralcarewoundcareandwomenshealth developmentofnewanddifferentiatedproductsandservicesto carefieldsaswellasnutritionalandoverthecounterpharmaceuti sustainlongtermgrowth calproductstheseproductsaremarketedtothegeneralpublic withmorethanoperatingcompanieslocatedin andsoldbothtoretailoutletsanddistributorsthroughouttheworld countriesthecompanyviewsitsprincipleofdecentralizedman thepharmaceuticalsegmentincludesproductsinthefollowing agementasanassetandfundamentaltothesuccessofabroadly therapeuticareasantiinfectiveantipsychoticcardiovascularcon basedbusinessitalsofostersanentrepreneurialspiritcombining traceptivedermatologygastrointestinalhematologyimmunology theextensiveresourcesofalargeorganizationwiththeabilityto neurologyoncologypainmanagementurologyandvirologythese reactquicklytolocalmarketchangesandchallenges productsaredistributeddirectlytoretailerswholesalersandhealth thecompanyiscommittedtodevelopingglobalbusinesslead careprofessionalsforprescriptionusethemedicaldevicesand erswhocandrivegrowthobjectivesbusinessesaremanagedforthe diagnosticssegmentincludesabroadrangeofproductsusedprin longterminordertosustainleadershippositionsandachievegrowth cipallyintheprofessionalfieldsbyphysiciansnursestherapists thatprovidesanenduringsourceofvaluetoourshareholders hospitalsdiagnosticlaboratoriesandclinicstheseproducts unifyingthemanagementteamandthecompanysdedicated includecordiscirculatorydiseasemanagementproductsdepuys employeesinachievingtheseobjectivesisourcredoourcredo orthopaedicjointreconstructionspinalcareandsportsmedicine providesacommonsetofvaluesandservesasaconstantreminder productsethiconssurgicalcareaestheticsandwomenshealth ofthecompanysresponsibilitiestoitscustomersemployeescom productsethiconendosurgerysminimallyinvasivesurgicalprod munitiesandshareholdersthecompanybelievesthatthesebasic uctslifescansbloodglucosemonitoringandinsulindelivery principlesalongwithitsoverallmissionofimprovingthequality productsorthoclinicaldiagnosticsprofessionaldiagnostic oflifeforpeopleeverywherewillenablejohnsonjohnsonto productsandvistakonsdisposablecontactlenses continuetobeamongtheleadersinthehealthcareindustry thecompanysstructureisbasedupontheprincipleof decentralizedmanagementtheexecutivecommitteeof resultsofoperations johnsonjohnsonistheprincipalmanagementgroupresponsible fortheoperationsandallocationoftheresourcesofthecompany analysisofconsolidatedsales thiscommitteeoverseesandcoordinatestheactivitiesofthe inworldwidesalesdecreasedtobillioncompared consumerpharmaceuticalandmedicaldevicesanddiagnostics toincreasesofinandinthesesales businesssegments changesconsistedofthefollowing inallofitsproductlinesthecompanycompeteswithcompa niesbothlocalandgloballocatedthroughouttheworldcompeti salesdecreaseincreasedueto volume tionexistsinallproductlineswithoutregardtothenumberandsize ofthecompetingcompaniesinvolvedcompetitioninresearch price involvingthedevelopmentandtheimprovementofnewandexisting currency productsandprocessesisparticularlysignificantthedevelopment total ofnewandinnovativeproductsisimportanttothecompanyssuc cessinallareasofitsbusinessthisalsoincludesprotectingthe salesbyuscompanieswerebillioninbillionin companysportfolioofintellectualpropertythecompetitiveenvi andbillioninthisrepresentsadecreaseof ronmentrequiressubstantialinvestmentsincontinuingresearchand inadecreaseofinandanincreaseofin inmaintainingsalesforcesinadditionthedevelopmentandmain salesbyinternationalcompanieswerebillionin tenanceofcustomerdemandforthecompanysconsumerproducts billioninandbillioninthisrepresentsa involvessignificantexpendituresforadvertisingandpromotion decreaseofinandincreasesofandin andrespectively johnson johnson annual reportusand salesby internationalsales segment foryears inbillionsofdollars inbillionsofdollars consumer us pharmaceutical international medicaldevices anddiagnostics thefiveyearcompoundannualgrowthratesforworldwide analysisofsalesbybusinesssegments usandinternationalsaleswereandrespec consumersegment tivelythetenyearcompoundannualgrowthratesforworldwide consumersegmentsalesinwerebillionadecreaseof usandinternationalsaleswereandrespectively fromwithofthischangeduetooperationalgrowth andnegativecurrencyimpactofusconsumersegment salesby saleswerebillionadecreaseofinternationalsaleswere geographic billionadecreaseofwithgrowthofachievedby region operationsandadecreaseofresultingfromthenegative inbillionsofdollars impactofcurrencyfluctuations us theoverthecounterotcpharmaceuticalsandnutritionals europe franchisesaleswerebillionadecreaseoffrom westernhemisphere thiswasprimarilyduetothenegativeimpactofcurrencyandlower excludingus asiapacificafrica salesoftheoverthecounterzyrtecallergyproductlinerelated totheinitialbuildofinventorybythetradeduringthelaunch yearthiswaspartiallyoffsetbysalesgrowthinthesplenda sweetenerproductlinetheusfoodanddrugadministration fdaiscurrentlyconsideringcertainrecommendationsmadeby itsadvisorycommitteeforreducingthepotentialforoverdosewith salesineuropeexperiencedadeclineofincludingopera acetaminophentheactiveingredientintylenolbrandproducts tionalgrowthofandanegativeimpactfromcurrencyof thecompanyhasprovidedthefdawithitsownrecommendations salesinthewesternhemisphereexcludingtheusexperienceda andwillcontinuetobeactivelyengagedwiththefdaonthistopic declineofincludingoperationalgrowthofandanegative indecemberthecompanyannouncedavoluntaryrecall impactfromcurrencyofsalesintheasiapacificafricaregion ofalllotsoftylenolarthritispaincountwithezopencap achievedgrowthofincludingoperationalgrowthofand followingreportsofanuncharacteristicsmellhowevertherewas anincreaseofrelatedtothepositiveimpactofcurrency aninsignificantimpactonsalesinjanuarythecompanyhas inandthecompanydidnothaveacus undertakenabroadervoluntaryrecalloftylenolandcertain tomerthatrepresentedormoreoftotalconsolidatedrevenues otcproductsasaprecautionaryaction resultsbenefitedfromtheinclusionofardweek theskincarefranchisesalesgrewbytobillionin seenotetotheconsolidatedfinancialstatementsforannual thesalesgrowthwasprimarilyduetotheaveeno closingdatedetailsthecompanyestimatedthatthefiscalyear neutrogenaanddabaoskincarelinesthebabycarefranchise growthratewasenhancedbyapproximatelywhile saleswerebillionadecreaseofprimarilyduetothe theadditionalweekaddedafewdaystosalesitalsoaddedafull negativeimpactofcurrencyandlowersalesforbabycentercomasa weeksworthofoperatingcoststhereforethenetearningsimpact resultofexitingtheonlineretailbusinesspartiallyoffsetbygrowth wasnegligible inthehaircareproductlinethewomenshealthfranchisesales werebillionadecreaseofprimarilyduetothenegative impactofcurrencypartiallyoffsetbyincreasedsalesassociated withtheacquisitionofajointventurepartnerinfranceinthefiscal majorconsumerfranchisesales change dollarsinmillions vs vs otcpharmaceuticalsnutritionals skincare babycare womenshealth oralcare woundcareother total managements discussion analysis results operations financial condition firstquarterofpriortotheacquisitionofthejointventure risperdalconstainjapanearlierintheyear partnersalesbythejointventurewerenotrecordedaspartofthe concertamethylphenidatehclaproductforthetreat companyssalestocustomerstheoralcarefranchisesaleswere mentofattentiondeficithyperactivitydisorderadhdachieved billionadecreaseofduetosoftnessinthecategoryinthe salesofbillioninrepresentinganincreaseofover uspartiallyoffsetbygrowthoflisterinemouthwashoutside salesresultsinwerefavorablyimpactedbyapproxi theusthewoundcareotherfranchisesalesgrewbyto matelymillionrelatedtoachangeintheestimateofaccrued billionprimarilyduetotherecentacquisitionsinthewellness salesreservesrelatedtosalesoutsidetheusalthoughtheoriginal andpreventionplatformandstrongsalesofpurellhandsanitizer concertapatentexpiredinthefdahasnotapprovedany consumersegmentsalesinwerebillionan genericversionthatissubstitutableforconcertapartieshave increaseofoverwithofthischangedueto filedabbreviatednewdrugapplicationsandasforgenericver operationalgrowthandtheremainingduetopositivecurrency sionsofconcertawhicharependingandmaybeapprovedat fluctuationsusconsumersegmentsaleswerebillionan anytimeanapprovalwouldleadtoalossofexclusivityandislikely increaseofinternationalsaleswerebillionanincreaseof toresultinasignificantreductioninsales withasaresultofoperationsandduetocurrency topamaxtopiramaterisperdalrisperidoneand fluctuationsover duragesicfentanyltransdermalfentanyltransdermalsystem experiencedsalesdeclinesinofand pharmaceuticalsegment respectivelyversustheprioryearduetogenericcompetitionmar pharmaceuticalsegmentsalesinwerebilliona ketexclusivityintheusexpiredfortopamaxtopiramatein decreaseoffromwithanoperationaldeclineof marchrisperdaloralinjuneandduragesicin andtheremainingduetothenegativeimpactofcurrencyfluc january tuationsussaleswerebillionadecreaseofinterna aciphexparietrabeprazolesodiumexperienceda tionalsaleswerebillionadecreaseofwhichincluded salesdeclineofduetocompetitioninthecategory operationalgrowthandadecreaseofresultingfromthe inotherpharmaceuticalsaleswerebillionrepre negativeimpactofcurrencyfluctuations sentingagrowthofovertheprioryearcontributorstothe remicadeinfliximababiologicapprovedforthetreat increaseweresalesofvelcadebortezomibaproductforthe mentofanumberofimmunemediatedinflammatorydiseases treatmentofmultiplemyelomaprezistadarunavirforthe achievedsalesofbillioninwithgrowthofover treatmentofhivaidspatientsintelenceetravirineforhiv theprioryearprimarilyattributabletostrongoverallmarketgrowth combinationtherapyandinvegapaliperidoneaoncedaily remicadeiscompetinginamarketwhichisexperiencing atypicalantipsychoticthegrowthwaspartiallyoffsetbytheimpact increasedcompetitionduetonewentrantsandtheexpansionof ofagenericversionoforthotricyclenloshippedbya indicationsforexistingcompetitors competitorsubsequentlythegenericmanufacturerrecognized procritepoetinalfaandeprexepoetinalfahadcom thevalidityofthepatentpaiddamagesforitsinfringingsalesand binedsalesofbillioninadeclineofcomparedto ceasedfurthershipmentsoftheproduct theprioryearlowersalesofprocritandeprexweredueto duringthecompanyreceivedregulatoryapprovalfor thedecliningmarketsforerythropoiesisstimulatingagentsesas severalnewmolecularentitiesnmesincludingstelara levaquinlevofloxacinfloxinofloxacinsaleswere ustekinumabintheusandeuropeanunioneuforthetreat billionadeclineofversustheprioryearduetocompeti mentofmoderatetosevereplaquepsoriasisinvega tioninthecategorythepatentforlevaquinlevofloxacinin sustennapaliperidonepalmitateextendedreleaseinjectable theuswillexpireindecemberapediatricextensionwas suspensionintheusfortheacuteandmaintenancetreatmentof grantedbythefdawhichextendsmarketexclusivityintheus schizophreniasimponigolimumabintheusandeuforthe throughjunetheexpirationoftheproductpatentorlossof treatmentofmoderatetosevereactiverheumatoidarthritisra marketexclusivityislikelytoresultinasignificantreductioninsales activeandprogressivepsoriaticarthritispsaandsevereactive risperdalconstarisperidonealongactinginjectable ankylosingspondylitisasandpriligydapoxetineinseveral forthetreatmentofschizophreniaachievedsalesofbillionin countriesfortheondemandtreatmentofprematureejaculation representinganincreaseofascomparedtotheprior nucyntatapentadolimmediatereleasetabletsforrelief yearthegrowthwasduetoapositiveshiftfromdailytherapiesto ofmoderatetosevereacutepainwasalsolaunchedintheus longeractingrisperdalconstaandthelaunchof majorpharmaceuticalproductrevenues change dollarsinmillions vs vs remicadeinfliximab procriteprexepoetinalfa levaquinfloxinlevofloxacinofloxacin risperdalconstarisperidone concertamethylphenidatehcl topamaxtopiramate aciphexparietrabeprazolesodium risperdalrisperidone duragesicfentanyltransdermalfentanyltransdermalsystem otherpharmaceuticals total johnson johnson annual reportthecompanyalsoreceivedapprovalsexpandingtheindica salesinthecordisfranchisewerebillionadeclineof tionsforseveralkeyproductsincludinginvegapaliperidone versustheprioryearthedeclinereflectslowersalesofthe extendedreleasetabletsintheusfortheacutetreatmentof cyphersirolimuselutingcoronarystentduetoincreasedglobal schizoaffectivedisorderrisperdalconstarisperidone competitionthedeclinewaspartiallyoffsetbygrowthofthe longactingtreatmentintheusasbothmonotherapyandadjunc biosensewebsterbusiness tivetherapytolithiumorvalproateinthemaintenancetreatmentof thevisioncarefranchiseachievedsalesofbillionin bipolaridisorderaswellasforthetreatmentofschizophreniain aincreaseoverprioryearprimarilyrelatedtogrowth japanprezistadarunavirintheeuwithlowdoseritonaviras intheastigmaticcontactlensproductlineoffsetbythenegative partofcombinationtherapyintreatmentnaveadultsaswellasfor impactofcurrency treatmentexperiencedpediatricpatientswithhiv salesinthediabetescarefranchisewerebillionin thecompanysubmittedanewdrugapplicationndatothe adeclineofversustheprioryeardeclinesinthelifescan fdafortapentadolextendedreleaseertabletsaninvestigational productlinewerepartiallyoffsetbygrowthoftheanimasinsulin oralanalgesicforthemanagementofmoderatetoseverechronic deliverybusinessresultingfromnewproductlaunchesand paininpatientsyearsofageorolderinadditionthecompany continueddevelopmentininternationalmarkets alsoinvestedinanumberofnewplatformsforgrowthinoncology theorthoclinicaldiagnosticsfranchiseachievedsalesof alzheimersdiseaseandvaccinesforthetreatmentandprevention billioninaincreaseovertheprioryearprimarilyattrib ofinfluenzaandotherinfectiousandnoninfectiousdiseases utabletotherecentlaunchofthevitrosandanalyzers pharmaceuticalsegmentsalesinwerebilliona themedicaldevicesanddiagnosticssegmentachievedsales decreaseoffromwithanoperationaldeclineofand ofbillioninrepresentinganincreaseofoverthe increaseduetothepositiveimpactofcurrencyfluctuations prioryearwithoperationalgrowthofandduetoaposi uspharmaceuticalsegmentsaleswerebillionadecreaseof tiveimpactfromcurrencyfluctuationsussaleswerebillion internationalpharmaceuticalsegmentsaleswerebillion anincreaseofinternationalsaleswerebillionan anincreaseofwhichincludedofoperationalgrowthand increaseofwithfromoperationsandapositive relatedtothepositiveimpactofcurrencyfluctuations currencyimpactof medicaldevicesanddiagnosticssegment analysisofconsolidatedearnings themedicaldevicesanddiagnosticssegmentachievedsalesof beforeprovisionfortaxesonincome billioninrepresentinganincreaseofovertheprior yearwithoperationalgrowthofandanegativecurrency consolidatedearningsbeforeprovisionfortaxesonincome impactofussaleswerebillionanincreaseof decreasedbybilliontobillioninascomparedtothe overtheprioryearinternationalsaleswerebillionadecrease billionearnedinadecreaseofthedecreasewas ofwithgrowthoffromoperationsandadecreaseof primarilyrelatedtolowersalesthenegativeimpactofproduct resultingfromthenegativeimpactofcurrencyfluctuations mixlowerinterestincomeduetolowerratesofinterestearnedand thedepuyfranchiseachievedsalesofbillionina restructuringchargesofbillionthiswaspartiallyoffsetby increaseovertheprioryearthiswasprimarilyduetogrowth lowersellingmarketingandadministrativeexpensesduetocost inthespinehipandkneeproductlinesadditionallynewproduct containmenteffortsacrossallthebusinessesincludedpur launchesinthemiteksportsmedicineproductlinecontributedto chasedinprocessresearchanddevelopmentiprdchargesof thegrowth billionandincreasedinvestmentspendinginsellingmarketing theethiconendosurgeryfranchiseachievedsalesofbil andadministrativeexpensesutilizedfromtheproceedsassociated lioninaincreaseovertheprioryearthiswasattributable withthedivestitureoftheprofessionalwoundcarebusinessof togrowthintheendoscopyharmonicensealandadvanced ethiconinctheincreaseinofoverthebillion sterilizationproductlines inwasprimarilyduetoloweriprdchargesofbil theethiconfranchiseachievedsalesofbillionina liongainsfromdivestituresofbillionandhigherlitigation increaseovertheprioryearthiswasattributabletogrowthin gainsofbillionversusrestructuringchargesofbillion thesuturesbiosurgicalandmeshproductlinesinadditiontosales andthewritedownofthenatrecorintangibleassetof ofnewlyacquiredproductsfromtheacquisitionsofomrixbiophar billionrecordedinasapercenttosalesconsolidated maceuticalsincandmentorcorporationthegrowthwaspartially earningsbeforeprovisionfortaxesonincomeinwas offsetbythedivestitureoftheprofessionalwoundcarebusinessof versusin ethiconincinthefiscalfourthquarterof majormedicaldevicesanddiagnosticsfranchisesales change dollarsinmillions vs vs depuy ethiconendosurgery ethicon cordis visioncare diabetescare orthoclinicaldiagnostics total prioryearamountshavebeenreclassifiedtoconformtocurrentpresentation managements discussion analysis results operations financial condition thesectionsthatfollowhighlightthesignificantcomponents incostofproductssoldasapercenttosalesremained ofthechangesinconsolidatedearningsbeforeprovisionfortaxes flattotheprioryearthechangeinthemixofbusinesseswith onincome highersalesgrowthintheconsumerbusinessandaslightsales declineinthepharmaceuticalbusinesshadanegativeimpacton costofproductssoldandsellingmarketingandadministrative thecostofproductssoldasapercenttosalesinthiswasoff expensescostofproductssoldandsellingmarketingand setbymanufacturingefficienciesandnonrecurringpositiveitems administrativeexpensesasapercenttosaleswereasfollows inandnegativeitemsintherewasanincreaseinthe ofsales percenttosalesofsellingmarketingandadministrativeexpensesin costofproductssold primarilyduetothechangeinthemixofbusinesseswhereby percentpointincreaseovertheprioryear agreaterproportionofsaleswereattributabletotheconsumer segmentwhichhashighersellingmarketingandadministrative sellingmarketingandadministrativeexpenses spendingadditionallyinthecompanyutilizedthegainasso percentpointdecreaseincreaseoverthe ciatedwiththedivestitureoftheprofessionalwoundcarebusiness prioryear ofethiconinctofundincreasedinvestmentspendingthiswas incostofproductssoldasapercenttosalesincreased partiallyoffsetbyongoingcostcontainmentefforts primarilyduetothecontinuednegativeimpactofproductmixand intherewasanincreaseinthepercenttosalesofcostof inventorywriteoffsassociatedwiththerestructuringactivityaddi productssoldprimarilyduetotheimpactofnewlyacquiredcon tionallyincludedsomenonrecurringpositiveitemstherewas sumerbrandstherewasanincreaseinthepercenttosalesofsell adecreaseinthepercenttosalesofsellingmarketingandadminis ingmarketingandadministrativeexpensesinprimarilydueto trativeexpensesinprimarilyduetocostcontainmentefforts theimpactofnewlyacquiredconsumerbrandspartiallyoffsetby acrossallthebusinessesandtheannualizedsavingsrecognizedfrom costcontainmentefforts therestructuringprogramadditionallyutilizedthe proceedsassociatedwiththedivestitureoftheprofessionalwound carebusinessofethiconinctofundincreasedinvestmentspending researchanddevelopmentexpenseexcludingpurchasedinprocessresearchanddevelopmentchargesbysegment ofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevicesanddiagnostics totalresearchanddevelopmentexpense percentdecreaseincreaseovertheprioryear asapercenttosegmentsales researchanddevelopmentexpenseresearchanddevelopment capitalizedandtestedforimpairmentthecompanycapitalized activitiesrepresentasignificantpartofthecompanysbusiness billionofiprdinprimarilyassociatedwiththeacquisi theseexpendituresrelatetothedevelopmentofnewproducts tionsofcougarbiotechnologyincandsubstantiallyalloftheassets improvementofexistingproductstechnicalsupportofproducts andrightsofelansimmunotherapyprogram andcompliancewithgovernmentalregulationsfortheprotection inthecompanyrecordedachargeforiprdofmil ofconsumersandpatients lionbeforeandaftertaxrelatedtotheacquisitionsofamicab inandthereductioninthepharmaceutical surgrxinchealthmediaincandomrixbiopharmaceuticalsinc researchanddevelopmentspendingwasprimarilyduetoincreased healthmediaincaprivatelyheldcompanythatcreateswebbased efficienciesinpharmaceuticalresearchanddevelopmentactivities behaviorchangeinterventionsaccountedformillionbeforetax oftheiprdchargesandwasincludedintheoperatingprofitof restructuringinthecompanyannouncedglobalrestruc theconsumersegmenttheiprdchargesforallofthefollowing turinginitiativesthatareexpectedtogeneratepretaxannualcost acquisitionswereincludedintheoperatingprofitofthemedical savingsofbillionwhenfullyimplementedinwith devicesanddiagnosticssegmentamicabaswedishdeveloper billionexpectedtobeachievedintheassociated ofinvitrodiagnostictechnologiesforuseinpointofcareand savingswillprovideadditionalresourcestoinvestinnewgrowth nearpatientsettingsoutsidethephysicalfacilitiesoftheclinical platformsensurethesuccessfullaunchofthecompanysmany laboratoryaccountedformillionbeforetaxoftheiprd newproductsandcontinuedgrowthofthecorebusinessesand chargessurgrxincaprivatelyhelddeveloperoftheadvanced provideflexibilitytoadjusttothechangedandevolvingglobalenvi bipolartissuesealingsystemusedintheensealfamilyofdevices ronmentinthefiscalfourthquarterofthecompanyrecorded accountedformillionbeforetaxoftheiprdchargesomrixbio apretaxchargeofbillionofwhichmillionisincludedin pharmaceuticalsincafullyintegratedbiopharmaceuticalcompany costofproductssold thatdevelopsandmarketsbiosurgicalandimmunotherapyprod therestructuringprogramannouncedinhasbeencom uctsaccountedformillionbeforetaxoftheiprdcharges pletedseenotetotheconsolidatedfinancialstatementsfor inthecompanyrecordedachargeforiprdof additionaldetailsrelatedtotherestructuring millionbeforeandaftertaxrelatedtotheacquisitionofconor purchasedinprocessresearchanddevelopmentinin medsystemsinctheiprdchargewasincludedintheoperating accordancewithusgaapforbusinesscombinationspurchasedin profitofthemedicaldevicesanddiagnosticssegment processresearchanddevelopmentiprdisnolongerexpensedbut johnson johnson annual reportotherincomeexpensenetotherincomeexpensenet chargesofmillionandmillionforthenatrecor includesgainsandlossesrelatedtothesaleandwritedownofcer intangibleassetwritedownrecordedin taininvestmentsinequitysecuritiesheldbyjohnsonjohnson medicaldevicesanddiagnosticssegmentintheoperating developmentcorporationgainsandlossesonthedisposalof profitinthemedicaldevicesanddiagnosticssegmentincreased propertyplantandequipmentcurrencygainsandlossesnon fromtheimprovedoperatingprofitwasdueto controllinginterestslitigationsettlementsandliabilitiesandroyalty milliongainfromnetlitigationsettlementsfavorableproductmix incometheunfavorablechangeofbillioninotherincome manufacturingefficienciesandcostcontainmentinitiativesrelated expensenetfromtowasprimarilyduetoagainof tosellingmarketingandadministrativeexpensesthiswaspartially billionfromthedivestitureoftheprofessionalwoundcare offsetbymillioninrestructuringchargesintheoperat businessofethiconincin ingprofitinthemedicaldevicesanddiagnosticssegmentincreased inotherincomeexpensenetincludedincomefrom fromtheimprovedoperatingprofitwastheresultof netlitigationsettlementsandawardsofbillionandagainof themilliongainfromnetlitigationsettlementsfavorableprod billionfromthedivestitureoftheprofessionalwoundcare uctmixmanufacturingefficienciesandloweriprdchargesof businessofethiconincinotherincomeexpensenet millioninversusmillioninadditionally includedachargeofbillionbeforetaxrelatedtothe millionofrestructuringchargeswererecordedin natrecorintangibleassetwritedown interestincomeexpenseinterestincomeindecreasedby operatingprofitbysegment millionduetolowerratesofinterestearneddespitehigher operatingprofitsbysegmentofbusinesswereasfollows averagecashbalancesthecashbalanceincludingmarketable securitieswasbillionattheendofandaveraged percentof billionascomparedtothebillionaveragecashbalance segmentsales intheincreaseintheaveragecashbalancewasprimarily dollarsinmillions duetocashgeneratedfromoperatingactivities consumer interestexpenseinincreasedbymillionduetoahigher pharmaceutical debtbalancethenetdebtbalanceattheendofwasbil meddevicesanddiagnostics lionascomparedtobillionattheendofthehigheraver total agedebtbalanceofbillioninversusbillionin lessexpensesnotallocated wasprimarilyrelatedtofundingacquisitionsandinvestmentsand tosegments thepurchaseofthecompanyscommonstockundertheongoing earningsbeforeprovision commonstockrepurchaseprogramannouncedonjuly fortaxesonincome interestincomeindecreasedbymillionduetolower seenotetotheconsolidatedfinancialstatementsformoredetails ratesofinterestearneddespitehigheraveragecashbalancesthe amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrolling cashbalanceincludingmarketablesecuritieswasbillionat interestsandgeneralcorporateincomeexpense theendofandaveragedbillionascomparedtothe billionaveragecashbalanceintheincreaseinthe averagecashbalancewasprimarilyduetocashgeneratedfrom operatingactivities interestexpenseinincreasedbymillionduetoa higherdebtbalanceinthesecondhalfofthecompanycon vertedsomeofitsshorttermdebttofixedlongtermdebtathigher interestratesthenetdebtbalanceattheendofwasbil lionascomparedtobillionattheendofthehigherdebt balanceinwasprimarilyduetothepurchaseofthecompanys commonstockundertheongoingcommonstockrepurchase programannouncedonjulyandtofundacquisitions interestincomeindecreasedbymilliondueto loweraveragecashbalancesthedeclineintheaveragecash balancewasprimarilyduetotheacquisitionoftheconsumer consumersegmentinconsumersegmentoperatingprofit healthcarebusinessofpfizerincondecember decreasedfromtheprimaryreasonsforthedecreasein interestexpenseinincreasedbymillionascom operatingprofitwasmillionofrestructuringchargespartially paredtoprioryearduetoahigheraveragedebtbalancethenet offsetbycostcontainmentinitiativesininconsumer debtbalanceattheendofwasbillionascomparedto segmentoperatingprofitincreasedfromcostsyner billionattheendofthehigherdebtbalancein gieslowerintegrationcostsinrelatedtotheacquisitionofthe wasduetothedebtassociatedwiththeacquisitionofthecon consumerhealthcarebusinessofpfizerincandothercostcon sumerhealthcarebusinessofpfizerincandthecommonstock tainmentinitiativescontributedtotheincreasedoperatingprofit repurchaseprogramannouncedin provisionfortaxesonincometheworldwideeffectiveincometax pharmaceuticalsegmentinpharmaceuticalsegmentoper ratewasininandinthe atingprofitdecreasedfromtheprimaryreasonsfor taxratedecreasedascomparedtoduetoincreasesin thedecreaseinoperatingprofitweremillionofrestructuring taxableincomeinlowertaxjurisdictionsrelativetotaxableincome chargesmillionoflitigationexpenseandnegativeproduct inhighertaxjurisdictionsthetaxrateincreasedascompared mixduetothelossofmarketexclusivityfortopamaxand toduetoincreasesintaxableincomeinhighertaxjurisdic risperdaloralinpharmaceuticalsegmentoperating tionsrelativetotaxableincomeinlowerjurisdictionsinadditionthe profitincreasedfromtheprimarydriverofthe improvedoperatingprofitinwasduetotherestructuring managements discussion analysis results operations financial condition taxratebenefitedfromaonetimegainofmillionrelated swapcontractsbyapproximatelymillionineitherscenario toabusinessrestructuringofcertaininternationalsubsidiaries atmaturitythegainorlossontheswapcontractwouldbeoffsetby thegainorlossontheunderlyingtransactionandthereforewould liquidityandcapitalresources havenoimpactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfor liquiditycashflows tradingorspeculativepurposesfurtherthecompanyhasapolicy cashandcashequivalentswerebillionattheendof ofonlyenteringintocontractswithpartiesthathaveatleastana ascomparedwithbillionattheendoftheprimary orequivalentcreditratingthecounterpartiestothesecontracts sourcesofcashthatcontributedtothebillionincreaseversus aremajorfinancialinstitutionsandthereisnosignificantconcentra prioryearwerebillionofcashgeneratedfromoperatingactivi tionofexposurewithanyonecounterpartymanagementbelieves tiesandbillionnetproceedsfromlongandshorttermdebtthe theriskoflossisremote majorusesofcashwerecapitalspendingofbillionacquisitions thecompanyhasaccesstosubstantialsourcesoffundsat ofbillionnetinvestmentpurchasesofbilliondividendsto numerousbanksworldwideinseptemberthecompany shareholdersofbillionandtherepurchaseofcommonstocknet securedanewdaycreditfacilitytotalcreditavailabletothe ofproceedsfromtheexerciseofoptionsofbillion companyapproximatesbillionwhichexpiresseptember cashflowsfromoperationswerebillioninthe interestchargedonborrowingsunderthecreditlineagree majorsourcesofcashflowwerenetincomeofbillionadjusted mentsisbasedoneitherbidsprovidedbybankstheprimerateor fornoncashchargesfordepreciationamortizationandstockbased londoninterbankofferedratesliborplusapplicablemargins compensationofbillionrestructuringreservesofbillionand commitmentfeesundertheagreementarenotmaterial accountsreceivableandinventoriesofbillion theremaining totalborrowingsattheendofandwerebil changestooperatingcashflowwereauseoffundsofbillion lionandbillionrespectivelytheincreaseinborrowings relatedtopensionplancontributionsand decreasesinaccounts betweenandwasaresultoffinancinggeneralcorporate payablepartiallyoffsetbydecreasesinotherreceivablesprepaid purposesandthecontinuationofthecommonstockrepurchase expensesanddeferredtaxes programannouncedininnetcashcashandcurrent inthecompanycontinuedtohaveaccesstoliquidity marketablesecuritiesnetofdebtwasbillioncomparedtonet throughthecommercialpapermarketforadditionaldetailson cashofbillionintotaldebtrepresentedoftotal borrowingsseenotetotheconsolidatedfinancialstatements capitalshareholdersequityandtotaldebtinandof thecompanyanticipatesthatoperatingcashflowsexisting totalcapitalinshareholdersequitypershareattheendof creditfacilitiesandaccesstothecommercialpapermarketswill wascomparedwithatyearendan providesufficientresourcestofundoperatingneedsin increaseof johnsonjohnsoncontinuestobeoneofafewindustrial companieswithatripleacreditratingasummaryofborrowings canbefoundinnotetotheconsolidatedfinancialstatements contractualobligationsandcommitments thecompanyhascontractualobligationsprimarilyleasedebtand unfundedretirementplanswithnoothersignificantobligations tosatisfytheseobligationsthecompanywillusecashfromopera tionsthefollowingtablesummarizesthecompanyscontractual obligationsandtheiraggregatematuritiesasofjanuary seenotesandtotheconsolidatedfinancialstatementsfor furtherdetails longterm intereston unfunded financingandmarketrisk debt debt retirement operating thecompanyusesfinancialinstrumentstomanagetheimpactof dollarsinmillions obligations obligations plans leases total foreignexchangeratechangesoncashflowsaccordinglythecompany entersintoforwardforeignexchangecontractstoprotectthevalueof certainforeigncurrencyassetsandliabilitiesandtohedgefutureforeign currencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlying transactionsaappreciationoftheusdollarfromthejanuary marketrateswouldincreasetheunrealizedvalueofthecompanys total forwardcontractsbymillionconverselyadepreciationof theusdollarfromthejanuarymarketrateswoulddecrease fortaxmattersseenotetotheconsolidatedfinancialstatements theunrealizedvalueofthecompanysforwardcontractsbymillion ineitherscenariothegainorlossontheforwardcontractwouldbeoff sharerepurchaseanddividends setbythegainorlossontheunderlyingtransactionandtherefore onjulythecompanyannouncedthatitsboardofdirectors wouldhavenoimpactonfutureanticipatedearningsandcashflows approvedastockrepurchaseprogramauthorizingthecompanyto thecompanyhedgestheexposuretofluctuationsincurrency buybackuptobillionofthecompanyscommonstockthe exchangeratesandtheeffectoncertainassetsandliabilitiesin repurchaseprogramhasnotimelimitandmaybesuspendedfor foreigncurrencybyenteringintocurrencyswapcontractsa periodsordiscontinuedatanytimeanysharesacquiredwillbe changeinthespreadbetweenusandforeigninterestratesonthe availableforgeneralcorporatepurposesthecompanyfundsthe companysinterestratesensitivefinancialinstrumentswould sharerepurchaseprogramthroughacombinationofavailablecash eitherincreaseordecreasetheunrealizedvalueofthecompanys anddebtasofjanuarythecompanyrepurchasedan johnson johnson annual reportaggregateofmillionsharesofjohnsonjohnsoncommon thecompanyssalesreturnreservesareaccountedforinaccor stockunderthecurrentrepurchaseprogramatacostofbillion dancewiththeusgaapguidanceforrevenuerecognitionwhen inadditionthecompanyhasanannualprogramtorepurchase rightofreturnexistssalesreturnreservesarerecordedatfullsales sharesforuseinemployeestockandincentiveplans valuesalesreturnsintheconsumerandpharmaceuticalsegments thecompanyincreaseditsdividendinforthethcon arealmostexclusivelynotresalablesalesreturnsforcertainfran secutiveyearcashdividendspaidwerepersharein chisesinthemedicaldevicesanddiagnosticssegmentaretypically comparedwithdividendsofpershareinand resalablebutarenotmaterialthecompanyrarelyexchanges pershareinthedividendsweredistributedasfollows productsfrominventoryforreturnedproductsthesalesreturns reserveforthetotalcompanyhasrangedbetweenandof annualnettradesalesduringthepriorthreefiscalreportingyears firstquarter secondquarter promotionalprogramssuchasproductlistingallowancesand thirdquarter cooperativeadvertisingarrangementsarerecordedintheyear fourthquarter incurredcontinuingpromotionalprogramsincludecouponsand total volumebasedsalesincentiveprogramstheredemptioncostof consumercouponsisbasedonhistoricalredemptionexperienceby onjanuarytheboardofdirectorsdeclaredaregularquar productandvaluevolumebasedincentiveprogramsarebasedon terlycashdividendofpersharepayableonmarch estimatedsalesvolumesfortheincentiveperiodandarerecorded toshareholdersofrecordasoffebruarythecompany asproductsaresoldthecompanyalsoearnsservicerevenuefor expectstocontinuethepracticeofpayingregularcashdividends copromotionofcertainproductsforallyearspresentedservice revenueswerelessthanoftotalrevenuesandareincludedin otherinformation salestocustomersadditionallythesearrangementsareevaluated todeterminetheappropriateamountstobedeferred criticalaccountingpoliciesandestimates inadditionthecompanyentersintocollaborationarrangements managementsdiscussionandanalysisofresultsofoperations whichcontainmultiplerevenuegeneratingactivitiestherevenuefor andfinancialconditionarebasedonthecompanysconsolidated thesearrangementsisrecognizedaseachactivityisperformedor financialstatementsthathavebeenpreparedinaccordancewith deliveredbasedontherelativefairvalueupfrontfeesreceivedas accountingprinciplesgenerallyacceptedintheusgaapthe partofthesearrangementsaredeferredandrecognizedasrevenue preparationofthesefinancialstatementsrequiresthatmanagement earnedovertheobligationperiodseenotetotheconsolidated makeestimatesandassumptionsthataffecttheamountsreported financialstatementsforadditionaldisclosuresoncollaborations forrevenuesexpensesassetsliabilitiesandotherrelateddisclo reasonablylikelychangestoassumptionsusedtocalculate suresactualresultsmayormaynotdifferfromtheseestimatesthe theaccrualsforrebatesreturnsandpromotionsarenotanticipated companybelievesthattheunderstandingofcertainkeyaccounting tohaveamaterialeffectonthefinancialstatementsthecompany policiesandestimatesareessentialinachievingmoreinsightintothe currentlydisclosestheimpactofchangestoassumptionsinthe companysoperatingresultsandfinancialconditionthesekey quarterlyorannualfilinginwhichthereisamaterialfinancial accountingpoliciesincluderevenuerecognitionincometaxeslegal statementimpact andselfinsurancecontingenciesvaluationoflonglivedassets belowaretableswhichshowtheprogressionofaccrued assumptionsusedtodeterminetheamountsrecordedforpensions rebatesreturnspromotionsreservefordoubtfulaccountsand andotheremployeebenefitplansandaccountingforstockoptions reserveforcashdiscountsbysegmentofbusinessforthefiscal yearsendedjanuaryanddecember revenuerecognitionthecompanyrecognizesrevenuefrom productsaleswhengoodsareshippedordeliveredandtitleand riskoflosspasstothecustomerprovisionsforcertainrebatessales consumersegment incentivestradepromotionscouponsproductreturnsanddis balanceat balanceat countstocustomersareaccountedforasreductionsinsalesinthe beginning payments end sameperiodtherelatedsalesarerecorded dollarsinmillions ofperiod accruals ofperiod productdiscountsgrantedarebasedonthetermsofarrange mentswithdirectindirectandothermarketparticipantsaswell accruedrebates asmarketconditionsincludingpriceschargedbycompetitors accruedreturns rebatesthelargestbeingthemedicaidrebateprovisionareesti accruedpromotions matedbasedoncontractualtermshistoricalexperiencetrend subtotal analysisandprojectedmarketconditionsinthevariousmarkets reservefordoubtfulaccounts servedthecompanyevaluatesmarketconditionsforproductsor reserveforcashdiscounts groupsofproductsprimarilythroughtheanalysisofwholesalerand total otherthirdpartysellthroughandmarketresearchdataaswellas internallygeneratedinformation salesreturnsaregenerallyestimatedandrecordedbasedon accruedrebates historicalsalesandreturnsinformationproductsthatexhibit accruedreturns unusualsalesorreturnpatternsduetodatingcompetitionorother accruedpromotions marketingmattersarespecificallyinvestigatedandanalyzedaspart subtotal oftheaccountingforsalesreturnaccruals reservefordoubtfulaccounts salesreturnsallowancesrepresentareserveforproductsthat maybereturnedduetoexpirationdestructioninthefieldorinspe reserveforcashdiscounts cificareasproductrecallthereturnsreserveisbasedonhistorical total returntrendsbyproductandbymarketasapercenttogrosssales includesreserveforcustomerrebatesofmillionatjanuaryandmillion atdecemberrecordedasacontraasset managements discussion analysis results operations financial condition pharmaceuticalsegment ininaccordancewithusgaapthecompanyadopted thestandardrelatedtoaccountingforuncertaintyinincometaxes balanceat balanceat thecodificationprescribesarecognitionthresholdandmeasure beginning payments end dollarsinmillions ofperiod accruals ofperiod mentattributeforthefinancialstatementrecognitionandmeasure mentofataxpositiontakenorexpectedtobetakeninataxreturn accruedrebates thecodificationalsoprovidesguidanceonderecognitionclassifi accruedreturns cationandothermattersseenotetotheconsolidatedfinancial statementsforfurtherinformationregardingincometaxes accruedpromotions atjanuaryanddecemberthecumulative subtotal amountsofundistributedinternationalearningswereapproximately reservefordoubtfulaccounts billionandbillionrespectivelythecompanyintends reserveforcashdiscounts tocontinuetoreinvestitsundistributedinternationalearningsto total expanditsinternationaloperationsthereforenoustaxexpense hasbeenrecordedwithrespecttotheundistributedportionnot intendedforrepatriation accruedrebates accruedreturns legalandselfinsurancecontingenciesthecompanyrecords accruedpromotions accrualsforvariouscontingenciesincludinglegalproceedingsand subtotal productliabilitycasesastheseariseinthenormalcourseofbusi nesstheaccrualsarebasedonmanagementsjudgmentastothe reservefordoubtfulaccounts probabilityoflossesandwhereapplicableactuariallydetermined reserveforcashdiscounts estimatesadditionallythecompanyrecordsinsurancereceivable total amountsfromthirdpartyinsurerswhenrecoveryisprobableas includesreserveforcustomerrebatesofmillionatjanuaryand appropriatereservesagainstthesereceivablesarerecordedforesti millionatdecemberrecordedasacontraasset matedamountsthatmaynotbecollectedfromthirdpartyinsurers includesmillionadjustmentrelatedtopreviouslyestimatedaccruedsalesreserves longlivedandintangibleassetsthecompanyassesseschanges medicaldevicesanddiagnosticssegment ineconomicconditionsandmakesassumptionsregardingestimated futurecashflowsinevaluatingthevalueofthecompanysproperty balanceat balanceat plantandequipmentgoodwillandintangibleassetsasthese beginning payments end dollarsinmillions ofperiod accruals ofperiod assumptionsandestimatesmaychangeovertimeitmayormaynot benecessaryforthecompanytorecordimpairmentcharges accruedrebates employeebenefitplansthecompanysponsorsvariousretirement accruedreturns andpensionplansincludingdefinedbenefitdefinedcontribution accruedpromotions andterminationindemnityplanswhichcovermostemployees subtotal worldwidetheseplansarebasedonassumptionsforthediscount reservefordoubtfulaccounts rateexpectedreturnonplanassetsexpectedsalaryincreasesand reserveforcashdiscounts healthcarecosttrendratesseenotetotheconsolidatedfinan cialstatementsforfurtherdetailsontheseratesandtheeffecta total ratechangewouldhaveonthecompanysresultsofoperations stockbasedcompensationthecompanyrecognizescompensa accruedrebates tionexpenseassociatedwiththeissuanceofequityinstrumentsto accruedreturns employeesfortheirservicesthefairvalueofeachawardisesti accruedpromotions matedonthedateofgrantusingtheblackscholesoptionvaluation subtotal modelandisexpensedinthefinancialstatementsoverthevesting reservefordoubtfulaccounts periodtheinputassumptionsusedindeterminingfairvalueare reserveforcashdiscounts theexpectedlifeexpectedvolatilityriskfreerateandthedividend total yieldseenotetotheconsolidatedfinancialstatementsfor additionalinformation includesreserveforcustomerrebatesofmillionatjanuaryandmillion atdecemberrecordedasacontraasset includesmillionadjustmentrelatedtopreviouslyestimatedsalesrebatereserve newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecently incometaxesincometaxesarerecordedbasedonamountsrefund adoptedaccountingpronouncementsandrecentlyissuedaccount ableorpayableforthecurrentyearandincludetheresultsofany ingpronouncementsnotyetadoptedasofjanuary differencebetweengaapaccountingandtaxreportingrecorded asdeferredtaxassetsorliabilitiesthecompanyestimatesdeferred economicandmarketfactors taxassetsandliabilitiesbasedoncurrenttaxregulationsandrates thecompanyisawarethatitsproductsareusedinanenvironment changesintaxlawsandratesmayaffectrecordeddeferredtax whereformorethanadecadepolicymakersconsumersandbusi assetsandliabilitiesinthefuturemanagementbelievesthat nesseshaveexpressedconcernsabouttherisingcostofhealthcare changesintheseestimateswouldnothaveamaterialeffectonthe inresponsetotheseconcernsthecompanyhasalongstanding companysresultsofoperationscashflowsorfinancialposition policyofpricingproductsresponsiblyfortheperiodin theunitedstatestheweightedaveragecompoundannualgrowth rateofthecompanysnetpriceincreasesforhealthcareproducts johnson johnson annual reportprescriptionandoverthecounterdrugshospitalandprofessional commonstockmarketprices productswasbelowtheusconsumerpriceindexcpi thecompanyscommonstockislistedonthenewyorkstock inflationratescontinuetohaveaneffectonworldwide exchangeunderthesymboljnjthecompositemarketpriceranges economiesandconsequentlyonthewaycompaniesoperate forjohnsonjohnsoncommonstockduringandwere thecompanywillaccountforoperationsinvenezuelaashighly inflationaryinasthepriorthreeyearcumulativeinflation high low high low ratehassurpassedinthefaceofincreasingcoststhecom firstquarter panystrivestomaintainitsprofitmarginsthroughcostreduction secondquarter programsproductivityimprovementsandperiodicpriceincreases thirdquarter thecompanyisexposedtofluctuationsincurrencyexchange ratesachangeinthevalueoftheusdollarascomparedto fourthquarter allforeigncurrenciesinwhichthecompanyhadsalesincomeor yearendclose expenseinwouldhaveincreasedordecreasedthetranslation offoreignsalesbymillionandincomebymillion cautionaryfactorsthatmayaffect thecompanyfacesvariousworldwidehealthcarechanges futureresults thatmaycontinuetoresultinpricingpressuresthatincludehealth carecostcontainmentandgovernmentlegislationrelatingtosales thisannualreportcontainsforwardlookingstatementsforward promotionsandreimbursement lookingstatementsdonotrelatestrictlytohistoricalorcurrentfacts changesinthebehaviorandspendingpatternsofpurchasers andanticipateresultsbasedonmanagementsplansthataresub ofhealthcareproductsandservicesincludingdelayingmedical jecttouncertaintyforwardlookingstatementsmaybeidentified proceduresrationingprescriptionmedicationsreducingthefre bytheuseofwordssuchasplansexpectswillanticipates quencyofphysicianvisitsandforegoinghealthcareinsurance estimatesandotherwordsofsimilarmeaninginconjunctionwith coverageasaresultofthecurrentglobaleconomicdownturnmay amongotherthingsdiscussionsoffutureoperationsfinancial continuetoimpactthecompanysbusinesses performancethecompanysstrategyforgrowthproductdevelop thecompanyalsooperatesinanenvironmentwhichhas mentregulatoryapprovalmarketpositionandexpenditures becomeincreasinglyhostiletointellectualpropertyrightsgeneric forwardlookingstatementsarebasedoncurrentexpectations drugfirmshavefiledabbreviatednewdrugapplicationsandas offutureeventsthecompanycannotguaranteethatanyforward seekingtomarketgenericformsofmostofthecompanyskeyphar lookingstatementwillbeaccuratealthoughthecompanybelieves maceuticalproductspriortoexpirationoftheapplicablepatents thatithasbeenreasonableinitsexpectationsandassumptions coveringthoseproductsintheeventthecompanyisnotsuccessful investorsshouldrealizethatifunderlyingassumptionsproveinac indefendingthepatentclaimschallengedinandafilingsthe curateorthatunknownrisksoruncertaintiesmaterializeactual genericfirmswillthenintroducegenericversionsoftheproduct resultscouldvarymateriallyfromthecompanysexpectationsand atissueresultinginthepotentialforsubstantialmarketshareand projectionsinvestorsarethereforecautionednottoplaceundue revenuelossesforthatproductforfurtherinformationseethe relianceonanyforwardlookingstatementsthecompanydoesnot discussiononlitigationagainstfilersofabbreviatednewdrug undertaketoupdateanyforwardlookingstatementsasaresultof applicationsinnotetotheconsolidatedfinancialstatements newinformationorfutureeventsordevelopments risksanduncertaintiesincludegeneralindustryconditions legalproceedings andcompetitioneconomicconditionssuchasinterestrateand thecompanyisinvolvedinnumerousproductliabilitycasesinthe currencyexchangeratefluctuationstechnologicaladvances unitedstatesmanyofwhichconcernallegedadversereactionsto newproductsandpatentsattainedbycompetitorschallenges drugsandmedicaldevicesthedamagesclaimedaresubstantial inherentinnewproductdevelopmentincludingobtainingregula andwhilethecompanyisconfidentoftheadequacyofthewarnings toryapprovalschallengestopatentsusandforeignhealthcare andinstructionsforusewhichaccompanysuchproductsitisnot reformsandgovernmentallawsandregulationstrendstoward feasibletopredicttheultimateoutcomeoflitigationhoweverthe healthcarecostcontainmentincreasedscrutinyofthehealth companybelievesthatifanyliabilityresultsfromsuchcasesit careindustrybygovernmentagenciesproductefficacyorsafety willbesubstantiallycoveredbyexistingamountsaccruedinthe concernsresultinginproductrecallsorregulatoryaction companysbalancesheetunderitsselfinsuranceprogramandby thecompanysreportonformkfortheyearended thirdpartyproductliabilityinsurance januaryincludesinexhibitadiscussionofadditional thecompanyisalsoinvolvedinanumberofpatenttrademark factorsthatcouldcauseactualresultstodifferfromexpectations andotherlawsuitsaswellasinvestigationsincidentaltoitsbusi thecompanynotesthesefactorsaspermittedbytheprivate nesstheultimatelegalandfinancialliabilityofthecompanyin securitieslitigationreformactof respecttoallclaimslawsuitsandproceedingsreferredtoabove cannotbeestimatedwithanycertaintyhoweverinthecompanys opinionbasedonitsexaminationofthesemattersitsexperience todateanddiscussionswithcounseltheultimateoutcomeoflegal proceedingsnetofliabilitiesalreadyaccruedinthecompanys balancesheetisnotexpectedtohaveamaterialadverseeffecton thecompanysfinancialconditionalthoughtheresolutioninany reportingperiodofoneormoreofthesematterscouldhavea significantimpactonthecompanysresultsofoperationsand cashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsfor furtherinformationregardinglegalproceedings managements discussion analysis results operations financial condition consolidated balance sheets johnson johnson subsidiaries january december dollars millions except share per share data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson annual reportconsolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes cash dividends per share basic average shares outstanding notes diluted average shares outstanding notes see notes consolidated financial statements consolidated financial statements consolidated statements equity johnson johnson subsidiaries accumulated treasury comprehensive retained comprehensive common stock stock dollars millions note total income earnings income issued amount amount balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges total comprehensive income balance january see notes consolidated financial statements johnson johnson annual reportconsolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation purchased inprocess research development intangible asset writedown natrecor deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions decreaseincrease accounts receivable decreaseincrease inventories decreaseincrease accounts payable accrued liabilities decreaseincrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents increase cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions see notes consolidated financial statements consolidated financial statements notestoconsolidatedfinancialstatements summaryofsignificantaccountingpolicies duringthefiscalsecondquarterofinaccordancewith principlesofconsolidation usgaapthecompanyadoptedthestandardsonsubsequent theconsolidatedfinancialstatementsincludetheaccountsof eventsthispronouncementestablishesstandardsofaccounting johnsonjohnsonandsubsidiariesthecompanyinter foranddisclosureofeventsthatoccurafterthebalancesheet companyaccountsandtransactionsareeliminated datebutbeforefinancialstatementsareissuedseenotefor relateddisclosure descriptionofthecompanyandbusinesssegments duringthefiscalfirstquarterofinaccordancewithus thecompanyhasapproximatelyemployeesworldwide gaapthecompanyadoptedthestandardsonbusinesscombina engagedintheresearchanddevelopmentmanufactureandsaleof tionsandnoncontrollinginterestsinconsolidatedfinancialstate abroadrangeofproductsinthehealthcarefieldthecompany mentsthesestandardsaimtoimprovesimplifyandconverge conductsbusinessinvirtuallyallcountriesoftheworldanditspri internationallytheaccountingforbusinesscombinationsandthe maryfocusisonproductsrelatedtohumanhealthandwellbeing reportingofnoncontrollinginterestsinconsolidatedfinancialstate thecompanyisorganizedintothreebusinesssegments mentsthesestandardshaveanimpactonthemannerinwhichthe consumerpharmaceuticalandmedicaldevicesanddiagnostics companyaccountsforacquisitionsbeginninginthefiscalyear theconsumersegmentmanufacturesandmarketsabroadrange significantchangesincludethecapitalizationofpurchased ofproductsusedinthebabycareskincareoralcarewoundcare inprocessresearchanddevelopmentiprdexpensingofacqui andwomenshealthcarefieldsaswellasnutritionalandoverthe sitionrelatedrestructuringactionsandtransactionrelatedcostsand counterpharmaceuticalproductstheseproductsaremarketedto therecognitionofcontingentpurchasepriceconsiderationatfair thegeneralpublicandsoldbothtoretailoutletsanddistributors valueattheacquisitiondateinadditionchangesinaccountingfor throughouttheworldthepharmaceuticalsegmentincludesprod deferredtaxassetvaluationallowancesandacquiredincometax uctsinthefollowingtherapeuticareasantiinfectiveantipsychotic uncertaintiesafterthemeasurementperiodwillberecognizedin cardiovascularcontraceptivedermatologygastrointestinalhema earningsratherthanasanadjustmenttothecostofacquisition tologyimmunologyneurologyoncologypainmanagementurol thisaccountingtreatmentfortaxesisapplicabletoacquisitionsthat ogyandvirologytheseproductsaredistributeddirectlytoretailers occurredbothpriorandsubsequenttotheadoptionofthestandard wholesalersandhealthcareprofessionalsforprescriptionusethe operatingprofitattributabletononcontrollinginterestsisreported medicaldevicesanddiagnosticssegmentincludesabroadrangeof inotherincomeexpensenetandtherelatedtaximpacttothe productsusedprincipallyintheprofessionalfieldsbyphysicians provisionfortaxesadditionallyequityattributabletonon nursestherapistshospitalsdiagnosticlaboratoriesandclinics controllinginterestsisrecordedinothernoncurrentliabilities theseproductsincludecordiscirculatorydiseasemanagement noncontrollinginterestsasrelatedtothecompanysfinancial productsdepuysorthopaedicjointreconstructionspinalcareand statementsareimmaterialandthereforenotseparatelydisclosed sportsmedicineproductsethiconssurgicalcareaestheticsand duringthefiscalfirstquarterofinaccordancewithus womenshealthproductsethiconendosurgerysminimallyinva gaapthecompanyadoptedthestandardrelatedtodisclosures sivesurgicalproductslifescansbloodglucosemonitoringand aboutderivativeinstrumentsandhedgingactivitieswhich insulindeliveryproductsorthoclinicaldiagnosticsprofessional enhancedthedisclosureregardingthecompanysderivativeand diagnosticproductsandvistakonsdisposablecontactlenses hedgingactivitiestheadoptionofthisstandarddidnothavea materialimpactonthecompanysresultsofoperationscashflows newaccountingpronouncements orfinancialpositionseenoteforenhanceddisclosures recentlyadoptedaccountingpronouncements duringthefiscalfirstquarterofinaccordancewithus duringthefiscalfourthquarterofinaccordancewithus gaapthecompanyadoptedthestandardoncollaborativearrange gaapthecompanyadoptedtheauthoritativeguidancefor mentsrelatedtothedevelopmentandcommercializationofintel employersdisclosuresaboutpostretirementbenefitplanassetsto lectualpropertythisstandardaddressestheincomestatement enhancethedisclosureregardingthetypesofassetsandassociated classificationofpaymentsmadebetweenpartiesinacollaborative risksinanemployersdefinedbenefitpensionorotherpostretire arrangementtheimpactoftheadoptionofthisstandardrelatedto mentplanaswellaseventsintheeconomyandmarketsthatcould allcollaborationagreementsthatexistedasofjanuaryand haveasignificanteffectonthevalueoftheplanassetstheadop decemberwasimmaterialtothecompanysresultsof tionofthisstandarddidnothaveamaterialimpactonthecom operationscashflowsorfinancialposition panysresultsofoperationscashflowsorfinancialpositionsee duringthefiscalfirstquarterofinaccordancewithus noteforenhanceddisclosures gaapthecompanyadoptedthestandardrelatedtodefensive duringthefiscalthirdquarterofthecompanyadopted intangibleassetsthisstandardappliestoacquiredintangible thefasbaccountingstandardscodificationtmascorcodification assetsinsituationsinwhichanentitydoesnotintendtoactivelyuse andthehierarchyofgenerallyacceptedaccountingprinciplesgaap theassetbutintendstoholdtheassettopreventothersfrom whichestablishesthecodificationasthesolesourceforauthorita obtainingaccesstotheassetexceptforintangibleassetsthatare tiveusgaapandwillsupersedeallaccountingstandardsinus usedinresearchanddevelopmentactivitiestheadoptionofthis gaapasidefromthoseissuedbythesectheadoptionofthecod standarddidnothaveamaterialimpactonthecompanysresultsof ificationdidnothaveanimpactonthecompanysresultsofopera operationscashflowsorfinancialposition tionscashflowsorfinancialpositionsincetheadoptionofthe accountingstandardscodificationascthecompanysnotesto recentlyissuedaccountingstandards theconsolidatedfinancialstatementswillnolongermakereference notadoptedasofjanuary tostatementoffinancialaccountingstandardssfasorotherus thefasbissuedguidanceandamendmentstothecriteriaforsepa gaappronouncements ratingconsiderationinmultipledeliverablerevenuearrangements johnson johnson annual reporttheguidanceandamendmentsareexpectedtoaprovideprinci itscarryingvalueifquotedmarketpricesarenotavailablethe plesandapplicationguidanceonwhethermultipledeliverables companywillestimatefairvalueusingadiscountedvalueof existhowthearrangementshouldbeseparatedandtheconsidera estimatedfuturecashflows tionallocatedbrequireanentitytoallocaterevenueinan arrangementusingestimatedsellingpricesofdeliverablesifaven revenuerecognition dordoesnothavevendorspecificobjectiveevidenceorthirdparty thecompanyrecognizesrevenuefromproductsaleswhenthe evidenceofsellingpriceandceliminatetheuseoftheresidual goodsareshippedordeliveredandtitleandriskoflosspasstothe methodandrequireanentitytoallocatetherevenueusingthe customerprovisionsforcertainrebatessalesincentivestradepro relativesellingpricemethodtheguidancesignificantlyexpandsthe motionscouponsproductreturnsanddiscountstocustomersare disclosurerequirementsformultipledeliverablerevenuearrange accountedforasreductionsinsalesinthesameperiodtherelated mentsthisguidanceiseffectiveprospectivelyforrevenuearrange salesarerecorded mentsenteredintoormateriallymodifiedinfiscalyearsbeginning productdiscountsgrantedarebasedonthetermsofarrange onorafterjuneearlyadoptionispermittedthecompany mentswithdirectindirectandothermarketparticipantsaswell adoptedthisguidanceinthefirstfiscalquarteroftheadop asmarketconditionsincludingpriceschargedbycompetitors tionwillnothaveamaterialimpactonthecompanysresultsof rebatesthelargestbeingthemedicaidrebateprovisionareesti operationscashflowsorfinancialpositionhoweveritwillexpand matedbasedoncontractualtermshistoricalexperiencetrend thedisclosuresforsucharrangements analysisandprojectedmarketconditionsinthevariousmarkets thefasbissuedastandardtoimprovefinancialreportingby servedthecompanyevaluatesmarketconditionsforproductsor enterprisesinvolvedwithvariableinterestentitiesthisstatement groupsofproductsprimarilythroughtheanalysisofwholesalerand iseffectiveforthecompanybeginningwiththefiscalyear otherthirdpartysellthroughandmarketresearchdataaswellas earlierapplicationisprohibitedtheadoptionofthisstandardwill internallygeneratedinformation nothaveamaterialimpactonthecompanysresultsofoperations salesreturnsaregenerallyestimatedandrecordedbasedon cashflowsorfinancialposition historicalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorother cashequivalents marketingmattersarespecificallyinvestigatedandanalyzedaspart thecompanyconsiderssecuritieswithmaturitiesofthreemonths oftheaccountingforsalesreturnaccrualssalesreturnsallowances orlesswhenpurchasedtobecashequivalents representareserveforproductsthatmaybereturnedduetoexpira tiondestructioninthefieldorinspecificareasproductrecallthe investments returnsreserveisbasedonhistoricalreturntrendsbyproductand shorttermmarketablesecuritiesarecarriedatcostwhichapproxi bymarketasapercenttogrosssalesinaccordancewiththecom matesfairvalueinvestmentsclassifiedasavailableforsaleare panysaccountingpoliciesthecompanygenerallyissuescreditto carriedatestimatedfairvaluewithunrealizedgainsandlosses customersforreturnedgoodsthecompanyssalesreturnreserves recordedasacomponentofaccumulatedothercomprehensive areaccountedforinaccordancewithusgaapguidanceregarding incomelongtermdebtsecuritiesthatthecompanyhastheability revenuerecognitionwhenrightofreturnexistssalesreturn andintenttoholduntilmaturityarecarriedatamortizedcost reservesarerecordedatfullsalesvaluesalesreturnsinthecon managementdeterminestheappropriateclassificationofits sumerandpharmaceuticalsegmentsarealmostexclusivelynot investmentindebtandequitysecuritiesatthetimeofpurchase resalablesalesreturnsforcertainfranchisesinthemedicaldevices andreevaluatessuchdeterminationateachbalancesheetdate anddiagnosticssegmentaretypicallyresalablebutarenotmate thecompanyperiodicallyreviewsitsinvestmentsinequity rialthecompanyrarelyexchangesproductsfrominventoryfor securitiesforimpairmentandadjuststheseinvestmentstotheir returnedproductsthesalesreturnsreserveforthetotalcompany fairvaluewhenadeclineinmarketvalueisdeemedtobeother hasrangedbetweenandofannualnettradesalesduring thantemporaryiflossesonthesesecuritiesareconsideredtobe thepriorthreefiscalreportingyears otherthantemporarythelossisrecognizedinearnings promotionalprogramssuchasproductlistingallowancesand cooperativeadvertisingarrangementsarerecordedintheyear propertyplantandequipmentanddepreciation incurredcontinuingpromotionalprogramsincludecouponsand propertyplantandequipmentarestatedatcostthecompany volumebasedsalesincentiveprogramstheredemptioncostof utilizesthestraightlinemethodofdepreciationovertheestimated consumercouponsisbasedonhistoricalredemptionexperienceby usefullivesoftheassets productandvaluevolumebasedincentiveprogramsarebasedon theestimatedsalesvolumesfortheincentiveperiodandare buildingandbuildingequipment years recordedasproductsaresoldthecompanyalsoearnsservicerev landandleaseholdimprovements years enueforcopromotionofcertainproductsandincludesitinsalesto machineryandequipment years customersthesearrangementsareevaluatedtodeterminethe thecompanycapitalizescertaincomputersoftwareanddevelopment appropriateamountstobedeferred costsincludedinmachineryandequipmentwhenincurred inconnectionwithdevelopingorobtainingcomputersoftwarefor shippingandhandling internalusecapitalizedsoftwarecostsareamortizedoverthe shippingandhandlingcostsincurredweremillionmil estimatedusefullivesofthesoftwarewhichgenerallyrangefromto lionandmillioninandrespectivelyand years areincludedinsellingmarketingandadministrativeexpensethe thecompanyreviewslonglivedassetstoassessrecoverability amountofrevenuereceivedforshippingandhandlingislessthan usingundiscountedcashflowswhencertaineventsorchangesin ofsalestocustomersforallperiodspresented operatingoreconomicconditionsoccuranimpairmentassessment maybeperformedontherecoverabilityofthecarryingvalueof inventories theseassetsiftheassetisdeterminedtobeimpairedthelossis inventoriesarestatedatthelowerofcostormarketdeterminedby measuredbasedonthedifferencebetweentheassetsfairvalueand thefirstinfirstoutmethod notes consolidated financial statements intangibleassetsandgoodwill researchanddevelopmentexpensebecausetheperformanceof theauthoritativeliteratureonusgaaprequiresthatgoodwilland contractdevelopmentservicesisnotcentraltothecompanys intangibleassetswithindefinitelivesbeassessedannuallyfor operationsingeneraltheincomestatementpresentationfor impairmentthecompanycompletedtheannualimpairmenttest thesecollaborationsisasfollows forinthefiscalfourthquarterandnoimpairmentwasdeter minedfutureimpairmenttestswillbeperformedannuallyinthe naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomers fiscalfourthquarterorsoonerifatriggeringeventoccurs intangibleassetsthathavefiniteusefullivescontinuetobe royaltiesmilestonespaidto collaborativepartner amortizedovertheirusefullivesandarereviewedforimpairment postregulatoryapproval costofgoodssold whenwarrantedbyeconomicconditionsseenoteforfurther royaltiesreceivedfrom detailsonintangibleassetsandgoodwill collaborativepartner otherincomeexpensenet upfrontpaymentsmilestones financialinstruments paidtocollaborativepartner asrequiredbyusgaapallderivativeinstrumentsarerecordedon preregulatoryapproval researchexpense thebalancesheetatfairvaluechangesinthefairvalueofderivatives researchanddevelopmentpayments arerecordedeachperiodincurrentearningsorothercomprehensive tocollaborativepartner researchexpense incomedependingonwhetherthederivativeisdesignatedaspartof researchanddevelopmentpayments ahedgetransactionandifsothetypeofhedgetransaction receivedfromcollaborativepartner reductionofresearchexpense thecompanydocumentsallrelationshipsbetweenhedgeditems andderivativestheoverallriskmanagementstrategyincludesrea milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldover theusefullife sonsforundertakinghedgetransactionsandenteringintoderivatives theobjectivesofthisstrategyareminimizeforeigncurrencyexpo advertising suresimpactonthecompanysfinancialperformanceprotectthe costsassociatedwithadvertisingareexpensedintheyearincurred companyscashflowfromadversemovementsinforeignexchange andareincludedinthesellingmarketingandadministrative ratesensuretheappropriatenessoffinancialinstrumentsand expensesadvertisingexpensesworldwidewhicharecomprisedof managetheenterpriseriskassociatedwithfinancialinstitutions televisionradioprintmediaandinternetadvertisingwerebil seenoteforadditionalinformationonfinancialinstruments lioninbillioninandbillionin productliability incometaxes accrualsforproductliabilityclaimsarerecordedonanundis thecompanyintendstocontinuetoreinvestitsundistributed countedbasiswhenitisprobablethataliabilityhasbeenincurred internationalearningstoexpanditsinternationaloperationsthere andtheamountoftheliabilitycanbereasonablyestimatedbased forenoustaxexpensehasbeenrecordedwithrespecttothe onexistinginformationtheaccrualsareadjustedperiodicallyas undistributedportionnotintendedforrepatriationatjanuary additionalinformationbecomesavailableasaresultofcostand anddecemberthecumulativeamountofundistrib availabilityfactorseffectivenovemberthecompany utedinternationalearningswereapproximatelybillionand ceasedpurchasingthirdpartyproductliabilityinsurancebasedon billionrespectively theavailabilityofpriorcoveragereceivablesforinsurancerecover deferredincometaxesarerecognizedfortaxconsequences iesrelatedtoproductliabilityclaimsarerecordedonanundis oftemporarydifferencesbyapplyingenactedstatutorytaxrates countedbasiswhenitisprobablethatarecoverywillberealized applicabletofutureyearstodifferencesbetweenthefinancial reportingandthetaxbasisofexistingassetsandliabilities researchanddevelopment researchanddevelopmentexpensesareexpensedasincurred netearningspershare upfrontandmilestonepaymentsmadetothirdpartiesinconnec basicearningspershareiscomputedbydividingnetearningsavail tionwithresearchanddevelopmentcollaborationsareexpensedas abletocommonshareholdersbytheweightedaveragenumberof incurreduptothepointofregulatoryapprovalpaymentsmadeto commonsharesoutstandingfortheperioddilutedearningsper thirdpartiessubsequenttoregulatoryapprovalarecapitalizedand sharereflectsthepotentialdilutionthatcouldoccurifsecurities amortizedovertheremainingusefullifeoftherelatedproduct wereexercisedorconvertedintocommonstockusingthetreasury amountscapitalizedforsuchpaymentsareincludedinother stockmethod intangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypically useofestimates withotherpharmaceuticalorbiotechnologycompaniestodevelop thepreparationofconsolidatedfinancialstatementsinconformity andcommercializedrugcandidatesorintellectualpropertythese withaccountingprinciplesgenerallyacceptedintheusrequires arrangementstypicallyinvolvetwoormorepartieswhoareactive managementtomakeestimatesandassumptionsthataffectthe participantsinthecollaborationandareexposedtosignificantrisks amountsreportedestimatesareusedwhenaccountingforsales andrewardsdependentonthecommercialsuccessoftheactivities discountsrebatesallowancesandincentivesproductliabilities thesecollaborationsusuallyinvolvevariousactivitiesbyoneor incometaxesdepreciationamortizationemployeebenefitscon morepartiesincludingresearchanddevelopmentmarketingand tingenciesandintangibleassetandliabilityvaluationsforinstance sellinganddistributionoftenthesecollaborationsrequireupfront indeterminingannualpensionandpostemploymentbenefitcosts milestoneandroyaltyorprofitsharepaymentscontingentuponthe thecompanyestimatestherateofreturnonplanassetsandthe occurrenceofcertainfutureeventslinkedtothesuccessoftheasset costoffuturehealthcarebenefitsactualresultsmayormaynot indevelopmentamountsduefromcollaborativepartnersrelatedto differfromthoseestimates developmentactivitiesaregenerallyreflectedasareductionof johnson johnson annual reportannualclosingdate reclassification thecompanyfollowstheconceptofafiscalyearwhichendson certainpriorperiodamountshavebeenreclassifiedtoconformto thesundaynearesttotheendofthemonthofdecembernormally currentyearpresentation eachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthe fiscalyearconsistsofweeksaswasthecaseinandwill bethecaseagainin cashcashequivalentsandcurrentmarketablesecurities january december amortized unrealized estimated amortized unrealized estimated dollarsinmillions cost gainslosses fairvalue cost gainslosses fairvalue currentinvestments cash governmentsecuritiesandobligations corporatedebtsecurities moneymarketfunds timedeposits totalcashcashequivalentsandcurrentmarketablesecurities asofjanuarycurrentmarketablesecuritiesconsistof thecompanycapitalizesinterestexpenseaspartofthecostof millionandmillionofgovernmentsecuritiesandobliga constructionoffacilitiesandequipmentinterestexpensecapital tionsandcorporatedebtsecuritiesrespectively izedinandwasmillionmillionand asofdecembercurrentmarketablesecuritiescon millionrespectively sistofmillionmillionandmillionofgovernment depreciationexpenseincludingtheamortizationofcapitalized securitiesandobligationscorporatedebtsecuritiesandtime interestinandwasbillionbillionand depositsrespectively billionrespectively fairvalueofgovernmentsecuritiesandobligationsand uponretirementorotherdisposalofpropertyplantandequip corporatedebtsecuritieswereestimatedusingquotedbroker mentthecostsandrelatedamountsofaccumulateddepreciation pricesinactivemarkets oramortizationareeliminatedfromtheassetandaccumulated thecompanyinvestsitsexcesscashinbothdepositswith depreciationaccountsrespectivelythedifferenceifanybetween majorbanksthroughouttheworldandotherhighqualitymoney thenetassetvalueandtheproceedsarerecordedinearnings marketinstrumentsthecompanyhasapolicyofmakinginvest mentsonlywithcommercialinstitutionsthathaveatleastana intangibleassetsandgoodwill orequivalentcreditrating attheendofandthegrossandnetamountsofintangi bleassetswere inventories dollarsinmillions attheendofandinventorieswerecomprisedof intangibleassetswithdefinitelives dollarsinmillions patentsandtrademarksgross rawmaterialsandsupplies lessaccumulatedamortization goodsinprocess patentsandtrademarksnet finishedgoods otherintangiblesgross lessaccumulatedamortization otherintangiblesnet propertyplantandequipment totalintangibleassetswithdefinitelivesgross attheendofandpropertyplantandequipmentatcost lessaccumulatedamortization andaccumulateddepreciationwere totalintangibleassetswithdefinitelivesnet intangibleassetswithindefinitelives dollarsinmillions landandlandimprovements trademarks buildingsandbuildingequipment purchasedinprocessresearchanddevelopment machineryandequipment totalintangibleassetswithindefinitelives constructioninprogress totalintangibleassetsnet purchasedinprocessresearchanddevelopmentwillbeaccountedforasanindefinite lessaccumulateddepreciation livedintangibleassetuntiltheunderlyingprojectiscompletedorabandoned notes consolidated financial statements goodwillasofjanuaryanddecemberas asrequiredbyusgaapforderivativeinstrumentsandhedg allocatedbysegmentofbusinessisasfollows ingactivitiesallderivativeinstrumentsaretoberecordedonthe balancesheetatfairvaluechangesinthefairvalueofderivatives meddev arerecordedeachperiodincurrentearningsorothercomprehen dollarsinmillions consumer pharm anddiag total siveincomedependingonwhetherthederivativeisdesignatedas goodwillatdecember partofahedgetransactionandifsothetypeofhedgetransaction acquisitions thedesignationasacashflowhedgeismadeattheentrance currencytranslationother dateintothederivativecontractatinceptionallderivativesare goodwillatdecember expectedtobehighlyeffectivechangesinthefairvalueofa acquisitions derivativethatisdesignatedasacashflowhedgeandishighly currencytranslationother effectivearerecordedinaccumulatedothercomprehensiveincome goodwillatjanuary untiltheunderlyingtransactionaffectsearningsandarethen reclassifiedtoearningsinthesameaccountasthehedgedtransac includesreclassificationbetweensegments tiongainslossesonnetinvestmenthedgesareaccountedfor theweightedaverageamortizationperiodsforpatentsand throughthecurrencytranslationaccountandareinsignificant trademarksandotherintangibleassetsareyearsandyears onanongoingbasisthecompanyassesseswhethereachderiva respectivelytheamortizationexpenseofamortizableassetsfor tivecontinuestobehighlyeffectiveinoffsettingchangesinthe thefiscalyearsendedjanuarydecemberand cashflowsofhedgeditemsifandwhenaderivativeisnolonger decemberwasmillionmillionandmil expectedtobehighlyeffectivehedgeaccountingisdiscontinued lionbeforetaxrespectivelycertainpatentsandintangibleassets hedgeineffectivenessifanyisincludedincurrentperiodearnings werewrittendowntofairvalueduringfiscalyearsand inotherincomeandexpensenetandwasinsignificantforthe withtheresultingchargeincludedinamortizationexpense fiscalyearendedjanuaryanddecemberrefer theestimatedamortizationexpenseforthefivesucceeding tonotefordisclosuresofmovementsinaccumulatedother yearsapproximatesmillionbeforetaxperyearsubstantially comprehensiveincome alloftheamortizationexpenseisincludedincostofproductssold asofjanuarythebalanceofdeferrednetgainson derivativesincludedinaccumulatedothercomprehensiveincome wasmillionaftertaxforadditionalinformationseenote fairvaluemeasurements thecompanyexpectsthatsubstantiallyalloftheamountrelated duringthefiscalfirstquarterofinaccordancewithus toforeignexchangecontractswillbereclassifiedintoearningsover gaapthecompanyadoptedthestandardrelatedtodisclosures thenextmonthsasaresultoftransactionsthatareexpectedto aboutderivativeinstrumentsandhedgingactivitiesthisstandard occuroverthatperiodthemaximumlengthoftimeoverwhichthe requiresqualitativedisclosuresaboutobjectivesandstrategiesfor companyishedgingtransactionexposureismonthsexcluding usingderivativesquantitativedisclosuresaboutfairvalueamounts interestrateswapstheamountultimatelyrealizedinearningswill ofgainandlossesonderivativeinstrumentsanddisclosuresabout differasforeignexchangerateschangerealizedgainsandlosses creditriskrelatedcontingentfeaturesinderivativeagreements areultimatelydeterminedbyactualexchangeratesatmaturityof thecompanyusesforwardexchangecontractstomanageits thederivative exposuretothevariabilityofcashflowsprimarilyrelatedtothefor thefollowingtableisasummaryoftheactivityforthefiscal eignexchangeratechangesoffutureintercompanyproductand yearendedjanuaryrelatedtodesignatedderivativesas thirdpartypurchasesofrawmaterialsdenominatedinforeigncur definedinthecodification rencythecompanyalsousescrosscurrencyinterestrateswapsto managecurrencyriskprimarilyrelatedtoborrowingsbothtypesof gainloss gainloss gainloss reclassedfrom recognized derivativesaredesignatedascashflowhedgesthecompanyalso recognizedin accumulated inother usesforwardexchangecontractstomanageitsexposuretothe cashflowhedges accumulated ociinto income dollarsinmillions oci income expense variabilityofcashflowsforrepatriationofforeigndividendsthese foreignexchangecontracts contractsaredesignatedasnetinvestmenthedgesadditionally thecompanyusesforwardexchangecontractstooffsetitsexpo foreignexchangecontracts b suretocertainforeigncurrencyassetsandliabilitiestheseforward foreignexchangecontracts c exchangecontractsarenotdesignatedashedgesandtherefore crosscurrencyinterestrateswaps changesinthefairvaluesofthesederivativesarerecognizedin foreignexchangecontracts e earningstherebyoffsettingthecurrentearningseffectofthe total relatedforeigncurrencyassetsandliabilitiesthecompanydoes effectiveportion notenterintoderivativefinancialinstrumentsfortradingorspecu ineffectiveportion lativepurposesorcontaincreditriskrelatedcontingentfeaturesor aincludedinsalestocustomer requirementstopostcollateralonanongoingbasisthecompany bincludedincostofproductssold monitorscounterpartycreditratingsthecompanyconsiderscredit cincludedinresearchexpense nonperformancerisktobelowbecausethecompanyentersinto dincludedininterestincomeinterestexpensenet agreementswithcommercialinstitutionsthathaveatleastana eincludedinotherincomeexpensenet orequivalentcreditratingasofjanuarythecompany hadnotionalamountsoutstandingforforwardforeignexchange forthefiscalyearendedjanuaryagainofmillionwas contractsandcrosscurrencyinterestrateswapsofbillionand recognizedinotherincomeexpensenetrelatingtoforeign billionrespectively exchangecontractsnotdesignatedashedginginstrumentsunder thecodification johnson johnson annual reportduringthefiscalfirstquarterofinaccordancewithus duringthecompanyacquiredsubstantiallyalloftheassets gaapthecompanyadoptedthestandardrelatedtofairvaluemeas andrightsofelansalzheimersimmunotherapyprogramthrougha urementsexceptfornonfinancialassetsandliabilitiesrecognizedor newlyformedcompanyjanssenalzheimerimmunotherapyjai disclosedatfairvalueonanonrecurringbasiswhichbecameeffec ofwhichthecompanyownsandelanownsinaddi tiveduringthefirstfiscalquarteroftheeffectofadoptionon tionthecompanypurchasedapproximatelymillionnewly decemberofthisstandardfornonfinancialassetsandlia issuedamericandepositaryreceiptsadrsofelanrepresenting bilitiesrecordedatfairvalueonanonrecurringbasisdidnothavea ofelansoutstandingordinarysharesaspartofthistransac materialimpactonthecompanysfinancialpositionandresultsof tionthecompanypaidmilliontoelanandcommittedtofund operationsthisstandarddefinesfairvalueestablishesaframework uptomillionofelansshareofresearchanddevelopment formeasuringfairvalueandexpandsdisclosuresaboutfairvalue spendingbyjaiofthistotalconsiderationofmillion measurementsduringthefiscalfirstquarterofthecompany millionrepresentsthefairvalueoftheinvestmentinelan adoptedthestandardrelatedtofairvalueoptionforfinancialassets basedonelanssharepriceinanactivelytradedmarketasofthe andfinancialliabilitiesthisstandardpermitsthecompanytomeas dateofthistransactiontheiprdrelatedtothistransactionwas urecertainfinancialassetsandfinancialliabilitiesatfairvaluethe millionandisassociatedwithbapineuzumabapotentialfirst companyassessedthefairvalueoptionmadeavailableuponadopting inclasstreatmentthatisbeingevaluatedforslowingtheprogres thisstandardandhaselectednottoapplythefairvalueoptiontoany sionofalzheimersdiseasethevalueoftheiprdwascalculated financialinstrumentsthatwerenotalreadyrecognizedatfairvalue usingcashflowprojectionsdiscountedfortheriskinherentinsuch usgaapdefinesfairvalueastheexitpricethatwouldbe projectsprobabilityofsuccessfactorsrangingfromwere receivedtosellanassetorpaidtotransferaliabilityfairvalueisa usedtoreflectinherentclinicalandregulatoryriskthediscount marketbasedmeasurementthatshouldbedeterminedusing rateappliedwasthenoncontrollinginterestrelatedtothis assumptionsthatmarketparticipantswoulduseinpricinganasset transactionwasmillionwhichthecompanyhasrecordedin orliabilitytheauthoritativeliteratureestablishesathreelevelhier othernoncurrentliabilities archytoprioritizetheinputsusedinmeasuringfairvaluethelevels duringthecompanyenteredintoastrategiccollabora withinthehierarchyaredescribedinthetablebelowwithlevel tionwithcrucellnvwhichwillfocusonthediscoverydevelop havingthehighestpriorityandlevelhavingthelowest mentandcommercializationofmonoclonalantibodiesandvaccines thefairvalueofaderivativefinancialinstrumentieforward forthetreatmentandpreventionofinfluenzaandotherinfectious exchangecontractcurrencyswapistheaggregationbycurrencyof andnoninfectiousdiseasesinadditionthecompanythroughits allfuturecashflowsdiscountedtoitspresentvalueattheprevailing affiliatepurchasedapproximatelyofcrucellsoutstanding marketinterestratesandsubsequentlyconvertedtotheusdollarat ordinarysharesforanaggregatepurchasepriceofmillion thecurrentspotforeignexchangeratethecompanydoesnot ofthetotalconsiderationpaidmillionrepresentsthefair believethatfairvaluesofthesederivativeinstrumentsmateriallydif valueoftheinvestmentbasedoncrucellssharepriceinanactively ferfromtheamountsthatcouldberealizeduponsettlementormatu tradedmarketasofthedateofthetransactionwiththeexcess rityorthatthechangesinfairvaluewillhaveamaterialeffectonthe recordedtoresearchanddevelopmentexpensein companysresultsofoperationscashflowsorfinancialposition thecompanydidnothaveanyothersignificantfinancial thecompanyalsoholdsequityinvestmentswhichareclassi assetsorliabilitieswhichwouldrequirerevisedvaluationsunder fiedaslevelsincetheyaretradedinanactiveexchangemarket thisstandardthatarerecognizedatfairvalue thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryanddecemberwereasfollows significant quotedpricesin significant activemarketsfor observable unobservable identicalassets inputs inputs dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets foreignexchangecontracts crosscurrencyinterestrateswaps total liabilities foreignexchangecontracts crosscurrencyinterestrateswaps total derivativesnotdesignatedashedginginstruments assets foreignexchangecontracts liabilities foreignexchangecontracts otherinvestments assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedaslevel includesmillionofnoncurrentassets includesmillionofnoncurrentliabilities seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet notes consolidated financial statements borrowings thecompanyfiledashelfregistrationwiththesecuritiesand thecomponentsoflongtermdebtareasfollows exchangecommissionthatbecameeffectivemarchwhich enablesthecompanytoissueanunlimitedaggregateprincipal effective effective amountindebtsecuritiesandwarrantstopurchasedebtsecurities dollarsinmillions rate rate aggregatematuritiesoflongtermobligationscommencingin notesdue debenturesdue debenturesdue dollarsinmillions debenturesdue debenturesdue notesdue beurobeuro incometaxes zerocouponconvertible theprovisionfortaxesonincomeconsistsof subordinateddebenturesdue debenturesdue dollarsinmillions currentlypayable notesdue mmgbp ustaxes mmgbp internationaltaxes notesdue debenturedue deferred notesdue ustaxes debenturesdue internationaltaxes otherincludesindustrial revenuebonds lesscurrentportion acomparisonofincometaxexpenseattheusstatutoryrateof inandtothecompanyseffectivetaxrate weightedaverageeffectiverate isasfollows translationrateatjanuary translationrateatdecember dollarsinmillions theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninand us billionin international fairvalueofthenoncurrentdebtwasestimatedusingmarket earningsbeforetaxesonincome priceswhichwerecorroboratedbyquotedbrokerpricesin taxrates activemarkets usstatutoryrate thecompanyhasaccesstosubstantialsourcesoffundsat irelandandpuertoricooperations numerousbanksworldwideinseptemberthecompany researchandorphandrugtaxcredits securedanewdaycreditfacilitytotalcreditavailabletothe usstateandlocal companyapproximatesbillionwhichexpiresseptember internationalsubsidiariesexcludingireland interestchargedonborrowingsunderthecreditlineagree usmanufacturingdeduction mentsisbasedoneitherbidsprovidedbybankstheprimerateor londoninterbankofferedratesliborplusapplicablemargins inprocessresearchand developmentiprd commitmentfeesundertheagreementsarenotmaterial onjulyalzacorporationasubsidiaryofthe ustaxinternationalincome companycompletedaprivateofferingofthezerocoupon allother convertiblesubordinateddebentureswhichwereissuedata effectivetaxrate priceofperprincipalamountatmaturityunder thetermsofthedebenturesholdersareentitledtoconvert thecompanyhassubsidiariesmanufacturinginirelandunderan theirdebenturesintoapproximatelymillionsharesof incentivetaxrateinadditionthecompanyhassubsidiariesoperat johnsonjohnsonstockatapriceofpershareapproxi inginpuertoricoundervarioustaxincentivegrantsthedecrease matelymillionshareshavebeenissuedasofjanuary inthetaxratewasprimarilyduetoincreasesintaxable duetovoluntaryconversionsbynoteholdersattheoption incomeinlowertaxjurisdictionsrelativetotaxableincomeinhigher oftheholderthedebenturesmayberepurchasedbythe taxjurisdictionstheincreaseinthetaxratewasmainly companyonjulyatapurchasepriceequaltotheissue attributedtoincreasesintaxableincomeinhighertaxjurisdictions priceplusaccretedoriginalissuediscounttosuchpurchasedate relativetotaxableincomeinlowerjurisdictionsaswellasabusi thecompanyatitsoptionmayalsoredeemanyorallofthe nessrestructuringofcertaininternationalsubsidiariesin debenturesafterjulyattheissuepriceplusaccreted resultinginaonetimebenefitofmillionwhichreducedthe originalissuediscount effectivetaxrateby throughoutthecompanycontinuedtohaveaccessto liquiditythroughthecommercialpapermarketshorttermborrow ingsandthecurrentportionoflongtermdebtamountedtoapproxi matelybillionattheendofofwhichbillionwas borrowedunderthecommercialpaperprogramtheremainder representsprincipallylocalborrowingbyinternationalsubsidiaries johnson johnson annual reporttemporarydifferencesandcarryforwardsforand thecompanyclassifiesliabilitiesforunrecognizedtaxbenefits areasfollows andrelatedinterestandpenaltiesaslongtermliabilitiesinterest expenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclas sifiedasincometaxexpenseduringthefiscalyearendedjanuary deferredtax deferredtax thecompanyrecognizedmillionofinterestexpenseand dollarsinmillions asset liability asset liability millionofinterestincomewithanaftertaximpactofmil employeerelatedobligations lionexpenseforthefiscalyearendeddecemberthe stockbasedcompensation companyrecognizedmillionofinterestexpensewithanafter depreciation taximpactofmillionforthefiscalyearendeddecember nondeductibleintangibles thecompanyrecognizedmillionofinterestexpenseand internationalrdcapitalized millionofinterestincomewithanaftertaximpactofmil fortax lionexpensethetotalamountofaccruedinterestwasmillion reservesliabilities andmillioninandrespectively incomereportedfor taxpurposes netoperatingloss employeerelatedobligations carryforwardinternational attheendofandemployeerelatedobligations miscellaneousinternational recordedontheconsolidatedbalancesheetwere miscellaneousus dollarsinmillions totaldeferredincometaxes pensionbenefits postretirementbenefits thedifferencebetweenthenetdeferredtaxonincomeperthe postemploymentbenefits balancesheetandthenetdeferredtaxaboveisincludedintaxes deferredcompensation onincomeonthebalancesheettheanddeferred taxmiscellaneoususincludescurrentyeartaxreceivablesthe totalemployeeobligations companyhasawhollyownedinternationalsubsidiarywhichhas lesscurrentbenefitspayable cumulativenetlossesthecompanybelievesthatitismorelikely employeerelatedobligationslongterm thannotthatthesubsidiarywillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxassets prepaidemployeerelatedobligationsofmillionandmil thefollowingtablesummarizestheactivityrelatedto lionforandrespectivelyareincludedinotherassetson unrecognizedtaxbenefits theconsolidatedbalancesheet dollarsinmillions beginningofyear pensionsandotherbenefitplans increasesrelatedtocurrentyeartaxpositions thecompanysponsorsvariousretirementandpensionplans increasesrelatedtopriorperiodtaxpositions includingdefinedbenefitdefinedcontributionandtermination decreasesrelatedtopriorperiodtaxpositions indemnityplanswhichcovermostemployeesworldwidethe settlements companyalsoprovidespostretirementbenefitsprimarilyhealth lapseofstatuteoflimitations caretoallusretiredemployeesandtheirdependents endofyear manyinternationalemployeesarecoveredbygovernment sponsoredprogramsandthecosttothecompanyisnotsignificant retirementplanbenefitsareprimarilybasedontheemployees thecompanyhadbillionandbillionofunrecognizedtax compensationduringthelastthreetofiveyearsbeforeretirement benefitsasofjanuaryanddecemberrespec andthenumberofyearsofserviceinternationalsubsidiarieshave tivelyalloftheunrecognizedtaxbenefitsofbillionatjanuary plansunderwhichfundsaredepositedwithtrusteesannuitiesare ifrecognizedwouldaffectthecompanysannualeffective purchasedundergroupcontractsorreservesareprovided taxratethecompanyconductsbusinessandfilestaxreturnsin thecompanydoesnotfundretireehealthcarebenefitsin numerouscountriesandcurrentlyhastaxauditsinprogresswitha advanceandhastherighttomodifytheseplansinthefuture numberoftaxauthoritiestheusinternalrevenueserviceirs thecompanyusesthedateofitsconsolidatedfinancialstate hascompleteditsauditforthetaxyearsthroughinother mentsjanuaryanddecemberrespectivelyas majorjurisdictionswherethecompanyconductsbusinesstheyears themeasurementdateforallusandinternationalretirementand remainopengenerallybacktotheyearwithsomejurisdictions otherbenefitplans remainingopenasfarbackasthecompanydoesnotexpect inaccordancewithusgaapthecompanyhasadopted thatthetotalamountofunrecognizedtaxbenefitswillsignificantly therecentstandardsrelatedtoemployersaccountingfordefined changeoverthenexttwelvemonthsthecompanybelievesthatitis benefitpensionandotherpostretirementplans possiblethatwithinthenexttwelvemonthstheirsmaycomplete itsauditofthetaxyearsthecloseoftheauditmay resultinthereductionofunrecognizedtaxbenefitsthecompanyis notabletoprovideareasonablyreliableestimateofthetimingof anyotherfuturetaxpaymentsrelatingtouncertaintaxpositions notes consolidated financial statements netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecost amortizationofnettransitionasset recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost thenetperiodicbenefitcostattributabletousretirementplanswasmillionmillionandmillioninand respectively amountsexpectedtoberecognizedinnetperiodicbenefitcost lifeexpectancytheamortizationofgainsandlossesfortheother inthecomingyearforthecompanysdefinedbenefitretirement usbenefitplansisdeterminedbyusingacorridorofthe plansandotherpostretirementplans greaterofthemarketvalueofassetsortheprojectedbenefitobliga tiontotalunamortizedgainsandlossesinexcessofthecorridorare dollarsinmillions amortizedovertheaverageremainingfutureservice amortizationofnettransitionobligation priorservicecostsbenefitsfortheuspensionplansare amortizationofnetactuariallosses amortizedovertheremainingfutureserviceofplanparticipantsat amortizationofpriorservicecost thetimeoftheplanamendmentpriorservicecostbenefitforthe otherusbenefitplansisamortizedovertheaverageremaining unrecognizedgainsandlossesfortheuspensionplansareamor servicetofulleligibilityageofplanparticipantsatthetimeofthe tizedovertheaverageremainingfutureserviceforeachplanfor planamendment planswithnoactiveemployeestheyareamortizedovertheaverage theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalueofprojected benefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplans otherbenefitplans dollarsinmillions usbenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels internationalbenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsidering thefollowingtabledisplaystheassumedhealthcarecosttrend currentyieldcurvesrepresentinghighqualitylongtermfixed ratesforallindividuals incomeinstrumentstheresultingdiscountratesareconsistent healthcareplans withthedurationofplanliabilities healthcarecosttrendrateassumedfornextyear theexpectedlongtermrateofreturnonplanassetsassump ratetowhichthecosttrendrateisassumed tionisdeterminedusingabuildingblockapproachconsidering todeclineultimatetrend historicalaveragesandrealreturnsofeachassetclassincertain yeartheratereachestheultimatetrendrate countrieswherehistoricalreturnsarenotmeaningfulconsidera tionisgiventolocalmarketexpectationsoflongtermreturns aonepercentagepointchangeinassumedhealthcarecosttrend rateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation johnson johnson annual reportthefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearendandfor thecompanysdefinedbenefitretirementplansandotherpostretirementplans retirementplans otherbenefitplans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuariallossesgains divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnlossonplanassets companycontributions planparticipantcontributions settlements benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusatendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistofthefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinothercomprehensiveincome netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecost amortizationofpriorservicecost effectofexchangerates totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanydoesnotfundcertainplansasfundingisnotrequiredbillionoftheprojected benefitobligationandbillionoftheunderfundedstatusforeachofthefiscalyearsand relatestotheunfundedpensionplansbillionandbillionoftheaccumulatedbenefit obligationforthefiscalyearsandrespectivelyrelatetotheseunfundedpensionplans planswithaccumulatedbenefitobligationsinexcessofplanassetsconsistofthefollowing retirementplans dollarsinmillions accumulatedbenefitobligation projectedbenefitobligation planassetsatfairvalue notes consolidated financial statements thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplansgross medicarerebates otherbenefitplansnet inthecompanycontributedmillionandmillion thecompanyplanstocontinuetofunditsusdefinedbenefit toitsusandinternationalpensionplansrespectivelyinaddition planstocomplywiththeact thecompanyfundedmilliontoitsusplansinthefirstmonth internationalplansarefundedinaccordancewithlocal regulationsadditionaldiscretionarycontributionsaremadewhen incongresspassedthepensionprotectionactof deemedappropriatetomeetthelongtermobligationsoftheplans theactamendedtheemployeeretirementincomesecurityact forcertainplansfundingisnotacommonpracticeasfunding erisaforplanyearsbeginningafterandestablishednew providesnoeconomicbenefitconsequentlythecompanyhas minimumfundingstandardsforusemployerdefinedbenefitplans severalpensionplansthatarenotfunded thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfundedretirement planstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions unfundedusretirementplans unfundedinternationalretirementplans eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationandinvestmentofthepension plansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboardconsidersfactorsincludinglocalpensionrulesand regulationslocaltaxregulationsavailabilityofinvestmentvehiclesseparateaccountscommingledaccountsinsurancefundsetc fundedstatusoftheplansratioofactivestoretireesdurationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityof localmarketsandliquidityofbasecurrencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobe ongoingplanspermittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefundsanassetallocationofequitiesandfixedincomeisgenerallypursuedunlesslocalregulationsandilliquidity requireotherwise thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollows percentof target planassets allocation usretirementplans equitysecurities debtsecurities totalplanassets internationalretirementplans equitysecurities debtsecurities realestateandother totalplanassets thecompanysotherbenefitplansareunfundedexceptforuslife determinationoffairvalue insurancecontractassetsofmillionandmillionatjanuary theplanhasanestablishedandwelldocumentedprocessfor anddecemberrespectively determiningfairvaluesfairvalueisbaseduponquotedmarket thefairvalueofjohnsonjohnsoncommonstockdirectly priceswhereavailableiflistedpricesorquotesarenotavailable heldinplanassetswasmillionoftotalplanassetsat fairvalueisbaseduponmodelsthatprimarilyuseasinputs januaryandmillionoftotalplanassetsat marketbasedorindependentlysourcedmarketparameters december includingyieldcurvesinterestratesvolatilitiesequityordebt pricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriate andconsistentwithothermarketparticipantstheuseofdifferent methodologiesorassumptionstodeterminethefairvalueofcertain financialinstrumentscouldresultinadifferentestimateoffairvalue atthereportingdate johnson johnson annual reportvaluationhierarchy ifquotedmarketpricesarenotavailableforthespecificsecurity theauthoritativeliteratureestablishesathreelevelhierarchytopri thenfairvaluesareestimatedbyusingpricingmodelsquoted oritizetheinputsusedinmeasuringfairvaluethelevelswithinthe pricesofsecuritieswithsimilarcharacteristicsordiscountedcash hierarchyaredescribedinthetablebelowwithlevelhavingthe flowsandareclassifiedaslevelleveldebtinstrumentsare highestpriorityandlevelhavingthelowest pricedbasedonunobservableinputs afinancialinstrumentscategorizationwithinthevaluationhierar equitysecuritiescommonstocksarevaluedattheclosing chyisbaseduponthelowestlevelofinputthatissignificanttothe pricereportedonthemajormarketonwhichtheindividualsecuri fairvaluemeasurement tiesaretradedsubstantiallyallcommonstockisclassifiedwithin followingisadescriptionofthevaluationmethodologiesused levelofthevaluationhierarchy fortheinvestmentsmeasuredatfairvalue commingledfundstheinvestmentsarepublicinvestment shortterminvestmentscashandquotedshortterminstru vehiclesvaluedusingthenavprovidedbythefundadministrator mentsarevaluedattheclosingpriceortheamountheldondeposit thenavisbasedonthevalueoftheunderlyingassetsownedby bythecustodianbankotherinvestmentsarethroughinvestment thefundminusitsliabilitiesandthendividedbythenumberof vehiclesvaluedusingthenetassetvaluenavprovidedbythe sharesoutstandingassetsinthelevelcategoryhaveaquoted administratorofthefundthenavisbasedonthevalueofthe marketpriceinamarketthatisnotactive underlyingassetsownedbythefundminusitsliabilitiesandthen insurancecontractstheinstrumentsareissuedbyinsurance dividedbythenumberofsharesoutstandingthenavisaquoted companiesthefairvalueisbasedonnegotiatedvalueandthe priceinamarketthatisnotactiveandclassifiedaslevel underlyinginvestmentsheldinseparateaccountportfoliosaswell governmentandagencysecuritiesalimitednumberofthese asconsideringthecreditworthinessoftheissuertheunderlying investmentsarevaluedattheclosingpricereportedonthemajor investmentsaregovernmentassetbackedandfixedincome marketonwhichtheindividualsecuritiesaretradedwherequoted securitiesingeneralinsurancecontractsareclassifiedaslevelas pricesareavailableinanactivemarkettheinvestmentsareclassified therearenoquotedpricesnorotherobservableinputsforpricing withinlevelofthevaluationhierarchyifquotedmarketpricesare otherassetsotherassetsarerepresentedprimarilybylimited notavailableforthespecificsecuritythenfairvaluesareestimated partnershipsandrealestateinvestmentsaswellascommercial byusingpricingmodelsquotedpricesofsecuritieswithsimilar loansandcommercialmortgagesthatarenotclassifiedascorporate characteristicsordiscountedcashflowswhenquotedmarketprices debtotherassetsthatareexchangelistedandactivelytradedare forasecurityarenotavailableinanactivemarkettheyareclassified classifiedaslevelwhileinactivelytradedassetsareclassifiedas aslevel levelmostlimitedpartnershipsrepresentinvestmentsinprivate debtinstrumentsalimitednumberoftheseinvestmentsare equityandsimilarfundsthatarevaluedbythegeneralpartners valuedattheclosingpricereportedonthemajormarketonwhich theseaswellasanyotherassetsvaluedusingunobservableinputs theindividualsecuritiesaretradedwherequotedpricesareavail areclassifiedaslevel ableinanactivemarkettheinvestmentsareclassifiedaslevel thefollowingtablesetsforththetrustinvestmentsmeasuredatfairvalueasofjanuary quotedprices significant inactive significant marketsfor observable unobservable identicalassets inputs inputs dollarsinmillions level level level totalassets shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets trustinvestmentsatfairvalue levelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearendedjanuary debt equity commingled insurance total dollarsinmillions instruments securities funds contracts assets level balancedecember realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancejanuary notes consolidated financial statements savingsplan accumulatedothercomprehensiveincome thecompanyhasvoluntaryksavingsplansdesignedto componentsofothercomprehensiveincomelossconsistof enhancetheexistingretirementprogramscoveringeligibleemploy thefollowing eesthecompanymatchesapercentageofeachemployeescontri total butionsconsistentwiththeprovisionsoftheplanforwhichheshe gains accumulated iseligibletotalcompanymatchingcontributionstotheplanswere foreign gains losseson millionmillionandmillioninand currency losseson employee derivatives comprehensive dollarsinmillions translation securities benefitplans hedges incomeloss respectively december changes capitalandtreasurystock unrealizedgainloss changesintreasurystockwere netamountreclassed tonetearnings amountsinmillionsexcepttreasurystock treasurystock netchanges numberofsharesinthousands shares amount december balanceatdecember changes employeecompensationandstockoptionplans unrealizedgainloss conversionofsubordinateddebentures netamountreclassed repurchaseofcommonstock tonetearnings balanceatdecember netchanges employeecompensationandstockoptionplans december conversionofsubordinateddebentures changes repurchaseofcommonstock unrealizedgainloss balanceatdecember netamountreclassed employeecompensationandstockoptionplans tonetearnings conversionofsubordinateddebentures netchanges repurchaseofcommonstock january balanceatjanuary thetaxeffectontheunrealizedgainslossesontheequitysecuri aggregatesharesofcommonstockissuedwereapproximately tieswasincomeofmillioninandexpenseofmillion millionsharesattheendofand andmillioninandrespectivelythetaxeffect cashdividendspaidwerepershareincompared relatedtoemployeebenefitplanswasmillionmillion withdividendsofpershareinandpershare andmillioninandrespectivelythetax effectonthegainslossesonderivativesandhedgeswasexpense ofmillionandmillioninandrespectivelyand incomeofmillioninseenoteforadditionalinformation relatingtoderivativesandhedging thecurrencytranslationadjustmentsarenotadjustedfor incometaxesastheyrelatetopermanentinvestmentsin internationalsubsidiaries johnson johnson annual reportinternationalcurrencytranslation rentalexpenseandleasecommitments fortranslationofitssubsidiariesoperatinginnonusdollarcur rentalsofspacevehiclesmanufacturingequipmentandofficeand renciesthecompanyhasdeterminedthatthelocalcurrenciesof dataprocessingequipmentunderoperatingleaseswereapproxi itsinternationalsubsidiariesarethefunctionalcurrenciesexcept matelymillioninmillioninandmillion thoseinhighlyinflationaryeconomieswhicharedefinedasthose whichhavehadcompoundcumulativeratesofinflationof theapproximateminimumrentalpaymentsrequiredunder ormoreduringthepastthreeyearsorwhereasubstantialportion operatingleasesthathaveinitialorremainingnoncancelablelease ofitscashflowsarenotinthelocalcurrency termsinexcessofoneyearatjanuaryare inconsolidatinginternationalsubsidiariesbalancesheetcur dollarsinmillions rencyeffectsarerecordedasacomponentofaccumulatedother total comprehensiveincomethisequityaccountincludestheresults oftranslatingallbalancesheetassetsandliabilitiesatcurrent exchangeratesexceptforthoselocatedinhighlyinflationary commitmentsundercapitalleasesarenotsignificant economiesthetranslationofbalancesheetaccountsforhighly inflationaryeconomiesarereflectedintheoperatingresults ananalysisofthechangesduringandfor commonstockstockoptionplansandstock foreigncurrencytranslationadjustmentsisincludedinnote compensationagreements netcurrencytransactionandtranslationgainsandlosses stockoptions includedinotherincomeexpensewerelossesofmillion atjanuarythecompanyhadstockbasedcompen millionandmillioninandrespectively sationplansthesharesoutstandingareforcontractsunderthe companysandstockoptionplansthelong termincentiveplanthenonemployeedirectorsplanand earningspershare thealzainvernessandsciosstockoptionplansduring thefollowingisareconciliationofbasicnetearningspershareto nooptionsorrestrictedsharesweregrantedunderanyofthese dilutednetearningspershareforthefiscalyearsendedjanuary plansexceptunderthelongtermincentiveplan decemberanddecember thecompensationcostthathasbeenchargedagainstincome fortheseplanswasmillionmillionandmillionfor sharesinmillionsexceptpersharedata andrespectivelythetotalincometaxbenefit basicnetearningspershare recognizedintheincomestatementforsharebasedcompensation averageshares costswasmillionmillionandmillionfor outstandingbasic andrespectivelysharebasedcompensationcosts potentialsharesexercisable capitalizedaspartofinventorywereinsignificantinallperiods understockoptionplans stockoptionsexpireyearsfromthedateofgrantandvest lesssharesrepurchased overserviceperiodsthatrangefromsixmonthstofiveyearsall undertreasurystockmethod optionsaregrantedattheaverageofthehighandlowpricesofthe convertibledebtshares companyscommonstockonthenewyorkstockexchangeon adjustedaverageshares thedateofgrantunderthelongtermincentiveplanthe outstandingdiluted companymayissueuptomillionsharesofcommonstock dilutednetearningspershare sharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendof thedilutednetearningspersharecalculationincludesthedilutive thecompanysettlesemployeestockoptionexerciseswith effectofconvertibledebtthatisoffsetbytherelatedreduction treasurysharestreasurysharesarereplenishedthroughoutthe ininterestexpenseofmillionaftertaxforyears yearforthenumberofsharesusedtosettleemployeestock optionexercises dilutednetearningspershareexcludesmillionmillion thefairvalueofeachoptionawardwasestimatedonthedate andmillionsharesunderlyingstockoptionsforand ofgrantusingtheblackscholesoptionvaluationmodelthatuses respectivelyastheexercisepriceoftheseoptionswas theassumptionsnotedinthefollowingtableexpectedvolatility greaterthantheiraveragemarketvaluewhichwouldresultinan representsablendedrateofyeardailyhistoricalaveragevolatility antidilutiveeffectondilutedearningspershare rateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyears historicaldataisusedtodeterminetheexpectedlifeoftheoption theriskfreeratewasbasedontheustreasuryyieldcurvein effectatthetimeofgrant notes consolidated financial statements theaveragefairvalueofoptionsgrantedwasand stockoptionsexercisableatdecemberanddecember inandrespectivelythefairvaluewas wereatanaveragepriceofandanaverage estimatedbasedontheweightedaverageassumptionsof lifeofyearsandatanaveragepriceofandan averagelifeofyearsrespectively riskfreerate restrictedshareunits expectedvolatility thecompanygrantsrestrictedshareunitswithavestingperiod expectedlife yrs yrs yrs ofthreeyearsthecompanysettlesemployeestockissuancewith dividendyield treasurysharestreasurysharesarereplenishedthroughoutthe yearforthenumberofsharesusedforemployeestockissuances asummaryofoptionactivityundertheplanasofjanuary asummaryofshareactivityundertheplanasofjanuary decemberanddecemberandchangesduring theyearsendingonthosedatesispresentedbelow outstanding sharesinthousands shares aggregate sharesatdecember weighted intrinsic sharesgranted outstanding average value sharesinthousands shares exerciseprice dollarsinmillions sharesissued sharesatdecember sharescanceledforfeited optionsgranted sharesatdecember optionsexercised sharesgranted optionscanceledforfeited sharesissued sharesatdecember sharescanceledforfeited sharesatdecember optionsgranted sharesgranted optionsexercised sharesissued optionscanceledforfeited sharescanceledforfeited sharesatdecember sharesatjanuary optionsgranted optionsexercised theaveragefairvalueoftherestrictedshareunitsgrantedwas optionscanceledforfeited andinandrespectively sharesatjanuary usingthefairmarketvalueatthedateofgrantthefairvalueof restrictedshareunitswasdiscountedfordividendswhicharenot thetotalintrinsicvalueofoptionsexercisedwasmillion paidontherestrictedshareunitsduringthevestingperiodthefair millionandmillioninandrespectivelythe valueofrestrictedshareunitssettledwasmillionmil totalunrecognizedcompensationcostwasmillionasofjanu lionandmillioninandrespectively arymillionasofdecemberandmil lionasofdecembertheweightedaverageperiodforthis costtoberecognizedwasyearsyearsandyearsfor andrespectively thefollowingtablesummarizesstockoptionsoutstandingand exercisableatjanuary sharesinthousandsoutstanding exercisable average average exercise average exercise exercise pricerange options life price options price averagecontractualliferemaininginyears johnson johnson annual reportsegmentsofbusinessandgeographicareas salestocustomers dollarsinmillions consumer unitedstates international total pharmaceutical unitedstates international total medicaldevicesanddiagnostics unitedstates international total worldwidetotal operatingprofit identifiableassets dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics segmentstotal generalcorporate worldwidetotal salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincomeexpense generalcorporateincludescashandmarketablesecurities includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnostics segmentsrespectivelyincludesmillionoffourthquarternetlitigationgaincomprisedofamillionexpenseinthepharmaceuticalsegmentandagainofmillioninthe medicaldevicesanddiagnosticssegment includesmillionandmillionofiprdfortheconsumerandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionoffourthquarternetlitigationgain comprisedofamillionexpenseintheconsumersegmentandagainofmillioninthemedicaldevicesanddiagnosticssegmentthemedicaldevicesanddiagnosticssegment alsoincludesmilliongainonthedivestitureoftheprofessionalwoundcarebusinessofethiconinc includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnosticssegments respectivelythemedicaldevicesanddiagnosticssegmentincludesmillionofiprdthepharmaceuticalsegmentalsoincludesmillionforthewritedownofthenatrecor intangibleasset longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyandintangibleassetsandgoodwillnetfor andofandrespectively notes consolidated financial statements selectedquarterlyfinancialdataunaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow first second third fourth first second third fourth dollarsinmillionsexceptpersharedata quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical meddevicesdiagnostics totalsales grossprofit earningsbeforeprovisionfortaxesonincome netearnings basicnetearningspershare dilutednetearningspershare thefourthquarterofincludesanaftertaxchargeofmillionforrestructuringandmillionaftertaxofincomefromnetlitigation thesecondquarterofincludesanaftertaxchargeofmillionforiprd thefourthquarterofincludesanaftertaxchargeofmillionforiprdmillionaftertaxofincomefromnetlitigationandmillionaftertaxgainonthedivestitureof theprofessionalwoundcarebusinessofethiconincthegainfromthedivestitureoftheprofessionalwoundcarebusinessofethiconincwasreinvestedinthebusiness businesscombinationsanddivestitures certainbusinesseswereacquiredformillionincashand certainbusinesseswereacquiredformillionincashand millionofliabilitiesassumedduringtheseacquisitions millionofliabilitiesassumedandnoncontrollinginterests wereaccountedforbythepurchasemethodandaccordingly duringtheseacquisitionswereaccountedforbythepur resultsofoperationshavebeenincludedinthefinancialstatements chasemethodandaccordinglyresultsofoperationshavebeen fromtheirrespectivedatesofacquisition includedinthefinancialstatementsfromtheirrespectivedates theacquisitionsincludedamicabaprivatelyheld ofacquisition swedishdeveloperofinvitrodiagnostictechnologiesforusein theacquisitionsincludedmentorcorporationaleading pointofcareandnearpatientsettingsbeijingdabaocosmetics supplierofmedicalproductsfortheglobalaestheticsmarket coltdacompanythatsellspersonalcarebrandsinchina cougarbiotechnologyincadevelopmentstagebiopharmaceutical surgrxincaprivatelyhelddeveloperoftheadvancedbipolar companywithaspecificfocusononcologyfinsburyorthopaedics tissuesealingsystemusedintheensealfamilyofdevices limitedaprivatelyheldukbasedmanufacturerandglobaldistrib healthmediaincaprivatelyheldcompanythatcreateswebbased utoroforthopaedicimplantsglostereuropeaprivatelyhelddevel behaviorchangeinterventionslgeperformancesystemsinca operofinnovativedisinfectionprocessesandtechnologiesto privatelyheldcompanyknownashumanperformanceinstitute preventhealthcareacquiredinfectionsandsubstantiallyallofthe whichdevelopssciencebasedtrainingprogramstoimprove assetsandrightsofelansalzheimersimmunotherapyprogram employeeengagementandproductivityandomrixbiopharmaceu throughanewlyformedcompanyofwhichthecompanyowns ticalsincafullyintegratedbiopharmaceuticalcompanythat andelanowns developsandmarketsbiosurgicalandimmunotherapyproducts theexcessofpurchasepriceovertheestimatedfairvalueof theexcessofpurchasepriceovertheestimatedfairvalueof tangibleassetsacquiredamountedtomillionandhasbeen tangibleassetsacquiredamountedtomillionandhasbeen assignedtoidentifiableintangibleassetswithanyresidualrecorded assignedtoidentifiableintangibleassetswithanyresidualrecorded togoodwillofthisamountapproximatelymillionhasbeen togoodwillapproximatelymillionhasbeenidentifiedasthe identifiedasthevalueofiprdprimarilyassociatedwiththeacqui valueofiprdassociatedwiththeacquisitionsofomrixbiophar sitionsofcougarbiotechnologyincandsubstantiallyallofthe maceuticalsincamicabsurgrxincandhealthmediainc assetsandrightsofelansalzheimersimmunotherapyprogram theiprdchargerelatedtotheacquisitionofomrixbiophar additionallyapproximatelymillionhasbeenidentifiedasthe maceuticalsincwasmillionandisassociatedwithstand valueofotherintangibleassetsincludingpatentstechnologyand aloneandcombinationbiosurgicaltechnologiesusedtoachieve customerrelationshipsprimarilyassociatedwiththeacquisitionof hemostasisthevalueoftheiprdwascalculatedusingcash mentorcorporation flowprojectionsdiscountedfortheriskinherentinsuchprojects theiprdrelatedtotheacquisitionofcougarbiotechnology probabilityofsuccessfactorsrangingfromwereused incwasmillionandisassociatedwithabirateroneacetatea toreflectinherentclinicalandregulatoryriskthediscountrate latestagefirstinclasscompoundforthetreatmentofprostatecan appliedwasasoftheendofthefiscalyearofthe certhevalueoftheiprdwascalculatedusingcashflowprojec outstandingsharesofcommonstockofomrixbiopharmaceuticals tionsdiscountedfortheriskinherentinsuchprojectsprobabilityof successfactorsrangingfromwereusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwas refertonoteforinformationrelatedtotheelantransaction johnson johnson annual reportinchadbeentenderedbystockholdersexcludingsharesthat notelegalproceedings weretenderedsubjecttoguaranteeddeliveryprocedures productliability oftheoutstandingsharesofcommonstockhadbeentendered thecompanyssubsidiariesareinvolvedinnumerousproduct ondecemberthecompanycompletedtheacquisition liabilitycasesintheunitedstatesmanyofwhichconcernalleged ofomrixbiopharmaceuticalsinc adversereactionstodrugsandmedicaldevicesthedamages theiprdchargerelatedtotheacquisitionofamicabwas claimedaresubstantialandwhilethecompanyisconfidentofthe millionandisassociatedwithpointofcaredeviceandcast adequacyofthewarningsandinstructionsforusethataccompany chiptechnologiesthevalueoftheiprdwascalculatedusing suchproductsitisnotfeasibletopredicttheultimateoutcomeof cashflowprojectionsdiscountedfortheriskinherentinsuch litigationhoweverthecompanybelievesthatifanyproductliabil projectsthediscountrateappliedwas ityresultsfromsuchcasesitwillbesubstantiallycoveredbyexist theiprdchargerelatedtotheacquisitionofsurgrxincwas ingamountsaccruedinthecompanysbalancesheetandwhere millionandisassociatedwithvesselcuttingandsealingsurgical availablebythirdpartyproductliabilityinsurance devicesthevalueoftheiprdwascalculatedusingcashflowpro multipleproductsofjohnsonjohnsonsubsidiaries jectionsdiscountedfortheriskinherentinsuchprojectsprobability aresubjecttonumerousproductliabilityclaimsandlawsuits ofsuccessfactorsrangingfromwereusedtoreflectinher thereareasignificantnumberofclaimantswhohavepending entclinicalandregulatoryriskthediscountrateappliedwas lawsuitsorclaimsregardinginjuriesallegedlyduetoortho theiprdchargerelatedtotheacquisitionofhealthmedia evrarisperdallevaquinduragesicthecharit incwasmillionandisassociatedprimarilywithprocess artificialdiscandcypherstenttheseclaimantsseeksub enhancementstosoftwaretechnologythevalueoftheiprdwas stantialcompensatoryandwhereavailablepunitivedamages calculatedusingcashflowprojectionsdiscountedfortheriskinher withrespecttorisperdaltheattorneysgeneralofeight entinsuchprojectsaprobabilityofsuccessfactorofwas statesandtheofficeofgeneralcounselofthecommonwealthof usedtoreflectinherentriskthediscountrateappliedwas pennsylvaniahavefiledactionsseekingreimbursementofmedicaid certainbusinesseswereacquiredformillionincashand orotherpublicfundsforrisperdalprescriptionswrittenfor millionofliabilitiesassumedduringtheseacquisitions offlabelusecompensationfortreatingtheircitizensforalleged wereaccountedforbythepurchasemethodandaccordingly adversereactionstorisperdalcivilfinesorpenaltiespunitive resultsofoperationshavebeenincludedinthefinancialstatements damagesorotherrelieftheattorneygeneraloftexashasjoineda fromtheirrespectivedatesofacquisition quitamactioninthatstateseekingsimilarreliefcertainofthese theacquisitionsincludedconormedsystemsinca actionsalsoseekinjunctivereliefrelatingtothepromotionof cardiovasculardevicecompanywithnewdrugdeliverytechnology risperdaltheattorneysgeneralofmorethanotherstates robertreidincajapaneseorthopedicproductdistributorand haveindicatedapotentialinterestinpursuingsimilarlitigation mayasmomincasocialmediacompany againstthecompanyssubsidiaryjanssenpharmaceuticainc theexcessofpurchasepriceovertheestimatedfairvalue janssennoworthomcneiljanssenpharmaceuticalsinc oftangibleassetsacquiredamountedtomillionandhas omjpiandhaveobtainedatollingagreementstayingtherun beenassignedtoidentifiableintangibleassetswithanyresidual ningofthestatuteoflimitationswhiletheyinquireintotheissues recordedtogoodwillapproximatelymillionhasbeenidenti inadditiontherearesixcasesfiledbyunionhealthplansseeking fiedasthevalueofiprdassociatedwiththeacquisitionofconor damagesforallegedoverpaymentsforrisperdalseveralof medsystemsinc whichseekcertificationasclassactionsinthecasebroughtbythe theiprdchargerelatedtotheacquisitionofconor attorneygeneralofwestvirginiabasedonclaimsforallegedcon medsystemsincwasmillionandisassociatedwithresearch sumerfraudastoduragesicaswellasrisperdaljanssen relatedtothediscoveryandapplicationofthestenttechnology nowomjpiwasfoundliableanddamageswereassessedat thevalueoftheiprdwascalculatedusingcashflowprojections millionomjpihasfiledanappeal discountedfortheriskinherentinsuchprojectsthediscountrate numerousclaimsandlawsuitsintheunitedstatesrelating appliedwas tothedrugpropulsidwithdrawnfromgeneralsalebythe supplementalproformainformationforand companysjanssennowomjpisubsidiaryinhavebeen inaccordancewithusgaapstandardsrelatedtobusinesscombi resolvedorarecurrentlyenrolledinsettlementprogramswithan nationsandgoodwillandotherintangibleassetsisnotprovidedas aggregatecapbelowmillionsimilarlitigationconcerning theimpactoftheaforementionedacquisitionsdidnothaveamate propulsidispendingincanadawhereanationalclassactionof rialeffectonthecompanysresultsofoperationscashflowsor personsallegingadversereactionstothedrughasbeencertified financialposition andasettlementprograminstitutedwithanaggregatecapbelow withtheexceptionofthedivestitureoftheprofessional million woundcarebusinessofethiconincwhichresultedinagainof millionbeforetaxandisrecordedinotherincomeexpense affirmativestentpatentlitigation netindivestituresinanddidnothavea inpatentinfringementactionstriedindelawarefederaldistrict materialeffectonthecompanysresultsofoperationscashflows courtinlatecordiscorporationcordisasubsidiaryof orfinancialposition johnsonjohnsonobtainedverdictsofinfringementandpatent validityanddamageawardsagainstbostonscientificcorporation bostonscientificandmedtronicaveincmedtronicbasedon anumberofcordisvascularstentpatentsindecemberthe juryinthedamageactionagainstbostonscientificreturnedaver dictofmillionandthejuryinthemedtronicactionreturneda verdictofmillionthecourtofappealsforthefederalcircuit hasupheldliabilityinthesecasesandonseptemberthe districtcourtenteredjudgmentsincludinginterestintheamounts ofmillionandmillionagainstbostonscientificand notes consolidated financial statements medtronicrespectivelymedtronicpaidmillioninoctober appealsforthefederalcircuitheldthedingpatentinvalidanda representingthejudgmentnetofamountsexchangedinset judgmentinfavorofcordisinthatcasehasbeenenteredinmarch tlementofanumberofotherlitigationsbetweenthecompanies thecourtofappealsforthefederalcircuitupheldthejudg thenetsettlementofmillionwasrecordedasacredittoother mentthatcordiscypherstentinfringedbostonscientificsjang incomeexpensenetintheconsolidatedstatementofearn patentthecasehasbeenremandedforatrialontheissuesofdam ingsinseptembercordissettledthiscasewithbostonscien agesandwillfulnessthejangcasehasbeendismissedaspartof tifictogetherwiththekasenthoferfontirrocheanddingcases thejanuarysettlementdescribedintheparagraphabove describedbelowforanetpaymentofmillionaspartofthat relatingtotheexpresstaxusandlibertestents settlementbostonscientificreceivedapaiduplicensetothe ingermanybostonscientifichadseveralactionsbasedonits fontirrochefamilyofpatentsworldwideandcordisreceivedapaid dingpatentspendingagainstthecordiscypherstentboston licensetothekastenhoferanddingfamiliesofpatentsworldwide scientificalsohadbroughtactionsinbelgiumthenetherlands andthepartiessettledallpendinglawsuitsworldwiderelatingto germanyfranceanditalyunderitskastenhoferpatentwhich thesepatentsthereceiptofmillionlesstheimpactofother purportstocovertwolayercatheterssuchasthoseusedtodeliver litigationmattersresultedinacredittootherincomeexpensenet thecypherstentthesecaseshavebeensettledaspartofthe ofmillioninthefiscalfourthquarterofinadditionin septembersettlementdescribedabove maymedtronicpaidmilliontosettleadditionalpatent trialinbostonscientificsuscasebasedonthekastenhofer infringementclaimsassertedbycordisbasedonitsvascularstent patentinfederaldistrictcourtincaliforniaconcludedinoctober patentswhichwasrecordedasacredittootherincomeexpense withajuryfindingthatthepatentwasinvalidthejuryalso netinthefiscalsecondquarterof foundforcordisonitscounterclaimthatsalebybostonscientificof injanuarycordisfiledapatentinfringementaction itsballooncathetersandstentdeliverysystemsinfringecordis againstbostonscientificindelawarefederaldistrictcourtaccus fontirrochepatentthecourthasdeniedbostonscientificspost ingitsexpresstaxusandlibertestentsofinfringingthepal trialmotionsthiscasewassettledaspartoftheseptember mazpatentthatexpiredinnovemberthelibertestentwas settlementdescribedabove alsoaccusedofinfringingcordisgraypatentthatexpiresin inmaycentocorinccentocornowcentocorortho injuneajuryfoundthattheexpresstaxusandliberte biotechinccobifiledalawsuitagainstgenentechincgenen stentsinfringedthepalmazpatentandthatthelibertestentalso techinusdistrictcourtforthecentraldistrictofcaliforniaseek infringedthegraypatentonmarchtheuscourtof ingtoinvalidatethecabillyiipatentpriortofilingsuitcentocor appealsforthefederalcircuitaffirmedthisjudgmentthecase hadasublicenseunderthispatentfromcelltechwhowaslicensed wasremandedtothedistrictcourtforatrialondamagesandwill bygenentechforremicadeandhadbeenpayingroyaltiesto fulnesscordisalsofiledalawsuitindelawarefederaldistrictcourt celltechcentocorhasterminatedthatsublicenseandstopped inoctoberofallegingthatbostonscientificssalesoftaxus payingroyaltiesgenentechhasfiledacounterclaimallegingthat andliberteafterjuneofinfringescordisgraypatenton remicadeinfringesitscabillyiipatentsandthatthemanufacture januarythesecasestogetherwiththejangcasereferred ofremicadestelarasimponiandreoproalsoinfringes tointheparagraphbelowweresettledunderthetermsoftheset oneofitsotherpatentsrelatingtothepurificationofantibodiesmade tlementbostonscientificpaidcordisbilliononfebruary throughrecombinantdnatechniquesthecourthasscheduleda andwillpaycordisanadditionalmillionplusintereston hearingforsummaryjudgmentmotionsinaugust januarycordisgrantedbostonscientificapaidupworld inaprilabenchtrialwasheldbeforethefederaldistrict widelicenseunderthepalmazandgraypatentsandbostonscien courtforthemiddledistrictoffloridaontheliabilityphaseof tificgrantedcordisapaidupworldwidelicenseunderthejang cibaspatentinfringementlawsuitallegingthatjohnsonjohnson patentsforallstentssoldbycordisexceptthemmsizecypher visioncareincsjjvcacuvueoasyslensesinfringethree cordishasseveralpendinglawsuitsinnewjerseyand oftheirnicholsonpatentsinaugustthedistrictcourtfound delawarefederaldistrictcourtagainstguidantcorporation twoofthesepatentsvalidandinfringedandenteredjudgment guidantabbottlaboratoriesincabbottbostonscientificand againstjjvcjjvchasappealedthatjudgmenttothecourtof medtronicallegingthatthexiencevabbottpromusboston appealsforthefederalcircuitonmarchthedistrict scientificandendeavormedtronicdrugelutingstentsinfringe courtwillholdahearingoncibasmotionforapermanentinjunc severalpatentsownedbyorlicensedtocordisinoneofthecases tionifthejudgmentisupheldonappealthecourtwillschedule againstbostonscientificallegingthatsalesoftheirpromusstent anothertrialtodeterminedamagesandwillfulness infringedwrightandfaloticopatentsonjanuarythe inmayabbottbiotechnologyltdfiledapatentinfringe districtcourtindelawarefoundthewrightfaloticopatentinvalid mentlawsuitagainstcentocornowcobiintheunitedstatesdis forlackofwrittendescriptionandorlackofenablementcordis trictcourtforthedistrictofmassachusettsthesuitallegesthat intendstoappealthisruling centocorssimponiproductahumanantitnfalphaantibody infringesabbottspatentthesalfeldpatentthecasehas patentlitigationagainstvarious beenstayedpendingtheresolutionofanarbitrationfiledbycento johnsonjohnsonsubsidiaries cordirectedtoitsclaimthatitislicensedunderthepatentthe theproductsofvariousjohnsonjohnsonsubsidiariesarethe arbitrationisscheduledformarch subjectofvariouspatentlawsuitstheoutcomesofwhichcould inaugustabbottgmbhcoabbottgmbhand potentiallyadverselyaffecttheabilityofthosesubsidiariestosell abbottbioresearchcenterfiledapatentinfringementlawsuit thoseproductsorrequirethepaymentofpastdamagesand againstcobiintheunitedstatesdistrictcourtforthedistrictof futureroyalties massachusettsthesuitallegesthatcobisstelaraproduct injulyajuryinfederaldistrictcourtindelawarefound infringestwouspatentsassignedtoabbottgmbhinaugust thatthecordiscypherstentinfringedbostonscientificsding cobifiledacomplaintforadeclaratoryjudgmentofnon patentandthatthecordiscypherandbxvelocity infringementandinvalidityoftheabbottgmbhpatentsinthe stentsalsoinfringedbostonscientificsjangpatentthejury unitedstatesdistrictcourtforthedistrictofcolumbiaonthe alsofoundbothofthosepatentsvalidinjanuarythecourtof samedatealsointheunitedstatesdistrictcourtforthedistrictof johnson johnson annual reportcolumbiacobifiledacomplaintforreviewofapatentinterfer texasonjuneajuryreturnedaverdictfindingthepatent encedecisiongrantingpriorityofinventionononeofthetwo validandwillfullyinfringedandawardedcentocordamagesof assertedpatentstoabbottgmbhinaugustabbottgmbh approximatelybillionabenchtrialonabbottsdefensesof andabbottlaboratorieslimitedbroughtapatentinfringementsuit inequitableconductandprosecutionlacheswasheldinaugust incanadaallegingthatstelarainfringesabbottgmbhscana andthedistrictcourtdecidedtheseissuesinfavorofcento dianpatentthecasesfiledbycobiinthedistrictofcolumbiahave corallofabbottsposttrialmotionshavebeendeniedexceptthat beentransferredtothedistrictofmassachusetts thedistrictcourtgrantedabbottsmotiontooverturnthejuryfind inaugustbayerhealthcarellcfiledsuitagainstcobi ingofwillfulnessjudgmentintheamountofbillionwas inmassachusettsdistrictcourtalleginginfringementbycobis enteredinfavorofcentocorindecemberandabbotthas simponiproductofitspatentrelatingtohumanantitnfanti filedanappealtothecourtofappealsforthefederalcircuitthe bodiesbayerhasalsofiledsuitunderitseuropeancounterpartto companyhasnotreflectedanyofthebillioninitsconsolidated thesepatentsingermanyandthenetherlands financialstatementscentocorhasalsofiledanewlawsuitinthe injunecentocorsnowcobilawsuitallegingthat easterndistrictoftexasseekingdamagesforinfringementofthe abbottshumiraantitnfalphaproductinfringescentocors patentattributabletosalesofhumirasubsequenttothejury patentwenttotrialinfederaldistrictcourtintheeasterndistrictof verdictinjune thefollowingchartsummarizesvariouspatentlawsuitsconcerningproductsofthecompanyssubsidiariesthathaveyettoproceed totrial jj plaintiff product company patents patentholder court trialdate datefiled cypherstent cordis wall wall edtx q cypherstent cordis saffran saffran edtx q bloodglucosemetersandstrips lifescan wilsey rochediagnostics dde remicadeustekinumab centocorcobi cabillyii genentech cdca golimumabreopro simponi centocorcobi salfeld abbottlaboratories simponi centocorcobi boyle bayerhealthcare stelara centocorcobi salfeld abbottgmbh madc trialdatetobescheduled qreflectsthecompanysfiscalquarter litigationagainstfilersofabbreviatednewdrug noninfringementinvalidityandunenforceabilityofthesepatents applicationsandas intheeventthesubsidiaryofthecompanyinvolvedisnotsuccess thefollowingchartindicateslawsuitspendingagainstgenericfirms fulintheseactionsorthestatutorymonthstayexpiresbeforea thatfiledabbreviatednewdrugapplicationsandasseekingto rulingfromthedistrictcourtisobtainedthefirmsinvolvedwillhave marketgenericformsofproductssoldbyvarioussubsidiariesof theabilityuponfdaapprovaltointroducegenericversionsofthe thecompanypriortoexpirationoftheapplicablepatentscovering productatissueresultinginverysubstantialmarketshareand thoseproductstheseandastypicallyincludeallegationsof revenuelossesfortheproductofthecompanyssubsidiary asnotedinthefollowingchartmonthstaysexpiredduringandwillexpireinandwithrespecttoanda challengesregardingvariousproducts brandname patentnda generic trial date month product holder challenger court date filed stayexpiration concerta mcneilppc andrx dde q none andmgcontrolled alza kudco dde releasetablet levaquinmgtablet orthomcneil lupin dnj orthotricyclenlo orthomcneil watson dnj mgmgmgmg sandoz dnj andmgmg dnj ultramermgtablet orthomcneilbiovail par dde q ultramermgtablet orthomcneilbiovail impax dde q ultramermgtablet orthomcneilbiovail paddock ddrdminn ultramermgtablet orthomcneilbiovail cipher dde ultramermgtablet orthomcneilbiovail lupin dde trialdatetobescheduled qreflectsthecompanysfiscalquarter notes consolidated financial statements intheactionagainstbarrpharmaceuticalsincbarrnowa thedelawaredecisioninvalidatingtherazadyneusepatent whollyownedsubsidiaryoftevapharmaceuticalindustriesltd asaresultthiscasewillnotbereopened regardingorthotricyclenloinjanuarythecom intheactionagainstlupinpharmaceuticalsinclupin panyssubsidiaryorthowomenshealthurologyadivisionof regardingitsandaconcerninglevaquinlupincontendsthat orthomcneiljanssenpharmaceuticalsincomjpiandbarr theuspatentandtrademarkofficeimproperlygrantedapatent agreedtoanonbindingtermsheettosettlethelitigationwhich termextensiontothepatentthatorthomcneilnowortho settlementdiscussionsarestillunderwaythetrialcourtpostponed mcneiljanssenpharmaceuticalsincomjpilicensesfrom thejanuarytrialwithoutsettinganewtrialdateinjune daiichipharmaceuticalsincdaiichilupinallegesthattheactive barrlauncheditsgenericproductatriskbeforetrialomjpi ingredientinlevaquinwasthesubjectofpriormarketingand soughtapreliminaryinjunctionandrecallofbarrproductwhichthe thereforewasnoteligibleforthepatenttermextensionlupincon courtgrantedinjulyinjulythepartiesenteredintoa cedesvalidityandthatitsproductwouldviolatethepatentifmar definitiveagreementtosettlethelawsuitunderthetermsofthe ketedpriortotheexpirationoftheoriginalpatenttermsummary settlementbarrobtainedareleaseforitssalesofitsgenericproduct judgmentagainstlupinwasgrantedinmayandlupin inexchangeforanundisclosedroyaltypaymentbarralsoobtaineda appealedoralargumentwasheldinseptemberadecision nonexclusiveroyaltybearinglicensetoreenterthemarketon ispending decemberorearlierincertainlimitedcircumstances intheultrameractionsorthomcneilpharmaceutical inoctoberthecompanyssubsidiaryomjpifiledsuitin incorthomcneilnowomjpifiledlawsuitseachfordifferent federaldistrictcourtinnewjerseyagainstwatsonlaboratories dosagesagainstparpharmaceuticalsincandparpharmaceuticals incwatsoninresponsetowatsonsandaregardingortho companiesincparinmayjuneandoctoberontwo tricyclenloinjunethecompanyssubsidiaryomjpi tramadolerformulationpatentsownedbypurduepharma filedsuitinfederaldistrictcourtinnewjerseyagainstsandoz productslppurdueandnapppharmaceuticalgroupltdnapp laboratoriesincsandozinresponsetosandozsandaregarding omjpialsofiledlawsuitseachfordifferentdosagesagainstimpax orthotricyclenlothesandozandwatsoncaseshave laboratoriesincimpaxonatramadolerformulationpatent beenconsolidated ownedbypurdueandnappinaugustandnovemberpurdue injanuarythecompanyssubsidiaryomjpifiledsuitin nappandbiovaillaboratoriesinternationalsrlbiovailthenda federaldistrictcourtinnewjerseyagainstlupinltdandlupin holderjoinedascoplaintiffsinthelawsuitsagainstparandimpax pharmaceuticalsinccollectivelylupininresponsetolupins butbiovailandomjpiweresubsequentlydismissedforlackof andaregardingorthotricyclenlo standingthetrialagainstpartookplaceinaprilinaugust intheactionagainstbarrandalphapharmwithrespecttotheir thecourtissuedadecisionfindingthepatentsinsuitinvalid andachallengestotherazadynepatentthatjanssennow purduehasappealedthatdecisionthetrialagainstimpaxissched omjpilicensesfromsynaptechincsynaptechafourdaynon uledforjuneinnovemberthecaseagainstimpaxwas jurytrialwasheldinthefederaldistrictcourtindelawareinmay stayedwiththeconsentofallpartiesinseptemberandoctober inaugustthecourtheldthatthepatentwasinvalid respectivelypurduefiledsuitsagainstpaddocklaboratories becauseitwasnotenabledjanssenomjpiandsynaptechhave incpaddockandcipherpharmaceuticalsinccipheronits appealedthedecisionsincethecourtsdecisionmultiplegeneric tramadolerformulationpatents companieshavereceivedfinalapprovalsfortheirproductsandhave injanuarypurduefiledasuitagainstlupinltdlupin launchedatriskpendingappealadditionalgenericapprovalsand onitstramadolerformulationpatents launchescouldoccuratanytimeinseptemberthecourtof inseptembercentocororthobiotechproductslp appealsaffirmedthejudgmentthatthepatentisinvalid cobilpintervenedinaninventorshipdisputebetweenkansas intheactionbymcneilppcincmcneilppcandalza universitycenterforresearchkucrinvolvingcertainus corporationalzaagainstandrxcorporationandrxwith governmentownedvelcadeformulationpatentskucrbrought respecttoitsandachallengetotheconcertapatentsafive thisactionagainsttheusgovernmentinthedistrictofkansas daynonjurytrialwasheldinthefederaldistrictcourtindelaware seekingtoaddtwokansasuniversityscientiststothepatents indecemberinmarchthecourtruledthatone theusgovernmentlicensedthepatentsandtheirforeigncoun concertapatentwouldnotbeinfringedbyandrxsproposed terpartstomillenniumpharmaceuticalsincwhointurnsubli genericproductandthatthepatentwasinvalidbecauseitwasnot censedthepatentsandtheirforeigncounterpartstocobilp enabledthecourtdismissedwithoutprejudiceandrxsdeclaratory forcommercialmarketingoutsidetheusifkucrsucceedsinits judgmentsuitonasecondpatentforlackofjurisdictionmcneil coinventorshipclaimandestablishescoownershipintheus ppcandalzafiledanappealinmaytheappealscourt velcadeformulationpatentsweanticipatethatkucrwilliniti heardargumentonfebruaryadecisionispending ateactionstoestablishcoinventorshipandcoownershipwith alzaandomjpifiledasecondsuitinfederaldistrictcourtin respecttotheforeigncounterpartpatentsinthecountrieswhere delawareagainstkremersurbanllcandkudcoirelandltd cobilphascommercialmarketingrightsifkucrinkansasis kudcoinjanuaryinresponsetokudcosandachal successfulthismayadverselyaffectcobilpslicenserightsin lengeregardingconcertatabletsinitsnoticeletterkudco thosecountries contendsthattwoalzapatentsforconcertaareinvalidand notinfringedbyakudcogeneric averagewholesalepriceawplitigation intherazadyneercasesalawsuitwasfiledagainstbarr johnsonjohnsonandseveralofitspharmaceuticalsubsidiaries ontherazadyneusepatentthatjanssennowomjpilicenses alongwithnumerousotherpharmaceuticalcompaniesaredefen fromsynaptechinjuneinseptembertheabove dantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingalle discusseddelawaredecisioninvalidatingtherazadyneuse gationsthatthepricingandmarketingofcertainpharmaceutical patentresultedinentryofjudgmentforbarronthatpatentbutthe productsamountedtofraudulentandotherwiseactionableconduct casewillbereopenedifjanssennowomjpiandsynaptechwin becauseamongotherthingsthecompaniesallegedlyreportedan onappealbarrhasreceivedfdaapprovalofitsproductandhas inflatedaveragewholesalepriceawpforthedrugsatissue launchedatriskinseptemberthefederalcircuitaffirmed manyofthesecasesbothfederalactionsandstateactions johnson johnson annual reportremovedtofederalcourthavebeenconsolidatedforpretrialpur inseptemberplaintiffsinanemploymentdiscrimination posesinamultidistrictlitigationmdlinfederaldistrictcourt litigationinitiatedagainstthecompanyininfederaldistrict inbostonmassachusettstheplaintiffsinthesecasesinclude courtinnewjerseymovedtocertifyaclassofallafricanamerican classesofprivatepersonsorentitiesthatpaidforanyportionofthe andhispanicsalariedemployeesofthecompanyanditsaffiliatesin purchaseofthedrugsatissuebasedonawpandstategovernment theuswhowereemployedatanytimefromnovemberto entitiesthatmademedicaidpaymentsforthedrugsatissuebased thepresentplaintiffsseekmonetarydamagesfortheperiod onawp throughthepresentincludingpunitivedamagesandequitable themdlcourtidentifiedclassesofmassachusettsonlypri reliefthecourtdeniedplaintiffsclasscertificationmotionin vateinsurersprovidingmedigapinsurancecoverageandprivate decemberandtheirmotionforreconsiderationinapril payersforphysicianadministereddrugswherepaymentswere plaintiffssoughttoappealthesedecisionsandinaprilthe basedonawpclassandclassandanationalclassof courtofappealsruledthatplaintiffsappealofthedenialofclass individualswhomadecopaymentsforphysicianadministered certificationwasuntimelyinjulyplaintiffsfiledamotionfor drugscoveredbymedicareclassatrialofthetwomassachu certificationofamodifiedclasswhichthecompanyisopposing settsonlyclassactionsconcludedbeforethemdlcourtindecem plaintiffsareengagedinfurtherdiscoveryofindividualplaintiffs berinjunethemdlcourtissuedposttrialrulings claimsthehearingonplaintiffsmotionforclasscertificationis dismissingthejohnsonjohnsondefendantsfromthecaseregard scheduledforjuly ingallclaimsofclassesandandsubsequentlyofclassaswell inmarchdepuyorthopaedicsincdepuyajohnson plaintiffsappealedtheclassjudgmentandinseptember johnsonsubsidiaryreceivedasubpoenafromtheusattorneys thecourtofappealsvacatedthejudgmentandremandedfor officedistrictofnewjerseyseekingrecordsconcerningcontrac furtherproceedingsinthedistrictcourtawpcasesbroughtby tualrelationshipsbetweendepuyandsurgeonsorsurgeonsin variousattorneysgeneralhaveproceededtotrialagainstother traininginvolvedinhipandkneereplacementandreconstructive manufacturersonestatecaseagainstcertainofthecompanys surgerythisinvestigationwasresolvedbydepuyandthefourother subsidiarieshasbeensetfortrialinlateandotherstatecases leadingsuppliersofhipandkneeimplantsinlateseptember arelikelytobesetfortrialthereafter byagreementswiththeusattorneysofficeforthedistrictof newjerseythesettlementsincludedanmonthdeferredprose cutionagreementdpaacceptancebyeachcompanyofamoni injulycentocornowcobiajohnsonjohnsonsub tortoassurecompliancewiththedpaandwithrespecttofourof sidiaryreceivedarequestthatitvoluntarilyprovidedocumentsand thefivecompaniespaymentofsettlementmoniesandentryinto informationtothecriminaldivisionoftheusattorneysoffice fiveyearcorporateintegrityagreementsdepuypaidmillionas districtofnewjerseyinconnectionwithitsinvestigationintovari itssettlementthetermofthemonitorshipunderthedeferred ouscentocormarketingpracticessubsequentrequestsfordocu prosecutionagreementconcludedonmarchandanorder mentshavebeenreceivedfromtheusattorneysofficeboththe dismissingallchargeswasenteredonmarch companyandcentocorhaverespondedtotheserequestsfor innovembertheattorneygeneralofthecommon documentsandinformation wealthofmassachusettsissuedacivilinvestigativedemandto indecemberorthomcneilnowomjpireceiveda depuyseekinginformationregardingfinancialrelationships subpoenafromtheusattorneysofficeinbostonmassachusetts betweenanumberofmassachusettsbasedorthopedicsurgeons seekingdocumentsrelatingtothemarketingincludingallegedoff andprovidersanddepuydepuyisrespondingtomassachusetts labelmarketingofthedrugtopamaxtopiramateadditional additionalrequests subpoenasfordocumentshavebeenreceivedandcurrentandfor injulysciosincsciosajohnsonjohnsonsubsidiary meremployeeshavetestifiedbeforeagrandjurydiscussionsare receivedasubpoenafromtheusattorneysofficedistrictofmas underwayinanefforttoresolvethismatterbutwhetheragreement sachusettsseekingdocumentsrelatedtothesalesandmarketingof canbereachedandonwhattermsisuncertain natrecorsciosrespondedtothesubpoenainearlyaugust injanuaryjanssennowomjpireceivedasubpoena scioswasadvisedthattheinvestigationwouldbehandledby fromtheofficeoftheinspectorgeneraloftheusofficeofperson theusattorneysofficeforthenortherndistrictofcaliforniain nelmanagementseekingdocumentsconcerningsalesandmarket sanfranciscoadditionalrequestsfordocumentshavebeenreceived ingofanyandallpaymentstophysiciansinconnectionwithsales andrespondedtoandformersciosemployeeshavetestifiedbeforea andmarketingofandclinicaltrialsforrisperdalrisperidone grandjuryinsanfranciscothequitamcomplaintswereunsealed fromtodocumentssubsequenttohavealsobeen onfebruarytheusgovernmenthasintervenedinoneof requestedanadditionalsubpoenaseekinginformationaboutmar thequitamactionsandfiledacomplaintagainstsciosandthecom ketingofandadversereactionstorisperdalwasreceivedfrom panyinjunesciosandjohnsonjohnsonhavefiledamotion theusattorneysofficefortheeasterndistrictofpennsylvaniain todismissthequitamcomplaintfiledbythegovernmentandthat novembersubpoenasseekingtestimonyfromvariouswit motionwasdeniedthecriminalinvestigationiscontinuinganddis nessesbeforeagrandjuryhavealsobeenreceivedjanssenis cussionsareunderwayinanefforttosettlethismatterwhethera cooperatinginrespondingtoongoingrequestsfordocuments settlementcanbereachedandonwhattermsisuncertain andwitnessesthegovernmentiscontinuingtoactivelyinvestigate inseptemberthecompanyreceivedasubpoenafrom thismatterinfebruarythegovernmentservedcivilinvestiga theusattorneysofficedistrictofmassachusettsseekingdocu tivedemandsseekingadditionalinformationrelatingtosalesand mentsrelatedtosalesandmarketingofeightdrugstoomnicare marketingofrisperdalandsalesandmarketingofinvega incamanagerofpharmaceuticalbenefitsforlongtermcarefacili inseptemberorthobiotechincorthobiotechnow tiesthejohnsonjohnsonsubsidiariesinvolvedrespondedtothe cobireceivedasubpoenafromtheusofficeofinspectorgen subpoenaseveralemployeesofthecompanyspharmaceutical eralsdenvercoloradofieldofficeseekingdocumentsdirectedto subsidiarieshavebeensubpoenaedtotestifybeforeagrandjury thesalesandmarketingofprocritepoetinalfafrom inconnectionwiththisinvestigationinaprilthecompany tothepresentaswellastodealingswithusoncologyinca wasservedwiththecomplaintsintwocivilquitamcasesrelatedto healthcareservicesnetworkforoncologistsorthobiotechnow marketingofprescriptiondrugstoomnicareinconjanuary cobihasrespondedtothesubpoena notes consolidated financial statements thegovernmentfiledacomplaintinterveninginthecases withinthepharmaceuticalsectorbecausethisisasectorinquiry thecomplaintassertsclaimsunderthefederalfalseclaimsactand itisnotbasedonanyspecificallegationthatthecompanyhas arelatedstatelawclaiminconnectionwiththemarketingofseveral violatedeccompetitionlawtheinquirybeganwithunannounced drugstoomnicare raidsofasubstantialnumberofpharmaceuticalcompanies innovemberamgenincamgenfiledsuitagainst throughouteuropeincludingjohnsonjohnsonaffiliatesinmarch hoffmannlarocheincrocheintheusdistrictcourtforthe theecissueddetailedquestionnairestoapproximately districtofmassachusettsseekingadeclarationthattheroche companiesincludingjohnsonjohnsonaffiliatesinnovember productcerawhichrochehasindicateditwouldseektointroduce theecissuedapreliminaryreportsummarizingitsfindings intotheunitedstatesinfringesanumberofamgenpatentscon thefinalreportwasissuedonjuly cerningepoamgenlicensesepoforsaleintheunitedstatesto inmarchthecompanyreceivedaletterrequestfrom orthobiotechnowcobifornondialysisindicationstrialinthis theattorneygeneralofthestateofmichigantherequestseeks actionconcludedinoctoberwithaverdictinamgensfavor documentsandinformationrelatingtonominalpricetransactions findingthepatentsvalidandinfringedthejudgeissuedaprelimi thecompanyrespondedtotherequestandwillcooperatewiththe naryinjunctionblockingtheceralaunchandsubsequentlymade inquiry theinjunctionpermanentthefederalcircuitupheldtheentryofa injunethecompanyreceivedasubpoenafromthe permanentinjunctionthismatterhasbeensettledpursuanttoan unitedstatesattorneysofficeforthedistrictofmassachusetts agreementbetweentheparties relatingtothemarketingofbiliarystentsbythecompanyscordis infebruarythecompanyreceivedasubpoenafromthe subsidiarycordisiscooperatinginrespondingtothesubpoena ussecuritiesexchangecommissionsecrequestingdocu inseptembermultilanagmultilananindirectsub mentsrelatingtotheparticipationbyseveraljohnsonjohnson sidiaryofscheringploughcorporationcommencedarbitration subsidiariesintheunitednationsiraqoilforfoodprogramthe againstjanssenpharmaceuticanvforanallegedwrongfultermina subsidiariesarecooperatingwiththesecandusdepartmentof tionofanagreementrelatingtopaymentsinconnectionwithtermi justicedojinproducingresponsivedocuments nationofcertainmarketingrightsmultilanseeksdeclaratoryrelief infebruarythecompanyvoluntarilydisclosedtothe specificperformanceanddamagesthiscasewasrecentlysettled dojandthesecthatsubsidiariesoutsidetheunitedstatesare andachargewasrecordedtootherincomeexpensenetinthe believedtohavemadeimproperpaymentsinconnectionwiththe fiscalfourthquarterof saleofmedicaldevicesintwosmallmarketcountrieswhichpay infebruarybasileapharmaceuticaagbasileabrought mentsmayfallwithinthejurisdictionoftheforeigncorruptprac anarbitrationagainstthecompanyandvariousaffiliatesalleging ticesactfcpainthecourseofcontinuingdialogueswiththe thatthecompanybreachedthelicenseagreementforcefto agenciesotherissuespotentiallyrisingtotheleveloffcpaviola biprolebyamongotherthingsfailingtosecurefdaapprovalofthe tionsinadditionalmarketshavebeenbroughttotheattentionofthe csssiskinindicationandallegedlyfailingtoproperlydevelopthe agenciesbythecompanythecompanyhasprovidedandwillcon pneumoniaindicationbasileaisseekingtorecoverdamagesanda tinuetoprovideadditionalinformationtothedojandsecandwill declarationthatthecompanymateriallybreachedtheagreement cooperatewiththeagenciesreviewsofthesematterslawenforce thismatterhasbeenscheduledforanarbitrationhearingcom mentagenciesofanumberofothercountriesarealsopursuing mencinginjunefollowedbyposttrialsubmissions investigationsofmattersvoluntarilydisclosedbythecompanyto inaprilthecompanyreceivedahippasubpoena thedojandsecdiscussionsareunderwayinanefforttoresolve fromtheusattorneysofficeforthedistrictofmassachusetts thesemattersandtheiraqoilforfoodmatterreferencedabovebut bostonseekinginformationregardingthecompanysfinancial whetheragreementcanbereachedandonwhattermsisuncertain relationshipwithseveralpsychiatriststhecompanyisresponding inmarchthecompanyreceivedseparatesubpoenas tothisrequest fromtheusattorneysofficeinphiladelphiatheusattorneys inaprilorthoclinicaldiagnosticsincocdreceived officeinbostonandtheusattorneysofficeinsanfranciscothe agrandjurysubpoenafromtheusdepartmentofjustice subpoenasrelatetoinvestigationsbythesethreeofficesreferenced antitrustdivisionrequestingdocumentsandinformationforthe aboveconcerningrespectivelysalesandmarketingofrisperdal periodbeginningseptemberthroughthepresentpertaining byjanssennowomjpitopamaxbyorthomcneilnow toaninvestigationofallegedviolationsoftheantitrustlawsinthe omjpiandnatrecorbysciosthesubpoenasrequestinforma bloodreagentsindustrythecompanyisintheprocessofcomply tionregardingthecompanyscorporatesupervisionandoversight ingwiththesubpoenaintheweeksfollowingthepublicannounce ofthesethreesubsidiariesincludingtheirsalesandmarketingof mentthatocdhadreceivedasubpoenafromtheantitrust thesedrugsthecompanyrespondedtotheserequestsinaddition divisionmultipleclassactioncomplaintswerefiledthevarious theusattorneysofficeinbostonhasissuedsubpoenasforgrand caseswereconsolidatedforpretrialpurposesintheeastern jurytestimonytoseveralemployeesofjohnsonjohnson districtofpennsylvania inmaythenewyorkstateattorneygeneralissueda inmaythenewjerseyattorneygeneralissuedasub subpoenaseekinginformationrelatingtothemarketingandsafety poenatodepuyorthopaedicsincseekinginformationregarding ofprocritthecompanyisrespondingtotheserequests thefinancialinterestofclinicalinvestigatorswhoperformedclinical inaprilthecompanyreceivedtwosubpoenasfromthe studiesfordepuyorthopaedicsincanddepuyspineincthe officeoftheattorneygeneralofthestateofdelawarethesub companyisrespondingtotheserequests poenasseekdocumentsandinformationrelatingtonominalpricing inmaycobicommencedanarbitrationproceeding agreementsforpurposesofthesubpoenasnominalpricingagree beforetheamericanarbitrationassociationagainstschering mentsaredefinedasagreementsunderwhichthecompanyagreed ploughcorporationanditssubsidiaryscheringploughireland toprovideapharmaceuticalproductforlessthantenpercentofthe companycollectivelyscheringploughcobiandschering averagemanufacturerpricefortheproductthecompany plougharepartiestoaseriesofagreementsthedistribution respondedtotheserequests injanuarytheeuropeancommissionecbeganan industrywideantitrustinquiryconcerningcompetitiveconditions johnson johnson annual reportagreementsthatgrantscheringploughtheexclusiverighttodis ofmillionandmillionrelatedtoleaseholdandcontract tributethedrugsremicadeandsimponiworldwideexcept obligationsthemillionofassetwriteoffsrelatetoinventory withintheunitedstatesjapantaiwanindonesiaandthepeoples ofmillionrecordedincostofproductssoldpropertyplant republicofchinaincludinghongkongtheterritorycobi andequipmentofmillionintangibleassetsofmillionand distributesremicadeandsimponithenextgeneration otherassetsofmillionadditionallyaspartofthisprogramthe treatmentwithintheunitedstatesinthearbitrationcobi companyplanstoeliminateapproximatelypositionsofwhich seeksadeclarationthattheagreementandmergerbetween approximatelyhavebeeneliminatedsincetherestructuring merckcoincmerckandscheringploughconstitutesa wasannounced changeofcontrolunderthetermsofthedistributionagreements thefollowingtablesummarizestheseverancechargesandthe thatpermitscobitoterminatetheagreementsthetermination associatedspendingforthefiscalyearended ofthedistributionagreementswouldreturntocobitheright asset todistributeremicadeandsimponiwithintheterritory dollarsinmillions severance writeoffs total scheringploughhasfiledaresponsetocobisarbitrationdemand restructuringcharge thatdeniesthatithasundergoneachangeofcontrolthearbitra currentyearactivity torshavebeenselectedandthematterwillbeproceedingto reservebalance arbitrationinlateseptember january indecemberthestateofisraelshebamedicalcenter filedalawsuitagainstthreeomrixentitiesinthelawsuitthestate cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextto monthsinaccordancewiththecompanysplansandlocallaws claimedthatanemployeeofagovernmentownedhospitalwasthe inventoronseveralpatentsrelatedtofibringluetechnologythathe foradditionalinformationontherestructuringasitrelatestothe developedwhilehewasagovernmentemployeethestateclaims segmentsseenote thathehadnorighttotransferanyintellectualpropertytoomrix inthethirdquarterofthecompanyannouncedrestruc becauseitbelongstothestatethestateisseekingdamagesplus turinginitiativesinanefforttoimproveitsoverallcoststructure royaltyonquixilandeviceloralternativelytransferofthe thisactionwastakentooffsettheanticipatednegativeimpacts patentstothestate associatedwithgenericcompetitioninthepharmaceuticalsegment inrecentyearsthecompanyhasreceivednumerousrequests andchallengesinthedrugelutingstentmarketthecompanys fromavarietyofunitedstatescongressionalcommitteestopro pharmaceuticalssegmenthasreduceditscostbasebyconsolidat duceinformationrelevanttoongoingcongressionalinquiriesitis ingcertainoperationswhilecontinuingtoinvestinrecently thecompanyspolicytocooperatewiththeseinquiriesbyproduc launchedproductsanditslatestagepipelineofnewproductsthe ingtherequestedinformation cordisfranchisehasmovedtoamoreintegratedbusinessmodelto withrespecttoalltheabovemattersthecompanyandits addressthemarketchangesunderwaywithdrugelutingstentsand subsidiariesarevigorouslycontestingtheallegationsasserted tobetterservethebroadspectrumofitspatientscardiovascular againstthemandotherwisepursuingdefensestomaximizethe needswhilereducingitscostbasethecompanyacceleratedsteps prospectofsuccessthecompanyanditssubsidiariesinvolvedin tostandardizeandstreamlinecertainaspectsofitsenterprisewide thesematterscontinuallyevaluatetheirstrategiesinmanaging functionssuchashumanresourcesfinanceandinformationtech thesemattersandwhereappropriatepursuesettlementsandother nologytosupportgrowthacrossthebusinesswhilealsoleveraging resolutionswherethoseareinthebestinterestofthecompany itsscalemoreeffectivelyinareassuchasprocurementtobenefitits thecompanyisalsoinvolvedinanumberofotherpatent operatingcompaniesadditionallyaspartofthisprogramthe trademarkandotherlawsuitsincidentaltoitsbusinesstheulti companyeliminatedapproximatelypositions matelegalandfinancialliabilityofthecompanyinrespecttoall thecompanyrecordedmillioninrelatedpretaxcharges claimslawsuitsandproceedingsreferredtoabovecannotbeesti duringthefiscalthirdquarterofofwhichapproximately matedwithanycertaintyhoweverinthecompanysopinionbased millionofthepretaxrestructuringchargesrequiredcashpayments onitsexaminationofthesemattersitsexperiencetodateanddis themillionofrestructuringchargesconsistsofseverancecosts cussionswithcounseltheultimateoutcomeoflegalproceedings ofmillionassetwriteoffsofmillionandmillion netofliabilitiesaccruedinthecompanysbalancesheetisnot relatedtoleaseholdobligationsthemillionofassetwriteoffs expectedtohaveamaterialadverseeffectonthecompanysfinan relatetopropertyplantandequipmentofmillionintangible cialconditionalthoughtheresolutioninanyreportingperiodofone assetsofmillionandotherassetsofmilliontherestructur ormoreofthesematterscouldhaveasignificantimpactonthe inginitiativeannouncedinhasbeencompleted companysresultsofoperationsandcashflowsforthatperiod subsequentevents restructuring onjanuarythecompanycompletedtheacquisitionof inthefourthquarterofthecompanyannouncedglobal acclarentincforanetpurchasepriceofapproximatelymil restructuringinitiativesdesignedtostrengthenthecompanysposi lionacclarentincisamedicaltechnologycompanydedicatedto tionasoneoftheworldsleadingglobalhealthcarecompaniesthis designingdevelopingandcommercializingdevicesthataddress programwillallowthecompanytoinvestinnewgrowthplatforms conditionsaffectingtheearnoseandthroat ensurethesuccessfullaunchofitsmanynewproductsandcontin thecompanyhasperformedanevaluationofsubsequent uedgrowthofitscorebusinessesandprovideflexibilitytoadjustto eventsthroughmarchthedatethecompanyissuedthese thechangedandevolvingglobalenvironment financialstatements duringthefiscalfourthquarterofthecompany recordedbillioninrelatedpretaxchargesofwhichapproxi matelymillionofthepretaxrestructuringchargesare expectedtorequirecashpaymentsthebillionofrestructuring chargesconsistsofseverancecostsofmillionassetwriteoffs notes consolidated financial statements reportofindependentregisteredpublicaccountingfirm totheshareholdersandboardofdirectorsofjohnsonjohnson controlbasedontheassessedriskourauditsalsoincludedper formingsuchotherproceduresasweconsiderednecessaryinthe inouropiniontheaccompanyingconsolidatedbalancesheetsand circumstanceswebelievethatourauditsprovideareasonable therelatedconsolidatedstatementsofearningsstatementsof basisforouropinions equityandstatementsofcashflowspresentfairlyinallmaterial asdiscussedinnotetotheconsolidatedfinancialstatements respectsthefinancialpositionofjohnsonjohnsonanditssub thecompanychangedthemannerinwhichitaccountsforbusiness sidiariesthecompanyatjanuaryanddecember combinationsin andtheresultsoftheiroperationsandtheircashflowsfor acompanysinternalcontroloverfinancialreportingisa eachofthethreeyearsintheperiodendedjanuaryincon processdesignedtoprovidereasonableassuranceregardingthe formitywithaccountingprinciplesgenerallyacceptedintheunited reliabilityoffinancialreportingandthepreparationoffinancial statesofamericaalsoinouropinionthecompanymaintainedin statementsforexternalpurposesinaccordancewithgenerally allmaterialrespectseffectiveinternalcontroloverfinancialreport acceptedaccountingprinciplesacompanysinternalcontrolover ingasofjanuarybasedoncriteriaestablishedininternal financialreportingincludesthosepoliciesandproceduresthati controlintegratedframeworkissuedbythecommitteeofspon pertaintothemaintenanceofrecordsthatinreasonabledetail soringorganizationsofthetreadwaycommissioncosothe accuratelyandfairlyreflectthetransactionsanddispositionsofthe companysmanagementisresponsibleforthesefinancialstate assetsofthecompanyiiprovidereasonableassurancethattrans mentsformaintainingeffectiveinternalcontroloverfinancial actionsarerecordedasnecessarytopermitpreparationoffinancial reportingandforitsassessmentoftheeffectivenessofinternalcon statementsinaccordancewithgenerallyacceptedaccountingprin troloverfinancialreportingincludedintheaccompanyingman ciplesandthatreceiptsandexpendituresofthecompanyarebeing agementsreportoninternalcontroloverfinancialreportingour madeonlyinaccordancewithauthorizationsofmanagementand responsibilityistoexpressopinionsonthesefinancialstatements directorsofthecompanyandiiiprovidereasonableassurance andonthecompanysinternalcontroloverfinancialreporting regardingpreventionortimelydetectionofunauthorizedacquisi basedonourintegratedauditsweconductedourauditsinaccor tionuseordispositionofthecompanysassetsthatcouldhavea dancewiththestandardsofthepubliccompanyaccountingover materialeffectonthefinancialstatements sightboardunitedstatesthosestandardsrequirethatweplan becauseofitsinherentlimitationsinternalcontroloverfinan andperformtheauditstoobtainreasonableassuranceabout cialreportingmaynotpreventordetectmisstatementsalsopro whetherthefinancialstatementsarefreeofmaterialmisstatement jectionsofanyevaluationofeffectivenesstofutureperiodsare andwhethereffectiveinternalcontroloverfinancialreportingwas subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof maintainedinallmaterialrespectsourauditsofthefinancialstate changesinconditionsorthatthedegreeofcompliancewiththe mentsincludedexaminingonatestbasisevidencesupportingthe policiesorproceduresmaydeteriorate amountsanddisclosuresinthefinancialstatementsassessingthe accountingprinciplesusedandsignificantestimatesmadebyman agementandevaluatingtheoverallfinancialstatementpresenta tionourauditofinternalcontroloverfinancialreportingincluded obtaininganunderstandingofinternalcontroloverfinancialreport ingassessingtheriskthatamaterialweaknessexistsandtesting newyorknewyork andevaluatingthedesignandoperatingeffectivenessofinternal march johnson johnson annual reportmanagementsreportoninternalcontroloverfinancialreporting undersectionofthesarbanesoxleyactofmanage establishedbythecommitteeofsponsoringorganizationsofthe mentisrequiredtoassesstheeffectivenessofthecompanysinter treadwaycommissioncosoininternalcontrolintegrated nalcontroloverfinancialreportingasoftheendofeachfiscalyear frameworkthesecriteriaareintheareasofcontrolenvironment andreportbasedonthatassessmentwhetherthecompanys riskassessmentcontrolactivitiesinformationandcommunication internalcontroloverfinancialreportingiseffective andmonitoringthecompanysassessmentincludedextensive managementofthecompanyisresponsibleforestablishing documentingevaluatingandtestingthedesignandoperatingeffec andmaintainingadequateinternalcontroloverfinancialreporting tivenessofitsinternalcontrolsoverfinancialreporting thecompanysinternalcontroloverfinancialreportingisdesigned basedonthecompanysprocessesandassessmentas toprovidereasonableassuranceastothereliabilityofthecompanys describedabovemanagementhasconcludedthatasofjanuary financialreportingandthepreparationofexternalfinancialstate thecompanysinternalcontroloverfinancialreporting mentsinaccordancewithgenerallyacceptedaccountingprinciples waseffective internalcontrolsoverfinancialreportingnomatterhowwell theeffectivenessofthecompanysinternalcontrolover designedhaveinherentlimitationsthereforeinternalcontrolover financialreportingasofjanuaryhasbeenauditedby financialreportingdeterminedtobeeffectivecanprovideonly pricewaterhousecoopersllpanindependentregisteredpublic reasonableassurancewithrespecttofinancialstatementprepara accountingfirmasstatedintheirreportwhichappearsherein tionandmaynotpreventordetectallmisstatementsmoreover projectionsofanyevaluationofeffectivenesstofutureperiodsare subjecttotheriskthatcontrolsmaybecomeinadequatebecause ofchangesinconditionsorthatthedegreeofcompliancewiththe policiesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessof williamcweldon dominicjcaruso thecompanysinternalcontroloverfinancialreportingasofjanuary chairmanboardofdirectors vicepresidentfinance inmakingthisassessmentthecompanyusedthecriteria andchiefexecutiveofficer andchieffinancialofficer managements report internal control financial reporting summaryofoperationsandstatisticaldata dollarsinmillionsexceptpersharefigures salestocustomerus salestocustomerinternational totalsales costofproductssold sellingmarketingandadministrativeexpenses researchexpense purchasedinprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructuring earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearnings percentofsalestocustomers dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseoverpreviousyear salestocustomers dilutednetearningspershare supplementaryexpensedata costofmaterialsandservices totalemploymentcosts depreciationandamortization maintenanceandrepairs totaltaxexpense supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalassets longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillionsbasic diluted employeesthousands netofinterestandotherincome alsoincludedincostofmaterialsandservicescategory includestaxesonincomepayrollpropertyandotherbusinesstaxes summary operations statistical datashareholderreturnperformancegraphs shareholoder return performance graphs reconciliationofnongaapfinancialmeasures thetablesbelowareprovidedtoreconcilecertainfinancialdisclosuresinthelettertoshareholderspage vs vs dollarsinmillionsexceptpersharedata change change earningsbeforeprovisionfortaxesonincomeasreported purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown earningsbeforeprovisionfortaxesonincomeasadjusted netearningsasreported purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown internationaltaxgainonrestructuring netearningsasadjusted dilutednetearningspershareasreported purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown internationaltaxgainonrestructuring dilutednetearningspershareasadjusted vs vs dollarsinmillions change change netcashflowsfromoperatingactivities additionstopropertyplantandequipment freecashflow thecompanybelievesinvestorsgainadditionalperspectiveofunderlyingbusinesstrendsandresultsbyprovidingfreecashflowameasure ofearningsbeforetaxnetearningsanddilutednetearningspersharethatexcludesiprdchargesandotherspecialitemsinordertoeval uateongoingbusinessoperationsthesenongaapfinancialmeasuresshouldnotbeconsideredreplacementsforandshouldberead togetherwiththemostcomparablegaapfinancialmeasures reconciliation nongaap financial measuresprincip al office company required file exhibit dividend reinvestment plan one johnson johnson plaza fiscal year certifica plan allows full partial new brunswick new jersey tions section sarbanesoxley dividend reinvestment additional monthly act signed chief executive officer cash investments per year chief financial officer addition johnson johnson common stock without annual meeting company required submit certifica brokerage commissions service charges annual meeting shareholders take tion signed chief executive officer stock purchases interested place april hyatt regency new york stock exchange within days participating plan need authoriza new brunswick albany street new brunswick following annual meeting shareholders tion form andor information please call new jersey meeting convene copies certifications filed previous computershare trust company na shareholders cordially invited attend years posted companys corporate formal notice meeting proxy statement governance web site future certifications outside us proxy sent shareholders posted promptly upon filing hearing imp aired corporate governance common stock shareholders inquiries regarding copies companys annual report listed new york stock exchange stockrelated matters communicate directly quarterly reports form q stock symbol jnj computershare trust company na current reports form k via telecommunications device tdd securities exchange commission shareholder rela tions contact telephone number service proxy statement annual report steven rosenberg available online wwwinvestorjnjcom corporate secretary outside us secfilingscfm shareholders without charge upon written request secretary registered shareholders wish receive investor relations contact companys principal address calling electronic notice online access future louise mehrotra annual reports proxy materials instead vice president investor relations paper copies may register online addition companys corporate governance web site wwwcomputersharenacomgreen wwwinvestorjnjcomgovernancecfm beneficial johnson johnson shareholders transfer gent gistrar shareholders view companys questions regarding stock holdings shares broker bank principles corporate governance certificate replacementtransfer dividends register online delivery charters audit committee address changes directed materials going compensation benefits committee computershare trust company na httpenrollicsdeliverycomjnj nominating corporate governance royall street johnson johnson web committee policy business conduct canton company website wwwjnjcom employees code business conduct ethics members board outside us online annual report directors executive officers wwwcomputersharecom wwwinvestorjnjcom annualreport copies documents available company blog wwwjnjbtwcom shareholders without charge upon written paper used publication made johnson johnson history blog postconsumer recycled fiber request secretary companys forest stewardship council certified chain custody wwwkilmerhousecom principal address manufactured green energy credits purchase electricity generated renewableenergy sources facebook follow johnson johnson wind lowimpact hydro resources network twitter jnjcomm youtube wwwyoutubecomjnjhealth johnson johnson following trademark trade names johnson johnson affilia ted companies appear report day acuvue trueye acclarent aciphexpariet active naturals active naturals institute active photobarrier complex acuvue trueye aveeno biosense webster bx velocity carto cellsearch centocor ortho biotech centocor research development charit clean clear concerta cordis cougar biotechnology cypher depuy depuy institute depuy orthopaedics dabao diabetes care institute duragesic earthwards enseal ethicon ethicon endosurgery evicel feverfew pfe finsbury orthopaedics flex hd gloster europe harmonic helioplex intelence invega invega sustenna janssen alzheimer immunotherapy janssencilag johnson johnson johnson johnson consumer group companies johnson johnson diabetes institute johnson johnson pharmaceutical research development johnsons le petit marseillais levaquinfloxin lifescan listerine mcneil nutritionals memorygel mentor natrecor neutrogena nucynta oasys orthoclinical diagnostics ortho evra ortho tricyclen lo pinnacle complete prezista priligy procriteprex propulsid quixil razadyne reach realize remicade reopro risperdal risperdal consta roc sedasys silent simponi skin id splenda stelara sun crystals surgiflo tibotec tibotec pharmaceuticals tibotecvirco virology bvba topamax truvu ultram er vania expansion veridex vision care institute xianjanssen pharmaceutical following trademark trade names comp anies also appear report academy educational development american academy dermatology american society plastic surgeons bayer healthcare ag rivaroxaban children without worms cleveland clinic crucell elan forest stewardship council gilead sciences global alliance tb drug development good housekeeping grnenthal mayo clinic memorial sloankettering cancer center merck co mitsubishi tanabe pharma national childrens oral health foundation pfizer prix galien royal marsden hospital siemens healthcare diagnostics task force global health terracycle tianjin medical university cancer hospital us agency international development us food drug administration velcade millennium takeda oncology company world wildlife fund nucynta codeveloped grnenthal gmbh centocor ortho biotech inc marketing rights remicade us xianjanssen pharmaceutical ltd markets product china janssencilag hong kong distribution agreements place merck co inc mitsubishi tanabe pharma corporation markets throughout world corporate shareholder informationour c r e believe first responsibility doctors nurses patients mothers fathers others use products services meeting needs everything must high quality must constantly strive reduce costs order maintain reasonable prices customers orders must serviced promptly accurately suppliers distributors must opportunity make fair profit responsible employees men women work us throughout world everyone must considered individual must respect dignity recognize merit must sense security jobs compensation must fair adequate working conditions clean orderly safe must mindful ways help employees fulfill family responsibilities employees must feel free make suggestions complaints must equal opportunity employment development advancement qualified must provide competent management actions must ethical responsible communities live work world community well must good citizenssupport good works charities bear fair share taxes must encourage civic improvements better health education must maintain good order property privileged use protecting environment natural resources final responsibility stockholders business must make sound profit must experiment new ideas research must carried innovative programs developed mistakes paid new equipment must purchased new facilities provided new products launched reserves must created provide adverse times operate according principles stockholders realize fair return